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Invasive Lobular Carcinoma (ILC) is an understudied, unique subtype of breast cancer. E-cadherin 
(CDH1) loss is a hallmark of ILC that contributes to its many observed epithelial to mesenchymal 
transition (EMT)-like features. Though ILCs predominantly express clinically actionable target 
estrogen receptor alpha (ERα), common late recurrences suggest a role for endocrine therapy 
resistance. We recently identified de novo resistance to the partial estrogen receptor 
antagonist/agonist Tamoxifen (4OHT) in MDA-MB-134-VI ILC cells that was accompanied by 
upregulation of EMT transcription factor (EMT-TF) SNAIL (SNAI1). We therefore hypothesized 
that 4OHT induction of SNAIL contributes to endocrine therapy resistance in a subset of ILCs. 
We demonstrated estrogen induction of SNAI1 in multiple invasive ductal carcinoma (IDC) and 
ILC cell lines. In contrast, 4OHT induction of SNAI1 was restricted to ILC cells tested, and was 
associated with recruitment of ERα to the SNAI1 promoter. We observed upregulation of additional 
EMT genes in ILC cells, partially translatable to clinical samples. However, 4OHT regulation of 
SNAIL was unique, thus we pursued study of SNAIL-mediated phenotypes in ILC cells. 
Unfortunately, manipulation of SNAIL levels in ILC cells was challenging, with expression 
rebound in stable constitutive knockdown/overexpression attempts. Inducible SNAIL 
overexpression revealed unexpected repression of 2D and 3D proliferation. These data suggest a 
role for SNAIL in unexplored, critical ILC phenotypes (e.g. tumor dormancy). Lack of ILC models 
for these studies highlighted need for novel ILC cell lines. We therefore established and 
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 v 
characterized ILC cell line WCRC-25 from a pleural effusion from a patient with ER+ ILC. 
WCRC-25 maintained phenotypes consistent with other ILC cells (e.g. slow proliferation, poor 
soft agar formation). We identified a somatic CDH1 mutation (2240C>T, p.Q706*) in gDNA from 
WCRC-25 that we confirmed in liquid biopsies from the patient. DNA/RNA sequencing analyses 
are being performed using clinical samples from the patient. While loss of ER impeded testing 
endocrine therapy resistance in WCRC-25 cells, additional drug responses revealed sensitivity to 
a PI3K inhibitor. In summary, these studies provided the foundation for better understanding of 
the role of EMT-TF SNAIL in endocrine therapy resistance, and led to establishment and 
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1.0  INTRODUCTION 
1.1 BREAST CANCER 
Breast cancer is the most common cancer among women in the United States, and the second 
leading cause of cancer-related death[1]. In 2018, an estimated 268,670 patients will be diagnosed 
with breast cancer, and approximately 41,400 will succumb to the disease. Most of these patients 
are female, and thus are the focus of this work. The incidence of breast cancer has remained 
relatively stable over the past two decades, largely attributed to the multitude of environmental 
and physical factors that drive disease progression[2]. Epidemiologic studies have revealed that 
increasing rates of obesity among American women, as well as uses of postmenopausal hormonal 
therapy replacement, are linked to increased risk for breast cancer[3-5]. Beyond these factors, age, 
parity, lifestyle choices, and genetics also can play a role in the onset of disease[6]. These disparate 
entities all contribute to a disturbing reality: each woman in America faces a 1-in-8 risk in her 
lifetime of developing breast cancer. 
Various therapeutic agents are available for breast cancer patients, which will be described 
in detail in this work. Although these therapeutic classes available for breast cancer patients have 
been heralded as some of the most successful targeted therapies of all cancer treatments, 
recurrences due to resistance to these therapies remain the greatest clinical challenge[7, 8]. It is well 
understood that it is not the primary cancer that leads to a patient’s passing, but instead the 
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metastatic burden that infiltrates into various organ systems. For this reason, studies on recurrence, 
resistance, and metastatic disease have been central to the field of breast cancer research for 
decades. Beyond these molecular studies of disease, unique pathology within breast cancer has 
become an important focus in delineating patient subsets who should receive certain targeted 
therapies[9]. The work in this dissertation attempted to assess all of the aforementioned points: (1) 
to better understand the differences in therapeutic response in two major histological subtypes of 
breast cancer, (2) focus on the potential negative impacts of a widely used targeted therapy within 
one of these breast cancer subsets, and (3) generate and characterize a novel model for this subset 
to further the understanding of disease progression and resistance to therapeutics, providing a 
preclinical tool for breast cancer researchers to employ in future endeavors. 
1.1.1 Breast Cancer Development and Progression: A Historical and Ongoing Perspective 
Breast cancer is most adequately described as the malignant outgrowth of epithelial cells in the 
breast[6]. The first descriptions of breast cancer can be traced to approximately 3500 B.C. when 
ancient Egyptian physicians were stated to have removed breast tumors or ulcers by primitive 
burning methods[10]. Though various other citations regarding the disease have been found 
scattered across the subsequent few thousand years, the first postulations regarding origin of the 
carcinoma were not made until circa 200 A.D. by Greek physician Galen. Building off 
Hippocrates’ theory that all diseases are caused by an imbalance of four “humours” (blood, 
phlegm, yellow bile, and black bile), Galen suggested that an excess of black bile was the cause of 
breast cancer. This accepted paradigm remained unchallenged for nearly one thousand three 
hundred years, much to the disservice of afflicted individuals.      
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As interest in medicine gained ground in the 1600-1900s, new viewpoints arose from 
various physician scientists to describe the origin of breast cancer. The Lymph Theory proposed 
that an outgrowth of lymph from blood led to carcinoma[11]. Humours and lymph were finally 
discredited as sources of carcinoma in the mid-1800s when Muller first showed scientific evidence 
that carcinoma is derived from cells, and his student Virchow confirmed that cancer cells derive 
from other cells[12]. Virchow’s Omnis cellula e cellula, or “All cells come from cells,” became the 
paradigm shift that was required to move the fields of biology, pathology, and oncology in a 
forward trajectory. This Blastema Theory, as it was called, gave rise to three additional theories: 
Virchow and Dvorak’s Chronic Irritation Theory (cancer is a wound that does not heal), Ribbert’s 
Trauma Theory (cancer cells become free from tissues of origin by mechanical disruption), and 
Gye and Barnard’s Parasite Theory (viruses and other microbes cause cancer)[13-15]. While all 
theories held scientific merit in their approaches and syntheses of available evidence to describe 
the complex disease before them, it was not until the structure of DNA was solved by Wilkins, 
Franklin, Watson, and Crick that the opening floodgates of research in the burgeoning field of 
molecular biology could lay these theories to rest[16-18]. 
Anatomically, fully developed breasts are superior to the pectoral muscles[19]. Internally, 
each breast is comprised of approximately fifteen to twenty lobes. Each lobe contains twenty to 
forty lobules, in which milk is produced. From these lobules, ducts extend in intricate networks 
toward the nipple. In addition to these main components, the normal breast is filled with arteries, 
veins, nerves, connective tissue, and a large amount of adipose. As breast cancer arises from 
epithelial breast cells, the entire terminal ductal lobular unit (TDLU) is a site of origin for breast 
cancer. 
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Pathologically, breast cancer follows a progression from flat epithelial atypia (FEA) to 
atypical hyperplasia (AH) to carcinoma in situ (CIS) to carcinoma[20]. Each condition is a non-
obligate precursor to the next and, as such, the penultimate condition of CIS is a non-obligate 
precursor to the final state of carcinoma. Each transition is accompanied by increasing epithelial 
aberrancies, altered proliferation, and morphological changes. Epithelial cell infiltration of the 
surrounding stromal milieu marks the presence of carcinoma, as distinct or non-distinct tumors 
take form.  
Beyond these observations, much controversy remains regarding the specific cell origin of 
breast cancer[21, 22]. Two main hypotheses exist: (1) the Clonal Hypothesis and (2) the Stem Cell 
Hypothesis. In the former, a multitude of breast cancer cells are affected by mutations and those 
with the advantageous mutations are selected for to contribute to tumorigenesis. In the latter, a rare 
population of stem and progenitor cells initiates the tumor and potentiates its formation. These 
hypotheses have also been proposed to not exist in a vacuum, but to instead be a combined, 
dynamic model. To this end, no single cell of origin for breast cancer can currently be identified. 
The complexity of breast cancer begins to increase at the cellular level, as scientists now 
understand that each tumor is comprised of a heterogeneous population of cells that may each 
contribute to the lesion in different ways. 
The most complicated level of study within breast cancer, molecular development and 
progression of disease, is also the most recently investigated. Various somatic and germline 
aberrations have been identified that contribute to the development and progression of breast 
cancer[23, 24]. For example, from a developmental standpoint, BRCA1 and BRCA2 mutation carriers 
are susceptible to breast cancer, obtained from either somatic or germline events[25]. These genes 
both generate protein products, BRCA1 or BRCA2, that control DNA repair mechanisms. Without 
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these pertinent proteins operating in their normal capacity, cells become susceptible to genomic 
aberrancies that can allow for uncontrolled proliferation, evasion of apoptosis, and other 
mechanisms that lead to carcinogenesis. Mutations in the tumor suppressor gene, TP53, have been 
identified in nearly half of all cancers, and TP53 is among the most highly mutated genes in breast 
cancer[26]. Individuals afflicted with germline TP53 mutations are commonly diagnosed with Li-
Fraumeni cancer susceptibility syndrome, a disease that is known to confer a higher risk for breast 
cancer. TP53 functions revolve around control of apoptosis in response to various stimuli in the 
cell, including accumulated DNA damage. Loss of the protein product of TP53, p53, leads to 
evasion of apoptosis for genomically unstable cells.  
Additional genes that may contribute to the development and progression of breast cancer 
have been thoroughly studied. A highly notable gene includes epithelial marker CDH1, which 
encodes the protein for E-cadherin, a major focus of the second chapter of this dissertation[27, 28]. 
E-cadherin is a transmembrane protein that tethers neighboring cells together through a homotypic 
interaction with an adjoining E-cadherin protein. Further, E-cadherin is a master regulator of the 
continued connection between cells by binding to catenin molecules, which are secured to the 
internal actin cytoskeleton. This comprehensive interaction comprises what is known as the 
adherens junction. The functions of E-cadherin are imperative both in general anatomical 
development, as well as in carcinogenesis. Developmentally, E-cadherin expression is 
downregulated to alter polarity in epithelial cells during a controlled process called epithelial to 
mesenchymal transition (EMT). This controlled EMT leads to formation of the mesoderm, neural 
crest, and directs many other processes that contribute to proper development of an embryo. 
However, EMT is also utilized by cancer cells to disseminate from primary lesions to metastatic 
sites[29]. Loss of E-cadherin expression has become an important focus in breast cancer 
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development, particularly for major histological subtype Invasive Lobular Carcinoma (ILC), as 
described loss can be found predominantly in both ILC and its non-obligate precursor, Lobular 
Carcinoma in situ (LCIS)[30]. E-cadherin loss is observed less frequently in counterparts Ductal 
Carcinoma in situ (DCIS) and Invasive Ductal Carcinoma (IDC). This depletion of E-cadherin 
from LCIS/ILC cells is highly notable and unique within breast cancer, and suggests an EMT-like 
nature for these cells.  
Ongoing studies continue to probe the complicated biological consequences of various 
genetic and cellular abnormalities that drive development and progression of breast cancer. These 
elaborate mechanisms continue to provide evidence that the complexity of cancer is beyond the 
initial theories of humours that were first described many thousand years ago. Though an entire 
dissertation could be devoted solely to the discussion of further molecular abnormalities that 
contribute to breast carcinogenesis and maintenance, only one other major protein (Estrogen 
Receptor Alpha, ERα) is pertinent to the focus of this compiled work and will be expounded upon 
in the next section. 
1.1.2 Estrogen Receptor and its Role in Breast Cancer 
Estrogen Receptor (ER) is the most commonly overexpressed entity in breast cancer, identified in 
60-70% of all tumors[31]. ER consists of two major forms, alpha (α) or beta (β), which are 
hormonally driven transcription factors[32, 33]. ERα and ERβ are encoded by two separate genes, 
ESR1 and ESR2, respectively. Though both genes/proteins are highly related in their structures and 
share some genomic targets, their chromosomal loci and patterns of tissue expression are 
different[34, 35]. In addition, ERα is the most commonly overexpressed form and is the focus of this 
work.  
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17β-estradiol, or estrogen (E2), is the natural steroid hormone ligand for ERα[34]. It is 
sourced primarily in premenopausal ovaries, or in postmenopausal women in adipose tissues from 
aromatization of the male sex hormone testosterone. Upon diffusion into a cell, E2 binds to ERα 
leading to activation of the transcriptional activator domain and causes rapid alterations in 
downstream associated target gene expressions[36-38]. This can happen either via genomic or non-
genomic mechanisms. In genomic signaling, E2 binds to ERα, which dimerizes in the nucleus and 
associates directly to Estrogen Response Elements (EREs) or indirectly through other proteins to 
non-EREs[39]. Either interaction occurs in combination with various coactivator or corepressor 
proteins and the general transcriptional machinery. In non-genomic signaling, E2 binds to ERα 
that is located near the plasma membrane and activates downstream signaling via various signaling 
pathways (e.g. PI3K/MAPK)[40]. Alternative signaling pathways may also influence ERα 
signaling. Genomic and non-genomic signaling can influence the expression of thousands of genes 




Figure 1: ERα Signaling is a Major Driver of Breast Cancer 
A simplified version of ERα signaling is displayed. E2 diffuses into a cell, and binds to ERα, which 
dimerizes in the nucleus of the cell to promote downstream transcription programs via direct 
interactions at EREs or indirectly through non-EREs. Additionally, ERα can be activated through 
cross-talk with other signaling pathways, such as those driven by growth factors (GFs) and growth 




In breast cancer, two main fields of thought exist to explain the implications of E2 in 
driving ERα-promoted carcinogenesis. First, ERα can promote proliferation in breast cancer 
cells[41, 42]. By inducing the expression of genes that drive the cell cycle (PCNA/MKI67) and 
repressing genes that normally contribute to cell cycle arrest (TP53/CDKN1A), ERα can push a 
cell into a cycle of uncontrolled proliferation. During uncontrolled proliferation, additional 
mutational events occur, leading cells to continue to contribute to tumor growth. Another 
understudied and controversial mechanism that may contribute to E2-driven breast cancer is the 
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metabolism of E2 itself, which has been shown to lead to both DNA adducts and oxygen free 
radicals[43]. These genotoxic metabolites are linked to DNA damage and eventual neoplasm 
formation. Both ERα-driven pathways lead to the formation of ERα-positive (ERα+) tumors. 
Therapeutic agents that are used to target the addiction of breast cancer cells to this oncogene will 
be covered in a later section of this chapter. 
1.2 SUBTYPES OF BREAST CANCER 
While ERα+ tumors encompass most breast cancers, other molecular subtypes also exist. Beyond 
these molecular subtypes, major histological subtypes can also be differentiated among breast 
tumors. Altogether, these heterogeneous populations of tumors are composed of further 
heterogeneous populations of cancer cells that make the overarching nomenclature of “breast 
cancer” seem an oversimplification for a collection of unique diseases. The identification of these 
tumor types is imperative for informing treatment options for patients, and for determining 
potential behaviors of tumors. Unfortunately, one major subtype, ILC, has been grossly 
understudied. 
1.2.1 Molecular Subtypes of Breast Cancer 
Recognition of the multitude of transcriptional and signaling programs that are observed as 
patterns in tumor subtypes have been made[44, 45]. However, it was not until 2000 that Perou and 
colleagues performed the first comprehensive expression analysis of sixty-five breast or breast 
metastatic specimens[46]. They analyzed the expression of 8,102 genes, and delineated the samples 
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into four major molecular subtypes. The first major subtype described was named luminal 
epithelial/ERα. The gene expression profile of this tumor subset was largely driven by ERα 
expression and related gene expression targets. The second subtype was comprised of tumors that 
were driven by overexpression of the growth factor receptor ERBB2, or HER2. The last two 
subtypes described in this original analysis were both basal in nature: one strictly deemed basal-
like, and the other more normal-like in patterns of gene expression. Only the luminal subtype was 
related to expression of ERα, while the remaining three subtypes were devoid of the expression of 
ERα. 
These subtypes have been further evaluated to test stability of clusters that were initially 
observed[46]. The first attempt at this expanded analysis occurred in 2001 by Sorlie and 
colleagues[47]. Not only were the original four clusters replicated in these analyses 
(Luminal/HER2/Basal/Normal), but luminal was further differentiated into two additional 
subtypes: Luminal A and Luminal B. The two luminal subtypes were separated primarily by 
outcome; patients with Luminal A tumors had better survival outcome than those with Luminal B 
tumors. An additional analysis was completed in 2012 and contained clinical specimens from 825 
patients quantified on five platforms covering mRNA expression, DNA methylation, Single 
Nucleotide Polymorphisms (SNPs), miRNA, and whole-exome sequencing[48]. 348 of the samples 
were also subjected to reverse-phase protein array (RPPA) analyses. Luminal tumors were overall 
more highly associated with increased rates of PIK3CA, GATA3, and FOXA1 mutations. Luminal 
A could be differentiated from Luminal B by many factors including, but not limited to, lower 
frequencies of TP53 mutations (12% versus 32%), cyclin D1 amplification (29% versus 58%), and 
high estrogen signaling (Luminal A > Luminal B). Their conclusions aligned with what has been 
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clinically observed: Luminal A is associated with less aggressive breast cancers, while Luminal B 
is associated with more aggressive breast cancers, when comparing both subtypes directly. 
Analyses related to the remaining three subtypes revealed additional details not uncovered 
by the first study. The HER2 subtype was found to have a specific HER2/EGFR gene expression 
signature that could separate the tumors into responders to HER2-targeted therapies, and those that 
would likely not respond[48]. Finally, the basal-like, largely comprised of triple negative breast 
cancers (TNBCs), had the highest rates of TP53 mutations (80%) and widespread genomic 
instability that was more commonly related to serous ovarian cancers as opposed to the other 
molecular breast cancer subtypes. Additional follow-up studies have concluded that basal-like 
tumors can also be further subdivided into other classes such as Claudin-Low, which are associated 
with upregulations of transcription factors SNAI1, TWIST1, and ZEB1, and are noted to have high 
immune infiltrate[49].  
The clinical implications of these molecular subtypes were noted after the first definitions 
of Luminal A/Luminal B/HER2/Basal/Normal were defined and are now commonly called the 
PAM50-based subtype classifier for the original 50 genes used to delineate the intrinsic 
subtypes[46-50]. Beyond survival differences (Luminal A > Luminal B > HER2 > Basal), the 
implications of these intrinsic breast cancer subtypes continue to be studied[51-54]. PAM50 was the 
first comprehensive test to give insight into personalized medicine in the field of breast cancer, 
and has inspired the use of subtyping in the clinical tailoring of treatments to tumors. From these 
subtypes, clinicians can now predict response to therapeutics based on the subtyping of a given 
tumor, whether in response to chemotherapy or targeted therapy.  
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1.2.2 Histologic Subtypes of Breast Cancer: A Comparison of ILC and IDC 
Though molecular subtyping is novel, it has not replaced the pathological subtyping that has been 
performed on breast tumors for nearly one hundred years. Breast cancer can be subdivided into 
two main histological subtypes: ILC and IDC[55-57]. ILCs account for 10-15% of all invasive breast 
carcinomas, and IDCs account for 80%. There are roughly 22 remaining histological subtypes 
which are much less frequent, and not a focus of this work[58]. After clinical sample acquisition, 
classical Hematoxylin and Eosin (H&E) staining can help pathologists to identify the subtype of 
tumor with which a patient is afflicted. 
 ILCs have a unique growth phenotype consisting of small, discohesive cellular growth 
throughout surrounding stroma (Figure 2)[59-61]. This linear growth pattern is caused by loss of the 
epithelial protein E-cadherin, a calcium-dependent transmembrane protein imperative for cell-cell 




Figure 2: ILC and IDC Have Different Presentations in Breast Tissue 
H&E stains for ILC and IDC were performed on primary tumors. The ILC lesion displayed a 




Previous studies have defined this loss of E-cadherin protein in 90-100% of primary ILCs by 
Immunohistochemistry (IHC) staining methods[64-66]. A more recent and comprehensive study 
performed by The Cancer Genome Atlas (TCGA) ILC working group utilized a cohort of n = 127 
primary ILCs to identify CDH1 mutations leading to truncated or missense mutated protein in 65% 
of all cases[67]. In addition, these CDH1 mutations often coincided with loss of heterozygosity 
(LOH) of 16q22, the chromosomal location of CDH1. Including the TCGA ILC working group’s 
studies regarding mutations, copy-number alterations (CNAs), mRNA downregulation, and 
protein downregulation, loss of E-cadherin was found in 95% of the tumors studied. Mechanisms 
of loss and other postulations regarding E-cadherin will be covered in depth in the second chapter 
of this dissertation. This loss of E-cadherin largely contributes to the unique growth pattern of 
ILCs, making the tumors more difficult to detect by palpation and standard mammographic 
methods[68-70]. As such, ILCs are often diagnosed at later stages, when at larger sizes. 
Approximately 90-95% of ILCs are ERα+, giving clinicians a choice of endocrine therapies for 
treatment of patients[71, 72]. IDCs, in contrast, do not tend to have loss of E-cadherin or a linear 
growth pattern[73]. Instead, they form classic palpable masses, more easily detected at early 
stages[74]. Loss of E-cadherin can occur in IDCs, but is more often associated with poorly 
differentiated or highly metastatic lesions[75-77]. A large proportion of IDCs also express ERα, 
making these tumors susceptible targets for endocrine therapy treatments. 
 Beyond the differences in E-cadherin expression and pathology in ILC compared to IDC, 
recent studies have focused on differences in metastatic lesion sites for the two diseases. Due to 
the abundance of ERα expression in both subtypes, bone is the most common metastatic site for 
both diseases[78, 79]. However, other sites of metastases can differ vastly between the two subtypes. 
While IDCs more commonly form secondary lesions in the lung or liver, ILCs are often found in 
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ovaries or the gastrointestinal tract[80-82]. Though these differences have been noted, the molecular 
mechanisms behind these unique metastatic sites have yet to be elucidated. These diverse 
presentations give further evidence to the uniqueness of ILC as compared to IDC as a subtype of 
breast cancer. 
Other clinical differences have been noted between ILC and IDC. As mentioned 
previously, larger ILCs are often found at later stage of diagnosis. The combination of larger size 
and E-cadherin loss can lead ILCs to present with spiculated or poorly-defined margins[83-86]. 
These diffuse margins, also present in early lesions, can be difficult for detection in imaging, and 
for surgeons to navigate in excision. This can lead to aggressive measures of mastectomy, which 
has been discovered to have similar rates of breast cancer-specific survival as breast conservation 
surgery in early-stage ILC patients[87]. Another clinical observation is that early lesions are often 
missed by typical mammographic or ultrasound methods, due to lack of desmoplastic reaction in 
surrounding stroma and the unique proliferation pattern of ILC[68, 88]. ILC patients are more likely 
to be afflicted with multicentric or multifocal disease and have prevalence of contralateral episodes 
of disease[89, 90]. These clinical presentations contribute to difficulty detecting ILC and can hinder 
the timely treatment of afflicted patients. 
At the molecular level, ILCs tend to have low mitotic indices and histological grade 
compared to IDCs, correlating with their lower rates of proliferation[65]. ILC nuclei can be 
proportionally larger and may exhibit hyperchromatism[91]. Ki67 levels are overall lower in ILC 
compared to IDC, contributing to lower proliferation rates[92]. The combination of ERα+/Ki67low 
status in ILCs translates to their predominant Luminal A subtyping, suggesting that these lesions 
are overall less aggressive and have increased survival compared to other breast cancer 
subtypes[67]. However, retrospective analyses regarding survival in relation to therapeutic regimen 
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have revealed a potentially different story; this will be detailed in the next section of this chapter. 
Loss of PTEN and alterations in PI3K/AKT/mTOR signaling have also been noted as driving 
pathways in ILC[67, 93, 94]. However, the molecular intricacies of ILC remain undefined, and are a 
leading rationale for this body of work. 
In summary, ILC and IDC are distinct diseases within breast cancer, with some clear 
clinical, morphological, and molecular differences largely defined in the last decade (Table 1). 
With approximately 39,000 new cases of ILC projected to be diagnosed in 2018 in the United 
States, ILC is the sixth most common type of cancer for women[1]. This prevalence and all the 
unique aspects of this breast cancer subtype merit an enhanced interest in treating patients afflicted 
with ILC differently than those affected by IDC. However, the research regarding these treatments 
and their implications for specific histological subtypes is in its infancy. Further recognition of the 
uniqueness of ILC will assist in informing clinical decisions related to treatment regimens that are 
prescribed to patients. Better distinction between the two major subtypes could promote better 










Table 1: Overview of Characteristics of ILC and IDC 
 ILC IDC 
Percent of Breast Cancers (%)[1, 27] 10 – 15 80 
Patients Annually Diagnosed in U.S.[1] 
 
Numbers Calculated from 2018 Diagnoses Projections 
            26,867 - 39,918 212,896 
Average Age of Patient Diagnosed[27, 95] 63.4 ± 12.7 59.5 ± 13.6 
Tissue Presentation (see Figure 2) Discohesive linear cords Distinct masses 
Detection[83-86] 
Less palpable until at later 
stages, difficult to observe 
with mammographic methods 
More often palpable during 
self-examination, more 
obvious masses during 
mammography 
Metastatic Sites[78-82] 
Major: Bone > CNS, Lung > Liver Bone > Lung > Liver > CNS 
Unique: GI Tract, Ovary -- 
ERα Expression[67, 71, 72] + 90-95% 
+ 
60-70% 





E-cadherin Expression[64-67] - Predominantly + 
TCGA CDH1 Mutation Significances[67] 
ILC versus IDC Comparisons Displayed 
3.40E-12 7.63E-03 
Selected Top Mutated Genes from 
TCGA Study[67] 
Data are Adapted from the Above Publication 
*Significant Differences in Mutation 
Frequencies When Directly Comparing 
Luminal A Subtypes  
PIK3CA 9.18E-13 6.79E-13 
RUNX1 9.18E-13 1.32E-05 
TP53 2.22E-04 6.79E-13* 
TBX3 4.01E-06* NS 
PTEN 8.86E-09* 5.63E-03 
FOXA1 6.53E-04* NS 
GATA3 NS    6.79E-13* 




1.3 BREAST CANCER TREATMENT REGIMENS 
Breast cancer treatments have evolved from the primitive burning methods of medieval times to 
targeted therapeutics that are on the cusp of the personalized medicine movement[96]. From classic 
methodologies that have been utilized for centuries (e.g. surgery), to the class of endocrine 
therapies that can be selected for patients’ tumors expressing ERα, the therapeutic landscape for 
breast cancer patients is a constantly evolving or changing entity. Further, differences in 
indications (e.g. ILC versus IDC) have the potential to influence the treatment course for a given 
patient. Herein, we give a brief overview of the major classes of treatment regimens and examples 
of some pertinent clinical study outcomes for breast cancer patients with a focus on ILC patient 
populations.  
1.3.1 Endocrine Therapies and Selected Clinical Studies 
Endocrine therapies are a class of targeted therapies that directly or indirectly inhibit ERα[97-99]. 
The major subclasses of endocrine therapies include Selective Estrogen Receptor Modulators 
(SERMs), Selective Estrogen Receptor Downregulators (SERDs), and Aromatase Inhibitors (AIs) 
(Figure 3). Each class is rationally chosen for patients based on their menopausal status, prior 
treatments, and progression of disease. Overall, these therapeutics have successfully contributed 




Figure 3: Endocrine Therapies Target ERα in Breast Cancer 
Three commonly used endocrine therapies and their simplified mechanisms are shown above as a 
modification of a similar scheme in Smith et al[98]. SERMs (4OHT), SERDs (ICI), and AIs all 
work to decrease ERα signaling in breast cancer through different mechanisms. 4OHT can directly 
bind to and inhibit ERα signaling by competing with E2. ICI prevents downstream signaling by 
inciting degradation of ERα in the proteasome. AIs inhibit aromatase in subcutaneous tissues (e.g. 
fat) to prevent conversion of testosterone to E2. It should be noted that alternative signaling 




SERMs include molecules that directly interact with ERα as partial agonists or partial antagonists, 
depending on the physiological context[97, 101]. There are currently 11 Federal Drug Administration 
(FDA)-approved SERMs, and an additional 22 or more that are under development or not currently 
approved for medical use[102, 103]. Despite this lengthy list, only two SERMs are currently indicated 
 19 
for the treatment of breast cancer: Tamoxifen and Toremifene. However, the approved patient 
subset for Toremifene is limited in the U.S., as it is given only to postmenopausal women with 
advanced metastatic ERα+ or unknown status tumors[104]. An additional SERM, Raloxifene, is 
FDA-approved; however, the current indications of use are only for prevention of breast 
cancer[105]. Thus, Tamoxifen remains the drug of choice for the class of SERMs. It is also the focus 
of the second chapter of this dissertation. 
Tamoxifen was first generated by scientists at Imperial Chemical Industries in 1966 under 
the name ICI 46,474[106]. The rationale for its generation was to find novel emergency 
contraceptives, but Tamoxifen failed to produce the results desired by Imperial Chemical 
Industries. Instead, nonsteroidal Tamoxifen’s estrogen-mimic molecular structure made it a ligand 
for ERα[107]. Tamoxifen is normally ingested as a tablet preparation in this prodrug state. Once in 
the liver, cytochrome P450 enzymes (CYP2D6 and CYP3A4) convert Tamoxifen into metabolites 
4-hydroxytamoxifen (4OHT), afimoxifene, and endoxifen[108]. The metabolites have a 
significantly higher affinity for ERα than does Tamoxifen itself, and are the primary molecules in 
competition with E2 for binding[109]. For the studies described in this dissertation, only 4OHT was 
utilized and will be the only metabolite mentioned from this point forward. The binding of 4OHT 
induces a conformational change in the receptor, preventing appropriate interaction with 
coactivators or corepressors and reducing interactions with DNA[110]. Thus, 4OHT leads to 
decreased ERα activity, arrest in G0/G1, induction of apoptosis, and inhibition of a multitude of 
other tumorigenic behaviors[111, 112]. The activity of SERMs is not restricted to ERα, but can also 
influence ERβ, a molecule not further covered in this dissertation[113]. Additionally, these 
therapeutics have a mixed antagonist-agonist nomenclature due to their ability to act as antagonists 
in tissues such as the target tissue of the breast, but as agonists in tissues such as bone, 
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endometrium, and uterus[114]. This mixed behavior can be beneficial (e.g. strengthening bone) or 
deleterious (e.g. increased risk for endometrial, uterine cancers, side effects including hot flashes 
or potential blood clots), but is still insufficient to detract from the clinical benefits of Tamoxifen 
for primarily premenopausal breast cancer patients.   
Tamoxifen is a common therapeutic for ILC and IDC ERα+ lesions in premenopausal 
women[115]. However, its utility in ILC has been questioned and pursued in recent clinical studies. 
A retrospective study by Smith and colleagues in 1987 observed n = 33 ILC versus n = 264 IDC 
advanced patient clinical data, and assessed that the survival outcomes between the two groups 
were not significantly different[116]. However, this study covered the broad class of endocrine 
therapies, and was not specific to Tamoxifen. Also, though 90% of the ILCs and 67% of the IDCs 
in this study expressed ERα, all patients were stated to have received endocrine therapy at relapse, 
regardless of receptor status. Patients only received chemotherapy if “life threatening disease 
dictated” necessity. A more focused retrospective study regarding Tamoxifen treatment was 
undertaken by Jïrstrom and colleagues with n = 43 ILC versus n = 411 IDC patients with 
multivariate analysis revealing no significant difference in survival for the two groups[117]. 
Interestingly, a small subgroup of the ILCs did not appear to respond effectively to Tamoxifen, 
but it was concluded that a more comprehensive meta-analysis was required to appropriately power 
the question of ILC versus IDC in relation to specific treatments. Shortly following this study, 
Rakha and colleagues utilized well-characterized clinical data with long-term follow-up from n = 
415 ILC and n = 2,901 IDC patients to first reveal a worse long-term outcome for ILC patients 
who took endocrine therapies compared to IDC patients[118]. A few months after the release of this 
study, Pestalozzi and colleagues performed a larger retrospective study using clinical data obtained 
from outcomes from pure ILCs and IDCs (ILC n = 767; IDC n = 8,607), and uncovered a 
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significant early advantage in disease-free and overall survival for ILC versus IDC patients (p < 
0.01) that was reversed at 6-10 years[119]. These patterns were observed in cohorts defined by ER 
status, suggesting a role for late endocrine therapy resistance in ILC patients. Patients in these 
latter two studies were classified as having received endocrine therapy, with no specific analyses 
applied to patients who received Tamoxifen exclusively, and conclusions thus are a broader 
observation regarding endocrine therapy resistance in ILC. 
Few other studies have reported direct comparisons between ILC and IDC patient 
outcomes, and only one study is currently completed that addresses the outcomes of ILC patients 
in relation to Tamoxifen. Metzger-Filho and colleagues recently completed retrospective BIG 1-
98 trial analyses to compare outcomes in ILC (n = 324) and IDC (n = 2,599) for patients who 
received Tamoxifen, AI Letrozole, or sequential treatments[120]. Overall outcomes revealed that 
there was greater survival benefit for ILC patients who received Letrozole compared to Tamoxifen, 
regardless of Luminal A or B subtype. In contrast, a survival benefit for IDC patients was apparent 
in the Luminal B subtype tumor group, but not the Luminal A. However, caution was noted in 
interpretation of these results until a validation cohort has been observed with similar outcomes 
prior to implementation in clinical practice.  
Two ongoing clinical trials will continue to assess the implications of Tamoxifen in the 
ILC subset of patients. At the University of Pittsburgh, Jankowitz and colleagues are actively 
recruiting patients with ER+ ILC to a three-armed endocrine therapy window trial (Tamoxifen, 
Anastrazole, Fulvestrant) to assess reductions in Ki67 and ER-regulated gene target 
expressions[121]. Metzger-Filho and colleagues are continuing to pursue differences in Tamoxifen 
and Letrozole for ILC and IDC patients with a new trial that appends newly FDA-approved 
CDK4/6 inhibitor Palbociclib (PELOPS)[122]. As both trials were initiated in 2014 and 2016, 
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respectively, and are still recruiting, it will take some time until the outcomes of these trials are 
known. Currently, our knowledge allows us to hypothesize a role for potential endocrine therapy 
and, exclusively, Tamoxifen resistance in ILC patients.   
1.3.1.2 Mechanisms of Tamoxifen Resistance 
Though Tamoxifen is often a successful treatment for ER+ breast cancers, multiple resistance 
mechanisms have been discovered in breast cancer cells that allow cancer to alleviate or inhibit 
the impacts of the therapeutic[122-126]. Some of the common mechanisms of resistance to Tamoxifen 
include (1) alterations in ERα expression levels (e.g. loss of ERα to prevent binding of Tamoxifen 
to target), (2) aberrancies in coregulatory protein expression/activity (e.g. upregulation of 
coactivators SRC1 or AIB1; downregulation of corepressor SMRT), and (3) implications of 
alternative signal transduction pathways to drive tumorigenesis (e.g. PI3K/AKT/mTOR 
signaling)[126-128]. This list is not inclusive of all mechanisms of resistance, as novel mechanisms 
including mutations in ERα or upregulation of EMT proteins (e.g. SNAIL, TWIST1, ZEB1) have 
also recently been implicated[129, 130]. However, most of these studies have been performed in IDC 
breast cancer cell lines and Tamoxifen-resistant derivatives (e.g. MCF-7, MCF-7TAMR, T47D)[131]. 
Understanding the role of Tamoxifen resistance and mechanisms in different histological contexts 
is imperative to generating better therapeutic options for patients, and thus, studies must also be 
extended to other major histological contexts, such as ILC.  
 To this end, our lab recently identified a role for de novo Tamoxifen resistance in an ILC 
cell line, MDA-MB-134-VI[132]. We performed dose response assays for E2 and 4OHT to uncover 
a unique phenotype for MDA-MB-134-VI cells treated with 4OHT; instead of inhibiting growth, 
or having no influence without competition provided by E2, 4OHT promoted the 2D proliferation 
of these cells (refer to Figure 5C within [132]). Additionally, we observed 4OHT upregulation of 
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SNAI1, suggesting that EMT may contribute to the 4OHT partial agonist-driven phenotypes 
observed (refer to Figure 6A within citation [132]). This striking and concerning observation, 
opposite of the intended roles of Tamoxifen in ER+ breast cancer cells, led to the follow-up studies 
provided in Chapter Two of this dissertation. The initial study suggested that differential ERα-
regulated gene expression and phenotypic programs exist in different histological subtypes of 
breast cancer (ILC versus IDC), and encourages researchers and clinicians to further examine the 
role for Tamoxifen in different subtype contexts.   
1.3.1.3 SERDs and AIs 
SERDs and AIs are two additional major classes of endocrine therapies that were not employed in 
this work, but are essential for any discussion regarding ER+ breast cancer. The most widely used 
SERD is Fulvestrant, or ICI 182,780 (ICI)[133]. ICI has a molecular affinity for ERα that is one 
hundred times greater than that of Tamoxifen, and upon binding causes rapid degradation of the 
receptor as a pure antagonist. While it may then seem more feasible to utilize ICI instead of 
Tamoxifen for the treatment of ER+ breast cancer, ICI is not currently FDA-approved as a first-
line therapy for breast cancer. The SWOG 0026 Phase III clinical trial recently evaluated the 
efficacy of ICI with the AI Anastrazole as a combination therapy in endocrine therapy-naïve 
patients and found that there was a significant improvement in progression free survival (PFS) in 
comparison to Anastrazole alone for postmenopausal ER+ patients[134]. Additionally, the FIRST 
Phase II and FALCON Phase III studies suggested a role for ICI as a first-line monotherapy 
compared to AIs[135, 136]. Despite these new clinical trials, it should be noted that the delivery route 
(painful intramuscular injection), slow absorption, and short maximum plasma concentration (5 
days) require patients to go to a treatment facility, usually monthly, for treatments[137]. In addition, 
ICI is not exempt from promoting its own mechanisms of resistance[138]. Ongoing development of 
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oral SERDs aims to combat the previously mentioned issues, but require much research to pursue 
their clinical development[139]. Though specific impacts for ILC in relation to ICI are not currently 
known, the previously described window trial by Jankowitz and colleagues will assess the effects 
of ICI in comparison to Tamoxifen or Anastrazole[121]. 
 AIs provide a different mechanism of targeting ERα as compared to Tamoxifen or ICI by 
inhibiting the enzyme aromatase that is responsible for the conversion of testosterone into E2[98]. 
Currently, third-line AIs include nonsteroidal Letrozole or Anastrazole, and steroidal 
Exemestane[140]. Nonsteroidal inhibitors prevent the binding of testosterone to aromatase by 
reversibly binding the enzyme, while steroidal inhibitors irreversibly bind to aromatase. The 
mechanism of AIs supports their utility in postmenopausal women in whom E2 is sourced from 
androgens in subcutaneous tissues. Though either Tamoxifen or AIs are acceptable modalities for 
postmenopausal women afflicted with ER+ breast cancer, the ATAC trial showed that Anastrazole 
significantly increased disease-free survival, time-to-recurrence, and reduced distant metastasis 
compared to Tamoxifen[141]. High levels of competing E2 in premenopausal women hinder the use 
of AIs in this patient subset, unless ovarian suppression is concomitantly administered by treatment 
with luteinizing hormone-releasing hormone (LHRH) therapy (e.g. Trelstar) or Salpingo-
oophorectomy[142, 143]. Oophorectomy is an irreversible ovarian ablation method, and many 
premenopausal women may not desire to either enter menopause prematurely or end their 
reproductive lives. Chemical suppression is beneficial, as it is reversible; recently completed 
clinical trials SOFT and TEXT have probed the combination of Tamoxifen/AIs and Trelstar in 
premenopausal women, and future studies will likely continue to evaluate the feasibility of these 
combinations. Beyond the previous clinical trials mentioned that included AI arms (BIG 1-98, 
ongoing PELOPS, and Jankowitz et al window trial), data obtained from AI window trial POETIC 
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will continue to yield both short-term information about ILC and IDC response to AIs and long-
term survival benefit with a follow-up of 10 years[120-122, 144].    
1.3.1.4 Reflections on Endocrine Therapy Clinical Studies Discussed and Overview 
Few clinical studies have been completed that adequately describe the specified outcomes for ILC 
patients who receive endocrine therapies. Data from retrospective studies have suggested worse 
long-term survival for ILC patients who receive endocrine therapy (Rakha et al, Pestalozzi et al), 
and outcomes may be worse for ILC patients who receive Tamoxifen as opposed to other endocrine 
modalities (BIG 1-98)[118-120]. These observations suggest a necessity for more clinical trials 
addressing the specific needs for this patient cohort, as well as long-term follow up to evaluate 
differences in survival and appropriate treatment during recurrence. The culmination of the 
ongoing clinical trials involving endocrine therapies of multiple classes will give the first 
information regarding the impacts of Tamoxifen, ICI, and AIs in ILC in new cohorts (Jankowitz 
et al window trial, PELOPS)[121, 122]. These data will be invaluable to our understanding of 










Table 2: Summary of Described Clinical Studies Involving Tamoxifen and ILC 





Smith et al[116] Retrospective 33 264 NS difference between ILCs and IDCs 
Rakha et al[118] Retrospective 415 2901 Worse long-term outcome in ILCs v IDCs 
Pestalozzi et al[119] Retrospective 767 8607 
Significant early survival 
advantage in ILC v IDC (p < 
0.01) followed by significant 
late survival advantage IDC v 







Jïrstrom et al[117] Retrospective 43 411 
NS difference between 
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early survival advantage that 
later converged with IDCs 
Retrospective 
BIG 1-98[120] Retrospective 324 2599 
Significant survival benefit for 
ILC patients who received 
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Anastrazole, and ICI will be 
compared for ILC patients 
with Ki67 and ER-regulated 







Combination of Palbociclib 
with endocrine therapies with 
Ki67 and pathologic complete 
response (pCR) measurement 
outcomes 
 
1.3.2 Other Chemotherapies/Targeted Therapies 
In contrast to IDCs, chemotherapy is rarely given as a primary monotherapy due to the 
predominance of ER+ lesions in ILC. Various clinical studies have indicated that ILCs can be less 
responsive to chemotherapy compared to IDCs[145-147]. Lips and colleagues further investigated 
this observation by combining retrospective data from two clinical trials, including n = 75 ILC 
patients[147]. Unlike previous studies, which focused on the definition of lobular histology as the 
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rationale for lower pCR, Lips et al adjusted for hormone receptor and HER2 status (ER+/HER2-) 
and found that this group of tumors was driving lower pCR for both ILC and IDC. As ILC is 
enriched for ER+/HER2-, this study identified the molecular phenotype, rather than lobular 
histology, as the rationale for ILC’s lower pCR. Many other retrospective studies have made these 
same observations, and thus, clinical recommendation has been to reserve chemotherapy 
monotherapy for ER- ILCs[148]. In the largest retrospective ILC versus IDC study by Chen and 
colleagues in 2017 (n = 85,048 ILCs; n = 711,287 IDCs), the observation of increased distant 
metastasis at late stage diagnosis for ILCs led to their suggestion that combination endocrine 
therapy and chemotherapy may be more beneficial for patients with ILC[30].   
 Chemotherapy or alternative targeted therapies as primary monotherapy may not be 
feasible for most ILC patients; however, combination of targeted therapy with endocrine therapy 
is currently under investigation. For example, the PELOPS trial by Metzger-Filho and colleagues 
will provide information regarding the combination of the CDK4/6 inhibitor, Palbociclib, with 
various endocrine modalities[122]. The rationale for use of CDK4/6 inhibitors lies in the need to 
combat endocrine therapy resistance[149]. Palbociclib directly inhibits the enzymes cyclin-
dependent kinases CDK4 or CDK6, master regulators of the transition through the restriction 
checkpoint and through G1 phase of the cell cycle. The pathways associated with CDK4/6 and 
cyclin D1 (CCND1) amplification have been uncovered as mechanisms of endocrine therapy 
resistance[150]. To this end, the PALOMA trials were performed to combine AI Letrozole with 
Palbociclib in ER+/HER2- advanced breast cancers. An ILC cohort was included in this study, 
however, the sample size was small and therefore result interpretation was limited (nILC Letrozole = 
19; nILC Letrozole + Palbociclib = 18). The success of these trials led to the FDA approval of combination 
Letrozole/Palbociclib in an accelerated manner and have now become a standard of care option in 
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the first and second-line setting. Interestingly, a role for CDK4/6 and CCND1 amplifications was 
also noted by our lab in the MDA-MB-134-VI de novo Tamoxifen resistance study, suggesting 
Palbociclib may influence mechanisms in ILC cells that display endocrine therapy resistance[132]. 
Another emerging pathway of interest to concurrently target in ILC ER+ tumors is 
PI3K/AKT/mTOR. The TCGA ILC working group previously described that ILCs have the 
highest PI3K/AKT activation signature of the breast cancer histological/molecular subtypes[67]. 
Oncogenic mutations in PIK3CA have also been described in ILC[94]. Various inhibitors for these 
pathways are currently under development by companies such as Novartis (BKM120, 
BYL719)[151]. Considering the observations made by the TCGA ILC working group and others, 
clinical trial design should include a focus on ILC patients. One pertinent analysis of an ILC cohort 
of notable importance to this pathway comes from the Phase III BOLERO-2 trial comprised of 
combination Exemestane and Everolimus (mTOR inhibitor) treatment of ER+ locally advanced or 
metastatic breast cancer patients with AI-refractory disease[152]. ILC patients in this study benefited 
from significantly increased PFS, suggesting rationale for follow-up studies with these inhibitors.  
Additional preclinical research and clinical trials are needed to assess the use of these and 
other inhibitors specifically in ILC. Increasing interest in ILC as a unique histological subtype with 
endocrine therapy resistance mechanisms will likely benefit ILC patients in the upcoming decades 
of clinical trials that have yet to be designed.     
1.3.3 Surgery and Radiation 
Surgery and radiation are common treatments for early-stage (stage I-III) breast cancer patients. 
For early-stage patients with ILC, breast conservation surgery (BCS) has been described to be as 
effective as total mastectomy, leading to no significant differences in survival[89, 153, 154]. Despite 
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these observations, late local recurrence is still an issue for patients who decline mastectomy[154, 
155]. This may be due to the significantly increased rate of positive margins often observed in ILC, 
which leads to re-excision of tissue or complete mastectomy upon recurrence[155]. Increased rates 
of mastectomy have been observed in the ILC subtype, as well as increased multifocal, 
multicentric, and contralateral occurrences[30, 89, 90]. A 15-year retrospective study performed by 
Fodor and colleagues observed the comparison of BCS in combination with radiation therapy and 
total mastectomy and concluded the same as studies performed since the 1990s[87, 89, 153, 154]. 
Radiation therapy is often combined with local resection of the primary ILC lesions, and offers an 
additional survival benefit to patients[156]. This may be due to the observation that ILCs have a 
higher radiosensitivity than IDCs[157-159]. Still, late recurrence continues to remain a clinical 
problem for ILC patients, suggesting that beyond the excision and radiation of disease, molecular 
control of these tumors is imperative to combatting disease progression, metastasis, and death.   
1.4 UNDERSTANDING THE IMPLICATIONS OF ENDOCRINE THERAPY 
RESISTANCE IN INVASIVE LOBULAR CARCINOMA 
Though understudied, the unique histological subtype of ILC has been observed as a separate 
disease from IDC within the overarching context of breast cancer. Differences in growth patterns 
(linear, discohesive; refer to Figure 2), molecular marker expressions (predominantly ER+), and 
responses to therapy (for endocrine therapy, refer to Table 2) are all paramount to understanding 
the clinical implications of appropriately treating ILC. Studies of the molecular controls for 
Tamoxifen resistance will contribute to informed clinical decisions that will likely influence 
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survival outcomes for patients[67, 71, 72]. This concept challenges the use of standard endocrine 
therapies for a large patient cohort, and required further investigation.  
As previously described, we observed 4OHT upregulation of SNAI1 in ILC cell line MDA-
MB-134-VI[132]. This upregulation of a vital component of the EMT program and the known loss 
of E-cadherin in this disease led us to consider the role of Tamoxifen in contributing to the EMT-
like phenotypes observed in ILC. We hypothesized that Tamoxifen resistance in ILC is driven 
by 4OHT upregulating resistance pathways that contribute to EMT-like phenotypes that 
have been observed in ILC, and hence metastatic progression. In addition to this hypothesis, 
we recognized the lack of research models available for ILC and undertook the task to 
establish and characterize a novel ILC cell line for use in current and future research 
endeavors. 
In the subsequent chapters, I describe studies performed to understand the upregulation of 
an EMT program in ILC, both basally and driven by 4OHT. We evaluated the feasibility of 
targeting this program, and suggest an alternative, understudied role for a well-studied protein 
involved in EMT. In the second part of this dissertation, we characterized a novel ILC cell line to 
assess its utility as an additional tool in the field of ILC research. Though outcomes of the testing 
of the initial hypothesis were unanticipated, these findings cumulatively represent a foundation for 
endocrine therapy resistance studies in ILC that will likely contribute to further development of 
appropriate treatments for this unique patient subset. 
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2.0  TARGETING THE EMT-LIKE PHENOTYPE IN INVASIVE LOBULAR 
CARCINOMA 
2.1 INTRODUCTION 
Loss of E-cadherin expression is the most common feature of ILC, and is highly characteristic of 
EMT, a major process in development and cancer[160, 161]. The transmembrane epithelial protein E-
cadherin is a calcium-dependent cell adhesion molecule that interacts with cadherin molecules on 
neighboring cells to create cell-cell contacts[29, 162-164]. E-cadherin is linked to the internal 
cytoskeleton through interactions with p120, β-catenin, and α-catenin, all components of the 
adherens junction. Loss of the components of the adherens junction leads to a loss of cell polarity 
and decreased cell-cell interactions, as well as mesenchymal phenotypes and tumorigenic 
behaviors.  
Recently, EMT has been associated with endocrine therapy resistance in breast cancer[165]. 
When IDC cell line MCF-7 is exposed to Tamoxifen to produce an outgrowth of resistant cells 
(MCF-7TAMR), crosstalk between ERα and growth signaling pathways (PI3K/AKT/mTOR) is 
upregulated; this upregulation drives resistance to endocrine therapies and promotes mesenchymal 
phenotypes[166]. Though this pathway crosstalk has been identified, the precise mechanism that 
drives the upregulation of this pathway remains to be elucidated. Other studies have also shown 
that Wnt/β-catenin signaling can be aberrantly driven in endocrine therapy resistant breast cancer, 
but these studies are restricted to IDC[167, 168]. These two facets have already been explored in ILC; 
mutations in PIK3CA and increased PI3K/AKT signaling have been described as major 
perturbations in ILC, and β-catenin is often not expressed in primary ILC tumors (Appendix B 
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Figure 64)[64, 67]. Further elaborations regarding these observations are currently ongoing in the 
ILC research field; for example, our lab has recently identified an increase of β-catenin mRNA 
expression in ovarian metastases from ILC patients relative to matched primary samples (Ahmed 
Basudan, MS unpublished results). However, the underlying mechanisms of Tamoxifen resistance 
that have been observed clinically, and pre-clinically by our group (see Chapter One), have overall 
remained unexplored. Further, the implications of EMT due to the genetic loss of E-cadherin in 
ILC have been unresolved. 
2.1.1 Loss of E-cadherin is a Key Step in EMT 
The generation of the neural crest during embryonic development is a prime example of 
appropriately timed EMT. This highly conserved process is observed from Xenopus to humans, 
and involves the direction of EMT transcription factor (EMT-TF) proteins such as SNAIL, SLUG, 
TWIST1, and ZEB1 to concomitantly downregulate the expression of epithelial marker E-cadherin 
while upregulating mesenchymal marker expressions (e.g. N-cadherin) to allow for cell migration 
and invagination of the early embryonic central nervous system[169]. However, cancer often hijacks 
this developmental process; in carcinogenesis and progression, EMT is a process by which tumor 
cells found in the primary lesion downregulate these same epithelial and upregulate these same 
mesenchymal programs to form a lesion[170]. This highly complex process allows for transition to 
a mesenchymal state by which cells lose cell-cell contacts, become more spindle-shaped, and gain 
phenotypes such as motility, migration, and invasion. Upon establishment at a metastatic site, cells 
will undergo the reverse process called mesenchymal to epithelial transition (MET) and will then 
continue to grow. This process, once thought to be fixed is instead plastic[161]. Cells can transition 
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from EMT to MET, and back again, or remain in an EMT-like state where certain beneficial EMT 
properties are consistently maintained by the cell. 
 Loss of E-cadherin is key to EMT because it is the molecular glue that holds cells together, 
whether normal or cancer. IDC cells often retain E-cadherin expression enabling them to grow 
together in clusters and to easily form cohesive masses[171]. As described previously, IDC cells 
undergo the typical EMT process to disseminate the cancer. However, as stated in Chapter One, 
ILCs do not express E-cadherin[71, 72, 172]. Unlike the epigenetic downregulation of E-cadherin that 
occurs during EMT, E-cadherin is lost at the genetic level in ILC. Typically, ILCs have mutations 
in CDH1 that lead to premature termination codons (PTC) or truncated forms of proteins that are 
degraded by the nonsense mediated decay (NMD) pathway[65, 172, 173]. Additionally, many ILCs 
harbor a deletion in one of the two alleles for CDH1, causing a LOH. This genetic loss and 
subsequent mRNA and protein losses of E-cadherin suggest that ILC cells are continually in an 
EMT-like state. The EMT-like phenotypes and mechanisms in ILC have not yet been detailed and, 
in the few studies available, are debated[64, 174]. Thus, we attempted to better define these entities 
in ILC, particularly in their relationship to commonly used therapeutic Tamoxifen.  
2.1.2 EMT is Known to Contribute to Tamoxifen Resistance via EMT-TFs Such as 
SNAIL 
Upregulation of EMT pathways has been shown to contribute to Tamoxifen resistance[175, 176]. 
Some studies have shown this upregulation contributes directly to metastatic phenotypes, while 
others have shown that this upregulation of programs causes stem-cell like phenotypes where cells 
are resistant to therapeutics given. A major driver of EMT, SNAIL, has also been shown to 
contribute to Tamoxifen resistance in breast cancer cells[130]. SNAIL is an evolutionarily conserved 
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29 kDa transcription factor that interacts with DNA at conserved E-box sites (CANNTG), often in 
conjunction with epigenetic repressor proteins such as lysine demethylase 1 (LSD1, KDM1A) to 
repress epithelial gene CDH1[177, 178]. SNAIL is also able to repress the expression of ESR1, which 
can lead to 4OHT-resistant phenotypes[179]. Outside of EMT, SNAIL has been observed to 
upregulate EGFR/ERK pathways in T47DTAMR cells to drive 4OHT resistance[130]. The direct 
mechanism of this upregulation remains unclear, but is not sufficiently recapitulated by repression 
of E-cadherin expression in T47D cells. These data suggest that SNAIL can also promote 4OHT 
resistance in EMT-independent manners. The implications of SNAIL in ILC have not been highly 
studied, and warranted further investigation in lieu of the observed 4OHT agonist promoting 
phenotypes in ILC cells[132]. 
2.1.3 Lack of Clarity in Role of EMT in ILC 
To date, only two studies have attempted to evaluate the expressions of EMT proteins in ILC. The 
first study, performed by King and colleagues, involved IHC staining of n = 36 patient mastectomy 
samples of pure LCIS (n = 11), concurrent LCIS/ILC (n = 18), or concurrent LCIS/IDC (n = 7) for 
EMT proteins SNAIL and TWIST1, along with other markers of interest[64]. One of their major 
conclusions included observing a significant increase from LCIS to LCIS/ILC to pure ILC for 
TWIST1 expression (p < 0.001). Although this pattern of increased expression was not present for 
SNAIL, they did note that most of these same lesions stained with 50%+ nuclear intensity, and 
that mRNA expressions for SNAI1 were higher in ILC than in IDC lesions. Due to their small 
sample size and inconclusive results, they concluded that further work was necessitated to evaluate 
the role of SNAI1 in ILC.  
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A more recent study performed by Simpson and colleagues also performed IHC staining 
on n = 148 primary ILC lesions for a panel of EMT markers including SNAIL, TWIST1, 
Fibronectin, Vimentin, N-cadherin, and others[174]. This study revealed that SNAIL expression was 
present in only 2.2% and TWIST1 expression in 3.8% of epithelial cells from tumors stained. 
However, it was noted that TWIST1 expression was present in stromal fibroblasts in lesions. In 
addition to their IHC, a meta-analysis of TCGA ILC tumor RNA expression was performed, and 
did not show a relationship between SNAI1 or TWIST1 expression and presence of WT CDH1 
allele. These highly opposing results to the study by King (high EMT-TF staining) and 
contradiction to a study by Yang and colleagues (70% of ILCs have high TWIST1 mRNA 
expression), created a lack of clarity for the expression of and potential role of EMT-TFs in 
ILC[180].   
With few studies regarding EMT proteins in ILC currently published, and the observed 
EMT-like phenotype of ILC cells, we felt it imperative to pursue a project to elucidate the 
expressions of these markers in ILC, understand their contribution to EMT-like phenotypes, and 
assess their potential role in endocrine therapy resistance. 
2.2 MATERIALS AND METHODS 
2.2.1 Tissue Culture 
MCF-7, T47D, MDA-MB-231, CAMA-1, ZR-75-30, SKBR3, MCF-10A, MDA-MB-134-VI, 
MDA-MB-330, HEK293T, and GP2-293 cells were obtained from the American Tissue Culture 
Collection (ATCC). BCK4 cells were generously given by the lab of Britta Jacobsen, PhD 
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(University of Colorado at Denver)[181]. Sum44PE cells were obtained from Asterand. IPH-926 
cells were obtained from Ulrich Lehmann, PhD (Hannover Medical School, Germany)[182]. 
Sum44/LCCTam (abbreviated Sum44TAMR) cells were provided by Rebecca Riggins, PhD 
(Georgetown University)[183]. T47D shRenilla and shCDH1 cells were generated by Tiffany Katz, 
PhD (unpublished). Briefly, cells were infected with retroviral miRE-LEPG containing 
shRenilla713 (referred to by Dr. Katz as “shRenilla”) or shCDH1 constructs (see Appendix A 
Table 9 for sequences). MDA-MB-134-VI rtTA cells were generated from retroviral infection of 
the rtTA construct by Kevin Levine, BS (a gift from Scott Lowe, PhD; Addgene#18782; modified 
by Dr. Lowe’s laboratory). The retroviral infection protocol is detailed in upcoming section 2.2.10. 
Cultures were maintained as follows: MCF-7 and MDA-MB-231 cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco#11965-092) supplemented with 5% Fetal 
Bovine Serum (FBS) (Gibco#26140-079), T47D and ZR-75-30 in Roswell Park Memorial Institute 
(RPMI) 1640 Medium (Gibco#11875-093) supplemented with 10% FBS, SKBR3 in McCoy’s 5A 
Modified Medium (Gibco#16600-082) supplemented with 10% FBS, MCF-10A in a 1:1 mixture 
of DMEM and Ham’s F-12 sans phenol red (Gibco#11039-021) supplemented with 5% Horse 
Serum (Sigma#H1270), 20 ng/mL EGF (Fisher#EA140), 0.5 mg/mL Hydrocortisone 
(Sigma#H6909-10ML), 100 ng/mL Cholera Toxin (Sigma Aldrich#C8052-1MG), and 10 µg/mL 
Insulin (Sigma#I2643-250MG), BCK4 in Modified Eagle Medium (MEM) (Gibco#11095-080) 
supplemented with 5% FBS, 1% Non-Essential Amino Acids (Thermo Fisher Scientific#11140-
050), and 1 nM Insulin, MDA-MB-134-VI in a 1:1 mixture of DMEM with Leibovitz-15 (L-15) 
(Gibco#11415-064) media supplemented with 10% FBS, MDA-MB-330, HEK293T, GP2-293, 
and CAMA-1 in DMEM supplemented with 10% FBS, Sum44PE in a 1:1 mixture of DMEM and 
Ham’s F-12 (F-12) (Gibco#11330-032) media supplemented with 2% dextran charcoal stripped 
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fetal bovine serum (CSS; Gibco#12676-027, Lot#1747185 or Gemini#100-119, Lot#A67F02H), 5 
mM Ethanolamine (Sigma#E0135-100ML), 1 µg/mL Hydrocortisone, 5 µg/mL Transferrin 
(Sigma#T2252-100MG), 10 nM Triiodothyronine (Sigma#T5516-1MG), 50 nM Sodium Selenite 
(Sigma#S9133-1MG), and 5 µg/mL Insulin, and IPH-926 in RPMI-1640 supplemented with 20% 
FBS, 10 mM HEPES (Fisher#15630080), 1 mM Sodium Pyruvate (ThermoScientific 
Hyclone#SH3023901), 2.5 g/L Glucose (Gibco#A2494001), and 10 µg/mL Insulin. Sum44TAMR 
cells were maintained in Modified Eagle’s Medium without phenol red (IMEM PRF) 
(ThermoFisher#A10488-01) supplemented with 2% CSS, 1 µg/mL Hydrocortisone, 5 µg/mL 
Insulin, and 500 nM 4-hydroxytamoxifen (4OHT, Sigma#H6278, dissolved in Dimethylsulfoxide 
(DMSO) (ATCC#4-X-5)). Tetracycline-Free FBS was a gift from Timothy Burns, MD, PhD. 
Routine culture was performed by removal of media, gentle rinsing of cells in 1X DPBS 
(Corning CellGro#21-031-CV), and treatment with 0.25% Trypsin-EDTA (Gibco#25200-056) 
until cells were in single-cell suspension. Trypsin was deactivated with base media, except for 
Sum44PE which were deactivated in DMEM supplemented with 5% FBS. Cells were always 
centrifuged at 14,000 rpm for 4 minutes at room temperature to completely remove trypsin prior 
to plating. Plating densities for given assays are included in each respective section, while routine 
maintenance was performed with no harsher than 1:2 or 1:3 splits for ILCs and 1:5 to 1:20 cells 
for IDC or control cell lines, as deemed necessary. Cells were authenticated at the University of 
Arizona Genetics Core by Short Tandem Repeat (STR) profiling, comparisons were made to 
available cell line profile databases, and cells used were taken from authenticated stocks stored in 
liquid nitrogen.  
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2.2.2 Estrogen Deprivation Studies 
Estrogen deprivation was performed as previously described[132]. Briefly, cells were either grown 
to 70-90% confluence and bulk deprived in T75 or T150 flasks, or plated directly into 12 (IDC: 
90,000 cells/well; ILC: 270,000 cells/well) or 6 welled (IDC: 1,000,000 cells/well; ILC: 2,000,000 
cells/well) plates for estrogen deprivation after seeding at set densities. Once cells were adherent 
for minimum 1.5 days in respective growth environments, they were washed 3-5 times per day, 
twice at each wash with half total volume of each container size (e.g. 1 mL wash in 6 welled plate, 
0.5 mL wash in 12 welled plate, etc.) with IMEM/PRF (ThermoFisher#A10488-01). Cells were 
then incubated in IMEM/PRF supplemented with 10% CSS with minimum one hour between wash 
sets. This was repeated for three days total. Splitting of cells was performed with phenol red free 
0.05% trypsin (Gibco#15400-054). Estradiol (E2) (Sigma#E2758) and 4OHT (described in 2.2.1) 
were dissolved in DMSO. ICI 182,780 (ICI) (Tocris Bioscience#1047) was dissolved in 100% 
Ethanol (Decon Laboratories#2701). 
2.2.3 Dose Response Assays 
Cells were seeded at 5,000 cells/well for IDCs or 15,000 cells/well for ILCs in six replicate wells 
of a 96 welled 2D (Fisher#353072) or flat bottomed ultra-low attachment (ULA) (Corning#3473) 
plate for each concentration of drug tested. Vehicle controls were always included, as well as 
media blank wells, and unused wells were given equal volume 1X DPBS to keep consistent surface 
tension across the plate, and to avoid evaporation of inner wells. Cells were seeded 1 to 1.5 days 
prior to treatment and typically collected at day 7 (D7) unless otherwise noted. Upon time point of 
collection, media was flicked off of 2D plates, extraneous media was wicked with a paper towel, 
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and plates were promptly frozen at -80°C. Plates were then thawed to room temperature and 
osmotic pressure was applied across entire plates at 100 µL/well water, with incubation at 37°C 
for one hour, and freezing plates again at -80°C. Plates were again thawed, and then Hoechst dye 
was applied and measurements assessed for fluorescence per manufacturer’s protocol of the 
FluoReporter Blue Fluorometric dsDNA Quantitation Kit (ThermoScientific#F2962) on a 
PerkinElmer 2030 Multilabel Reader with VictorX software. For ULA assessment, experimental 
plates were obtained from the incubator and brought to room temperature without exposure to light 
for approximately 30 minutes. Then, room temperature reagent from the CellTiter-Glo 
Luminescent Cell Viability Assay kit (Promega#PR-G7573) were prepared, applied, and stored per 
manufacturer’s protocol and added in a 1:1 ratio to well contents with rocking at 2 minutes without 
exposure to light to lyse cells, and further incubation at room temperature for 10 minutes to 
stabilize luminescence. Contents were then transferred to white walled luminescent plates 
(Corning#3912) and were measured on a Promega Glo-Max Microplate Reader. Data were 
corrected for each experiment by subtracting average background fluorescence (2D) or 
luminescence (ULA) from values, and normalizing to respective vehicle controls as “1.” Outliers 
were removed using Grubb’s Test at α = 0.05. Error was displayed as standard deviation of the 
mean (STDEV).   
2.2.4 Reverse-Phase Protein Array (RPPA) 
MDA-MB-134-VI and Sum44PE cells were seeded at 70-80% confluence and were incubated in 
media supplemented with serum or were deprived and treated for 24 hours ± 1 nM E2. Samples 
were collected in MD Anderson RPPA lysis buffer (1% Triton X-100 (Sigma#T8785-50ML) , 50 
mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF (New England 
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Biolabs#P0759L), 10 mM NaPyrophosphate, 1 mM Na3VO4 (New England Biolabs#P0758S), 10% 
Glycerol (Fisher#BP2291)), supplemented with 1X HaltTM Protease Phosphatase Inhibitor Cocktail 
(PPis) (Thermo Fisher Scientific#78430) by rocking samples on ice for 20 minutes. Samples were 
scraped into tubes and centrifuged for 10 minutes at 14,000 rpm at 4°C. Supernatant fractions were 
saved, quantified by BCA (Thermo Scientific#23225), and mixed with 1X final concentration 4X 
SDS sample buffer (40% Glycerol, 8% Sodium Dodecyl Sulfate (SDS) (Fisher#O2674-25), 0.25M 
Tris-HCl, pH 6.8, 1% β-mercaptoethanol (Sigma#M6250-100ML)) prior to freezing at -80°C. 
Samples were quantified for expression of 200 proteins or phospho-proteins at the Functional 
Proteomics Core of MD Anderson. Data were measured as log2-normalized, median centered 
values, and plotted with Multi Experiment Viewer v4.8.1.  
2.2.5 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
Triplicate samples of mRNA were isolated using manufacturer’s protocols of either the illustra 
RNAspin Mini Kit (GE Healthcare#25-0500-72) or NucleoSpin RNA Kit (Takara 
Clontech#740955.250) and quantified by NanoDrop Spectrophotometer (ThermoScientific). For 
deprivation studies, 250 ng of mRNA were converted to cDNA, and for endogenous studies 500 
ng of mRNA were converted, both using 1X iScript (BioRad#1708891) manufacturer’s protocol. 
Samples were assessed by qRT-PCR using SsoAdvancedTM Universal SYBR® Green Supermix 
(BioRad#1725274), Nuclease Free Water (Ambion#AM9938), and primers listed in Appendix A 
Table 5 with 0.5 µM final concentrations per reaction. All qRT-PCRs were performed in two to 
three independent experiments with data corrected to internal control gene RPLP0, outliers 
removed using Grubb’s Test for Outliers (standard α= 0.05), and shown relative to MCF-7 
(endogenous comparisons), Vehicle (deprivation studies) or Scramble/Renilla controls, if required. 
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2.2.6 Immunoblotting (IB) 
Protein was isolated according to experimental design. In deprivation studies, lysates were isolated 
using the MD Anderson RPPA protocol. Whole cell lysates in proteasomal degradation studies 
received vehicle (DMSO) or 5 µM MG132 (Sigma#M8699-1MG) (denoted in figure legend, as 
appropriate) for 2 hours prior to isolation. Protein in basal expression studies were isolated using 
RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40 (Sigma 
Aldrich#21-3277 SAJ), 0.5% NaDeoxycholate, 0.1% SDS) supplemented with 1X PPis, sonicated 
in a 4°C cup horn sonicator at amplitude 100 for 5-10 minutes total with 1-minute pulses and 30 
second pauses, and centrifuged for 10 minutes at 14,000 rpm at 4°C. All samples were quantified 
for protein concentration using BCA Assay and 25-50 µg per sample (noted in figure descriptions) 
were run on 15% or 4-15% gradient homemade SDS-PAGE gels with transfer to PVDF 
membranes (Millipore#IPFL00010). When utilizing the Odyssey system (LiCor), membranes were 
blocked using Odyssey PBS blocking buffer (LiCor#927-40000) for one hour and probed with 
primary antibodies listed in Appendix A Table 6. After removal of primary antibodies, blots were 
washed with 1X PBS-Tween 20 (0.1%) for 10 minutes, three times, followed by incubation in 
1:10,000 secondary antibodies (anti-mouse 800CW: LiCor#925-32210; anti-rabbit 800CW: 
LiCor#925-32211). Blots were again washed prior to imaging on the Odyssey Infrared Imaging 
system (LiCor). When using film methods, membranes were blocked in 5% BSA (Sigma 
Aldrich#A9647-500G) or 5% milk (Fisher#NC9121673) for one hour, and probed with primary 
antibodies as previously described. After removal of primary antibodies, blots were washed as 
previously, followed by incubation in 1:10,000 secondary antibodies (anti-mouse: anti-Mouse 
IgG, HRP-linked Ab Cell Signaling#7076; anti-rabbit: anti-Mouse IgG, HRP-linked Ab Cell 
Signaling#7074). Bands were visualized after application of Clarity Western ECL Substrate 
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(BioRad#170-5061) or Thermo SuperSignal West Femto Chemiluminescent Kit (Fisher#PI-34094) 
per manufacturer’s protocols, and exposure in a dark room to standard film (HyBlot CL 
Autoradiography Film, Denville Scientific#E3018), with standard film processing. Blots were 
stripped after two washes with rocking at room temperature in 1X PBS-Tween 20 (0.1%) for 5 
minutes, each, followed by application (with rocking) of 1X Newblot PVDF Stripping Buffer 
(LiCor#928-40032) diluted in water for 15 minutes, and washed again prior to blocking. Stripping 
was never performed more than twice, and Actin was always probed at the final step. 
2.2.7 Chromatin Immunoprecipitation (ChIP), IP Validation, and ChIP qRT-PCR 
For ERα ChIPs, MDA-MB-134-VI cells were 80-90% confluence prior to deprivation. After 
deprivation, cells were treated to ten-fold molar excess of top dose-response concentrations 
assessed for E2 or 4OHT. At the treatment time point, media was removed prior to further 
processing. At time of processing, cells were fixed in 1% Formaldehyde (Polysciences#18814) for 
10 minutes while rocked at room temperature. Quenching was then performed with 0.125 M 
Glycine for 5 minutes with rocking at room temperature, samples were washed three times in cold 
1X DPBS supplemented with 1X PPis, were scraped into tubes, and centrifuged at 2,500 rpm for 
5 minutes at 4°C. Supernatant were aspirated and pellets were resuspended in 1 mL Nuclei 
Preparation Buffer (5 mM PIPES, 85 mM KCl, 0.5% NP-40, pH 8.0, 1X PPis) with rotating at 4°C 
for 30 minutes. Samples were centrifuged at 2,500 rpm for 5 minutes at 4°C. Supernatant were 
again aspirated, and pellets were resuspended in 300 µL TE Buffer (10 mM EDTA, 50 mM Tris-
HCl, pH 8.1, 1X PPis, 1% final concentration SDS). Samples were sonicated at amplitude 100 for 
25 minutes total with 1 minute pulses and 30 second pauses, and then centrifuged at 14,000 rpm 
for 10 minutes at 4°C. Supernatant were collected and portions of samples were checked for DNA 
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shearing between 200-700 base pairs. Briefly, 10 µL of sample were combined with Elution Buffer 
(1% SDS, 0.1 M NaHCO3), boiled for 15 minutes at 100°C, cooled to room temperature, incubated 
with 1 µL of 10 mg/mL RNase A (Qiagen) for 15 minutes at room temperature, purification of 
DNA using manufacturer’s protocol of the QiaQuick PCR Purification Kit (Qiagen#28106), and 
15 µL of DNA product were run on a 1% agarose gel supplemented with 1X SYBR Safe (Thermo 
Scientific#S33102) with 1X final concentration DNA Loading Buffer (Thermo Scientific#R0611) 
against GeneRuler 1 kb Plus DNA Ladder (Thermo Scientific#SM1331) by standard 
electrophoresis, with assessment of smears by ultraviolet (UV) light. Upon confirmation of 
shearing, samples were quantified by BCA as previously described, portions of samples were 
saved for input use, and remaining samples were diluted 1:10 in Dilution Buffer (1% Triton X-
100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.1, 1X PPis) and were precleared with 
5 µg Rabbit Immunoglobulin G (IgG) and 135 µL Protein G-Sepharose (Thermo Fisher#10-1243) 
by rotating at 4°C for 2 hours. Beads were pelleted by centrifugation at 1,000 rpm for 1 minute at 
4°C, and supernatant were collected. Samples were split into fractions for IgG or antibody of 
interest (Appendix A Table 7) for immunoprecipitation (IP) or chromatin immunoprecipitation 
(ChIP) with rotation overnight at 4°C. Samples were given 55 µL Protein G-Sepharose beads the 
next morning, and samples were rotated for 1 hour at 4°C prior to centrifugation at 1,000 rpm for 
1 minute at 4°C. For IP sample verification, samples were washed three times in 1X DPBS 
supplemented with 1X PPis by rotating at 4°C for 5 minutes, and centrifugation at 1,000 rpm for 
1 minute at 4°C; upon completion of washes, protein were eluted from beads and samples were 
processed as previously described by standard immunoblotting technique against 10% input. For 
ChIP samples, pelleted samples were washed sequentially by rotating at 4°C for 5 minutes each, 
followed by centrifugation as previously with the following: TSE I (1% Triton X-100, 2 mM 
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EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl, 1X PPis), TSE II (1% Triton X-100, 2 mM 
EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl, 1X PPis), Buffer III (0.25 M LiCl, 1% NP-40, 
1% Deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1, 1X PPis) and twice with TE Buffer. 
ChIP samples were then combined with 100 µL Elution Buffer, vortexed, and incubated at 65°C 
for 30 minutes with rotation. Samples were centrifuged and supernatant were collected. Eluates 
were heated at 65°C for 6 hours along with input fractions that were combined with Elution Buffer. 
DNA was isolated using the Qiagen PCR Purification Kit protocol. ChIP qRT-PCR were 
performed using input samples diluted 1:5 and samples diluted 1:3, with 5 µL per technical 
replicate well. ChIP qRT-PCR Primers used are listed in Appendix A Table 8. ERα ChIPs were 
performed twice, independently. Data were analyzed using fold enrichment over IgG controls with 
removal of outliers by Grubb’s Test (α = 0.05), and displayed with STDEV for technical triplicates.  
2.2.8 Transient siRNA Knockdown Assays 
Cells were reverse transfected by LipofectamineTM RNAiMAX manufacturer’s protocol (Thermo 
Fisher Scientific#13778-150). For preliminary assessments, 10, 25, 50, or 100 nM were utilized to 
assess best dose. For subsequent assays, 10 nM were utilized for SNAI1 or KDM1A knockdown 
assays, and 25 nM were used for CDH1 (previously assessed by others in lab to be effective). For 
siSNAI1 assays, ON-TARGETplus Non-targeting Pool (Dharmacon#D-001810-10-05) or ON-
TARGETplus Human SNAI1 siRNA (Dharmacon#L-010847-01-0020) were used. For siKDM1A 
assays, the same siScramble was used as in siSNAI1 assays, and ON-TARGETplus Human 
KDM1A siRNA (Dharmacon#J-009223-07 or J-009223-08) were used. For siCDH1 assays, 
siGENOME Non-targeting siRNA Pool#2 (Dharmacon#D-001206-14-50) or siGENOME Human 
CDH1 siRNA Pool (Dharmacon#M-003877-02-0010) were used. In basal expression assays, siRNA 
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complexes were generated in Opti-MEM® I (Gibco#31985-070) for 24-48 hours prior to 
assessment of downstream applications. In deprivation assays, siRNA complexes were generated 
in Opti-MEM® I without phenol red (Life Technologies#11058-021). 
2.2.9 2D, ULA Proliferation Assays 
Cells were seeded at densities previously assessed to be appropriate given cell size and doubling 
time (Matthew Sikora, PhD unpublished data). Cells were plated in technical replicates of 3-6 at 
15,000 (ILC) or 5,000 (IDC) cells/well, and plates were collected at appropriate time points for 
each assay as previously described. Data were plotted after correction to background media 
fluorescence relative to initial day values, outliers were removed by Grubb’s Test (α = 0.05), and 
error displayed with STDEV. Non-linear exponential regressions were fitted to each data set and 
were used to test differences in rates of growth. ULA proliferation was performed as previously 
described with data processing as performed in this section. Inducible cells were treated to 
Doxycycline Hyclate (Dox; Sigma-Aldrich#D98981-1G; dissolved in water) in doses indicated in 
experimental legends. 
2.2.10 Generation of Virus for Stable Knockdown/Overexpression Cell Lines or Transient 
Virus Studies 
Plasmid information for Lentiviral shScramble/SNAI1, miRE-LEPG Retroviral shRenilla/SNAI1, 
LT3GEPIR shRenilla/SNAI1, pENTR221 SNAI1 ORF 124, Lentiviral W118, pINDUCER20-
SNAI1, and information regarding packaging plasmids are available in Appendix A Table 9, 10. 
Standard restriction enzyme digests were performed to generate backbones of interest and products 
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were ligated with T4 DNA Ligase (New England Biolabs#M0202M). Gateway Cloning was 
performed by manufacturer’s protocols using Gateway LR Clonase II Enzyme Mix 
(Invitrogen#11791-020). Third generation packaging systems were utilized in HEK293T 
(Lentiviral) or HEK293T-GP2 (Retroviral) cells by polyethylenimine (PEI) transfection (1 µg/mL; 
Polysciences#23966-2) with a 3:1 ratio of PEI to transfected DNA constructs. shPASHA was 
always transfected with shRNA of interest to inhibit the transfected cells’ capability of degrading 
potentially lethal shRNA complex generation. Target media for each respective cell line was placed 
on virus producing cells and collected at the 36- and 48-hour time points, filtered through 0.45 µm 
filters (Fisher#09-754-21), and combined with 1 μg/mL Polybrene (Sigma#107689-10G) to infect 
target cells. Target cells were recovered after two infections in media without antibiotics for two 
days, and then split into 1 µg/mL Puromycin (Life Technologies#A11138-03) or 1.25 mg/mL 
Geneticin G418 (Invitrogen#10131-035), depending upon the backbone of interest. Cells were 
always maintained in selection antibiotic.  
For transient virus assays, virus containing media were generated as in the previous 
paragraph, but were only placed on cells at the 24- to 36-hour time point post PEI transfection, and 
were removed 24 hours post infection of target cells with appropriate BSL2+ protocol. 
Downstream assays for mRNA, protein, and proliferation were performed as previously described 
(see 2.2.5, 2.2.6, and 2.2.9). 
2.2.11 Matrigel, Collagen I Assays 
For Matrigel (BD Biosciences#354230) assays, cells were seeded at 2,500 cells/well (MDA-MB-
231), 5,000 cells/well (MCF-7), or 15,000 cells/well (ILCs) in single wells of 8-welled LabTek 
Chambered Coverglass slides (Fisher#155409). Media was supplemented with 
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Penicillin/Streptomycin (Hyclone#SV30010). Media were changed every four days, and “on top” 
cultures were supplemented with 2% Matrigel each time a change occurred. ILC wells were 
additionally treated to control or Dox (0.5 µg/mL). Collagen I (Corning#354249) was utilized for 
Collagen assays in 24-welled plate formats with duplicate wells for each embedded cell 
type/treatment. Colonies were imaged on a Nikon Hammamatsu camera under phase microscopy 
of an Olympus IX83 (Olympus) inverted microscope. 
2.2.12 Mammosphere Assay 
Mammosphere media was composed of the following: 1:1 DMEM/Ham’s F-12 media, 20 ng/mL 
bFGF (BD Biosciences#354060), 20 ng/mL EGF (BD Biosciences#354001), B27 (Gibco#17504), 
2.5 mL Penicillin/Streptomycin, and 4 µg/mL Heparin (Sigma#H4784). Cells were cultured in 
triplicate wells of six welled ULA Plates (Corning#3471). Cells were trypsinized as previously 
described, centrifuged, and resuspended in 1X DPBS to remove serum from base media. Cells 
were then counted by Hemacytometer and were plated in single-cell suspensions for primary 
cultures; MCF-7 cells were plated at 20,000 cells/well in each of the replicate wells, and inducible 
ILC cells were plated at 60,000 cells/well in each of the replicate wells for control or Dox (0.5 
µg/mL) treatment. Plates were agitated by brief shaking every three days to prevent clumping of 
spheres, and 1 mL media (with or without Dox) were replenished every three to four days. 
Secondary and tertiary cultures were generated by hand-counting, collecting spheres, 
centrifugation at 1,000 rpm, trypsinization with 0.05% trypsin (Gibco#25300-054) for 10 minutes 
with refluxing of cells every 5 minutes, deactivation of trypsin with mammosphere media, and 
centrifugation at 1,000 rpm. Cells were counted with a Hemacytometer and plated for subsequent 
cultures at 2,000 (MCF-7) or 6,000 (ILCs) cells/well to enrich for stem-like cells. Spheres were 
 48 
imaged on days 4, 10, 17, 24, and 34 using a Nikon Hammamatsu camera under phase microscopy 
of an Olympus IX83 (Olympus) inverted microscope. Spheres larger than ~50 µm were hand-
counted on days 10 (primary), 20 (secondary), and 34 (tertiary) using a standard bright field 
microscope. 
2.2.13 Flow Cytometry Assays 
Cells were plated in triplicate at 300,000 cells/well in 6 welled plates, treated per experimental 
design ± 0.5 µg/mL Dox, and were collected by standard trypsinization and centrifugation, diluted 
to 1 x 106 cells/mL in standard media, with pellets were treated to 20 µg/mL Hoechst 33342 (Life 
Technologies#H3570) at 37°C, 5% CO2 while protected from light for 30 minutes. Just prior to 
measuring, 2.5 µg/mL Propidium Iodide (PI; Sigma#P4170) were spiked into the mixture. Cells 
were quantified on a BD LSR II Flow Cytometry machine with compensation controls previously 
provided for BCK4 cells by Nilgun Tasdemir, PhD. ALDH Flow Cytometry was performed by 
Jian Chen, MS, using the ALDEFLUOR protocol (STEMCell Technologies#01700). 
2.2.14 Immunohistochemistry (IHC) 
Formalin fixed paraffin embedded (FFPE) pellets were generated for BCK4 pINDUCER20-SNAI1 
± Dox and MDA-MB-134-VI as follows: upon collection of cells, media were removed, and cells 
were washed with 1X DPBS twice. Cells were then fixed in 10% neutral buffered formalin (Sigma 
Aldrich#F554-4L) for three hours at 4°C. Formalin was decanted to half-volume, and cells were 
scraped into a conical for centrifugation at 1,400 rpm for 4 minutes at room temperature. Pellets 
were transferred in small volumes of formalin to 1.5 mL centrifuge tubes and were centrifuged as 
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previously, with removal of all formalin prior to freezing at -80°C for one hour. Samples were 
processed for embedding in paraffin by the Magee-Womens Research Institute Histology and 
Microimaging Core facility and were cut at 5 µm sections on a standard microtome for staining on 
25 x 75 x 1.0 mm microscope slides (Fisher#12-550-20). Tissue Microarray (TMA) for ILC and 
IDC tumors was accessible from clinical samples obtained through the Health Sciences Tumor 
Bank (HSTB) at Magee-Womens Hospital, previously prepared by our lab (ILC samples from 
IRB#PRO11110119; IDC samples from an additional IRB, protocol number unavailable at time of 
dissertation submission). IHC was performed with SNAIL Cell Signaling antibody (Cell 
Signaling#3895S) with the collaboration of Ms. Kara Burlbaugh. 
2.2.15 Transient SNAIL-LSD1 Overexpression Study in HEK293T Cells and Endogenous 
Co-IP 
SNAIL-HA (a gift from Paul Wade, PhD; Addgene#31697) and LSD1-FLAG (collaboration with 
Yi Huang, PhD; originally purchased by Dr. Huang from GeneCopoeia) were transiently 
transfected into HEK293T cells using Lipofectamine3000 manufacturer’s protocol for 48 hours 
(ThermoFisher Scientific#L300015). Isolated samples were processed as previously described for 
IP (using Cell Signaling SNAIL antibody) and IB. Co-IPs were performed with ChIP-Grade 
antibodies using the ChIP IP protocol. 
2.2.16 Soft Agar Anchorage Independent Assays 
Soft Agar Anchorage Independent assays were performed in 35 mm culture dishes 
(Falcon#353001) arranged in 15 cm2 dishes with a constantly replenished 35 mm culture dish 
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containing water, as a modified humidifier chamber to prevent drying of agar. Due to length of 
assays, Enhanced Media (EM) was generated for each respective cell type, containing basal media, 
20% serum final concentration, and 2% NEAA. First, lower 0.6% final concentration agar mixtures 
were generated (Bacto-Agar; BD Biosciences#214050; autoclaved 1.2% stock in sterile water) by 
microwaving solidified agar and combining with EM for each respective cell type as a diluent. 
Agar was immediately incubated in a ~42-45°C water bath to prevent need to continue to 
microwave and compromise use of agar, and to not shock or kill cells in subsequent steps. Once 
lower layers were solidified at room temperature for approximately 30-45 minutes, upper layers 
of agar mixtures were generated. Cells were plated at 10,000 cells/dish for IDCs (standard density) 
or ILCs (low density), or 50,000-100,000 cells/dish for ILCs (high density, denoted in figure 
legends) gently on top of 0.6% layers. Upper layers contained 0.4% final concentration of agar, 
3% final concentration NEAA, and cells. Agar was always added last to the mixture prior to 
plating, as it solidified quickly and would cause clumps if not done in this fashion. Agar was added 
slowly enough to dispense evenly across the top layer and not to slip beneath 0.6% layer, but 
quickly enough to not induce clumps. Triplicate samples were generated for each cell type or 
plating density. “Blanks” containing no cells and only EM, additional 1% NEAA, and 0.4% final 
concentration agar were generated for each media type to be used in crystal violet background 
subtraction at the end of the experiment. Once all plates solidified for an additional 30 minutes at 
RT, they were placed in the modified humidifier chamber and into the respective incubator setting. 
Humidifier chambers were replenished as required, and dishes were collected at D14-28, and stained 
with 1 mL/dish 0.005% crystal violet (Sigma Aldrich#C3886) for 15 minutes at room temperature 
prior to washing agar gently with 1 mL/dish sterile water, twice. Blank and experimental dishes 
were then imaged immediately on an SZX16 (Olympus) dissecting microscope with a Nikon DP73 
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camera under bright field at 0.8X magnification to obtain whole field views. Colonies were 
counted using cellSens Dimension (Olympus) software on a consistent region of interest (ROI) 
after subtraction of background crystal violet staining. Colonies were defined as measured objects 
with a radius of 25 µm or greater. Debris or aberrancies in the agar were manually removed from 
counts. Representative images of colonies were obtained by bright field imaging at 10X 
magnification under an inverted IX83 microscope (Olympus).     
2.2.17 Protein Micropatterning/Coating Studies 
Protein micropatterning was performed in the Adam Feinberg, PhD laboratory located at Carnegie 
Mellon University (CMU). All materials and equipment except glass coverslips and tissue culture 
plates/media were provided by his laboratory. Standard polydimethylsiloxane (PDMS) 
micropatterning stamps with 20 µm linear patterns were generated by Rebecca Duffy, PhD and 
Rachelle Palchesko, PhD, who also assisted in training of the subsequent procedures. Glass 
coverslips (Fisher#12-545-86) were sonicated for 1 hour in 95% Ethanol, and were then dried in a 
sterile environment for 30 minutes prior to spin coating. PDMS was generated by mixing 10 parts 
Dow Corning Sylgard 184 elastomer base with 1 part Sylgard 184 elastomer curing agent, and 
degassing for 10-15 minutes in a THINKY Super Mixer. PDMS was used within 2 hours or less 
after generation. A standard spin coating machine was utilized to evenly coat the surface of each 
coverslip as follows: 1/3rd area of the coverslip was coated with a drop of PDMS, and then a 
sequence of Dispense 1, Ramp 5 – RPM 500 – Dwell 5, Ramp 5 – RPM 1000 – Dwell 5, Ramp 
10 – RPM 3000 – Dwell 10, Ramp 10 – RPM 4000 – Dwell 60, Ramp 10 – RPM 2000 – Dwell 
15, Ramp 10 – RPM 1000 – Dwell 10, and Ramp 5 – RPM 500 – Dwell 5 was performed 
(approximately 2 minutes and 45 seconds run time per coverslip). Coverslips were cured in a 65°C 
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oven overnight prior to patterning. The next day, micropatterning stamps were sonicated in a 
beaker with 50% Ethanol for 30 minutes and coverslips were treated to UV light and ozone gas to 
sterilize for 15 minutes. Stamps were dried using a nitrogen gun prior to use and after washing in 
between uses. Fibronectin (50 µg/mL final concentration), Collagen I (200 µg/mL final 
concentration), Collagen IV (200 µg/mL final concentration), and Laminin I (200 µg/mL final 
concentration) were prepared in sterile water, and were stored on ice during use. For the first 
coating process, each protein of interest was coated onto the surface of a stamp (200 – 300 µL 
mixture) and incubated at room temperature for one hour. The stamps were then rinsed in sterile 
water to remove extra protein and were applied to respective coverslips with slight pressure to 
generate diffraction pattern. The stamps were then rinsed with water, dried with a nitrogen gun, 
coated again (~100 µL/stamp after the first coating) with 10-minute incubation, and repeated 
stamping process. Upon completion of stamping, coverslips were submerged in 1% (w/v) Pluronic 
F-127 solution for five minutes to inhibit cell/protein adhesion to the regions between stamped 
protein lines. Coverslips were stored in 1X DPBS in 6 welled plates at 4°C until being used within 
2 weeks of generation. Complete protein coating studies were performed with the same 
concentrations described in the previous paragraph, but without micropatterning, on PDMS spin-
coated coverslips. Uncoated glass coverslips were used as controls for cell adhesion. Batimastat 
was a gift from Dr. Adam Feinberg. 
2.2.18 Statistics 
Technical or biological replicates were described in respective sections and detailed in figure 
legends. Experiments were repeated at minimum 2-3 times, unless otherwise noted, and data were 
combined when able or displayed as representative of multiple experimental outcomes. 
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Corrections, error, and normalization were also described in each respective section, and are 
highlighted in figure legends. Grubb’s test for outliers was used for data sets containing three or 
more values to remove outliers (α = 0.05). Graphs were generated in GraphPad Prism 5.0 or using 
R statistical software. Dose responses were fitted with three variable parameters to assess IC50 
values. 2D and ULA proliferation curve fitting was previously described with comparisons of rates 
between best-fit exponential growth curve fits. Two comparisons were performed with Students t-
test, and for data sets with more than two groups, One Way ANOVA followed by Tukey’s post-
test were performed (α = 0.05). Kevin Levine, BS and Ahmed Basudan, BS assisted with statistical 
analyses on clinical sample data (denoted in Figure legends). A collaboration with Li Zhu, MS of 
the George Tseng, PhD biostatistics laboratory at the University of Pittsburgh was utilized for 
comprehensive genomic analyses. 
2.3 RESULTS 
2.3.1 4OHT Acts as a Partial Agonist in Some ERα Positive ILC Cell Lines 
We previously identified a role for de novo 4OHT resistance in ILC cell line MDA-MB-134-VI; 
we observed that 4OHT treatment caused an induction of 2D proliferation in MDA-MB-134-VI 
over vehicle control treated cells[132]. We expanded our ILC panel to test for this partial agonist 
proliferation phenotype to include all ERα+ ILC cell lines available, and included E2 dose 
responses. The 4OHT partial agonist induction of 2D proliferation was reproducible in MDA-MB-
134-VI (1 µM 4OHT = +1.70 fold change (FC) relative to vehicle), however, it was not apparent 
in Sum44PE, BCK4, or MDA-MB-330 (Figure 4A). E2 induced proliferation in MDA-MB-134-
 54 
VI, Sum44PE, and BCK4, and only mildly in MDA-MB-330. This was not surprising, as the 
MDA-MB-330 have minimal ERα activity[132, 184]. Our lab has recently observed a preference for 
ILC cells to grow in ULA conditions (Nilgun Tasdemir, PhD data unpublished), so we asked if 
this 4OHT-inducing growth phenotype was also present in ULA conditions in a ULA proliferation 
assay with the maximal dose response concentrations from the 2D conditions (1 µM 4OHT or 1 
nM E2). Though E2 treatment significantly induced ULA proliferation (***p < 0.0001), 4OHT 
treatment did not induce proliferation in this environment, and instead had a suppressive impact 
on proliferation as compared to vehicle (**p = 0.0002) (Figure 4B). In contrast, the control 2D 
proliferation assay showed +1.8 FC 4OHT-induced proliferation relative to Vehicle control (**p 
= 0.0046). We thus concluded that 4OHT induced proliferation in MDA-MB-134-VI in the 2D 







Figure 4: 4OHT Induction of 2D Proliferation in MDA-MB-134-VI 
(A) E2 deprivation followed by treatment with increasing doses of 4OHT or E2 for 6-7 days was 
performed in ERα+ ILC cell lines. Non-linear, three parameter fits were applied to data. Data are 
representative of a single experiment with six technical replicates ± STDEV, except for MDA-
MB-134-VI, which was repeated independently at minimum three times with similar results. (B) 
2D and ULA proliferation were measured in MDA-MB-134-VI cells over 8 days with respective 
top dose response concentrations of 4OHT or E2. Exponential growth curves were fitted to four 
technical replicates ± STDEV, and rates were compared between vehicle and 4OHT or E2 treated 
cells (*p < 0.05, **p < 0.005, ***p < 0.0005). Data are representative of two independently 
performed experiments with similar results in both (2D), or a single experiment (ULA). 
 
2.3.2 SNAIL is Upregulated by 4OHT and E2 Treatments 
We next decided to probe the potential mechanism behind this 4OHT-driven induction of 2D 
proliferation in MDA-MB-134-VI cells. First, we mined previously generated NanoString array 
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data, which revealed EMT-TF SNAI1 to be the most potent 4OHT- and second most potent E2-
induced gene in MDA-MB-134-VI (+1.389 and +2.012 log2FCs, respectively, relative to time-
matched Vehicle control at 24 hours)[132]. To more comprehensively study the effects of E2 on 
protein regulation in ILC, we performed RPPA in the MDA-MB-134-VI and Sum44PE cells. 
SNAIL was upregulated by E2 in both cell lines, more potently in MDA-MB-134-VI (+1.491 
log2FC) and less robustly in Sum44PE (+0.185 log2FC) (Figure 5). ERα activating 
phosphorylation at S118 was the only other protein target on this array that was more highly 
induced than SNAIL in MDA-MB-134-VI cells. Additionally, there were various other targets that 





Figure 5: RPPA Reveals SNAIL is Induced by E2 in MDA-MB-134-VI and Sum44PE 
MDA-MB-134-VI and Sum44PE cells were deprived (Cont) of exogenous E2 for a period of three 
days followed by treatment with 1 nM E2 for 24 hours. Control, E2-treated, and Full Serum (FS) 
controls were assessed by RPPA. Single replicate samples were isolated and measured for each 
cell line and condition. Data were sorted by top ten MDA-MB-134-VI E2-upregulated and top ten 
E2-downregulated proteins. Extracted data for SNAIL is depicted in the table. 
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We next validated the E2 and 4OHT mRNA upregulation of SNAI1 in our panel of ILC 
ERα+ cell lines, and tested potential upregulation in two IDC ERα+ cell lines, MCF-7 and T47D. 
Upregulation of SNAI1 by 4OHT was observed in MDA-MB-134-VI and Sum44PE qRT-PCR, 
while not present in the other two ILC or two IDC cell lines tested (Figure 6). Instead, E2 
upregulated SNAI1 in most of the cell lines, though most significantly in MDA-MB-134-VI (***p 




Figure 6: SNAI1 Expression is Upregulated by 4OHT in Some ILC Cells, But Not IDC Cells 
SNAI1 qRT-PCR assessment of ILC (red) and IDC (blue) cells was performed at 24 hours post 
deprivation/treatments (Vehicle 0.1% DMSO). Quantifications are a representative single 
experiment ± STDEV of technical triplicates, with similar results in two additional independently 
performed experiments. Asterisks depict significance compared to Vehicle from One Way 




We also tested if E2 or 4OHT upregulation was restricted to SNAI1, or if it could impact 
expression of other family members such as SNAI2 or SNAI3. SNAI2 was only expressed in MCF-
7 and not significantly regulated by 4OHT or E2 treatments, and SNAI3 was not significantly 




Figure 7: SNAI2 and SNAI3 are Not Upregulated by 4OHT or E2 in ILC Cells 
qRT-PCR performed for (A) SNAI2 or (B) SNAI3 revealed that neither 4OHT or E2 could 
upregulate the expression of these genes in ILC cells. N.D. indicates “Not Detected.” 
Quantifications are a representative single experiment ± STDEV of technical triplicates (Vehicle 
0.1% DMSO). Asterisks depict significance compared to Vehicle from One Way ANOVA 
followed by Tukey’s post-test (*p < 0.05, **p < 0.005, ***p < 0.0005). 
 
 
In addition, 4OHT or E2 treatments did not impact expression of TWIST1, another prominent 
EMT-TF that has been noted to be expressed in LCIS and ILC (Appendix B Figure 66)[180]. 
Next, we examined expression of the SNAI1/SNAI2/SNAI3 family members by qRT-PCR 
in Sum44TAMR cells, a cell line model of 4OHT resistance[183]. This model was derived by selecting 
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for outgrowth of Sum44 cells in increasing concentrations of 4OHT over 18 passages. SNAI1 
baseline expression was decreased in the Sum44TAMR cells relative to parental cells, indicating that 
SNAI1 was not causative for 4OHT partial agonist activity in Sum44TAMR cells (Figure 8). SNAI2 
was not expressed in Sum44TAMR, and SNAI3 expression was not significantly impacted.  
 
 
Figure 8: SNAIL Family Members are Not Upregulated in Sum44TAMR Cells Relative to 
Parental Cells 
qRT-PCR was performed in parental Sum44 or derived Sum44TAMR cells. Two independent 
experiments of Sum44TAMR expression are shown. N.D. indicates “Not Detected.”  Quantifications 
for each respective bar are a representative experiment ± STDEV of technical triplicates. Asterisks 
depict significance compared to Parental from One Way ANOVA followed by Tukey’s post-test 
(*p < 0.05, **p < 0.005, ***p < 0.0005). 
 
 
We then asked if this 4OHT-SNAI1 induction was ILC-specific, or if loss of E-cadherin 
was sufficient to induce the 4OHT agonist induction of SNAI1. To test this question, we performed 
E2 deprivation and transiently knocked down CDH1 in IDC cell line T47D with treatments of 
4OHT or E2, as previously performed. SNAI1 was not induced by 4OHT in this setting, and only 
E2 induction of SNAI1 was decreased by loss of CDH1 expression (Figure 9A). As transient 
knockdown of CDH1 is not as complete as shRNA knockdown, we used T47D shCDH1 cells 
generated previously in our lab to test the same question. Stable lentiviral knockdown of CDH1 
was incapable of producing the 4OHT-SNAI1 induction, although it should be noted that we did 
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not detect the E2 induction in these cells (Figure 9B). Finally, we chose to use CAMA-1 and ZR-
75-30, two E-cadherin mutant cell lines that have been described as “ILC-like” to test the 
hypothesis that mutational loss of E-cadherin is sufficient to induce 4OHT-agonist induction of 
SNAI1[186]. First, we confirmed ERα positivity and complete loss of E-cadherin protein by IB 
(Figure 9C). Then, we performed the E2 deprivation and treatment followed by qRT-PCR. Still, 
mutated E-cadherin cell lines were not capable of producing the 4OHT-driven induction of SNAI1 
(Figure 9D). We thus concluded that loss of E-cadherin expression was not sufficient to allow for 










Figure 9: Loss of E-cadherin is Insufficient to Cause 4OHT-Induction of SNAI1 
(A) T47D cells were transiently reverse transfected with 25 nM siScramble (siScr) or siCDH1 in 
an E2 deprivation assay with qRT-PCR for SNAI1 or CDH1. (B) Stable shRenilla, or two of 
shCDH12,150 were utilized in an additional E2 deprivation/qRT-PCR assay. (C) Protein levels of 
E-cadherin, ERα, or internal control Actin were measured in a panel of IDC (blue), ILC (red), or 
ILC-like (orange) cell lines with 50 μg/lane. (D) E2 deprivation assay in two ILC-like cell lines, 
CAMA-1 and ZR-75-30, with qRT-PCR for SNAI1 was performed. For qRT-PCRs, 
quantifications for each respective bar are a representative single experiment ± STDEV of 
technical triplicates (Vehicle 0.1% DMSO). Asterisks depict significance compared to (A) siScr 
Vehicle, (B) shRenilla Vehicle, or (D) Vehicle from One Way ANOVA followed by Tukey’s post-
test (*p < 0.05, **p < 0.005, ***p < 0.0005). Protein is representative of a single experiment. 
 
 
Finally, we wanted to confirm that this transcriptional regulation lead to modulation of 
SNAIL protein levels. We performed E2 deprivation in MDA-MB-134-VI and Sum44PE, and 
found that both 4OHT and E2 treatments induced SNAIL protein expression at the 24-hour time 
point tested (Figure 10, Appendix B Figure 67). These data confirmed our previous qRT-PCR data 
that SNAIL is upregulated by 4OHT in a subset of ILC cell lines (MDA-MB-134-VI and 




Figure 10: SNAIL Protein is Upregulated by 4OHT, E2 Treatment in ILC cells 
IBs were performed in MDA-MB-134-VI and Sum44PE cells for SNAIL or Actin internal control 
after E2 deprivation assay with 50 μg protein/lane. Images are representative of three 




2.3.3 ERα is Recruited to the Promoter of SNAI1 After 4OHT, E2 Treatment 
To determine if the upregulation of SNAI1 by 4OHT was through a direct transcriptional 
mechanism by ERα, we performed ChIP and ChIP qRT-PCR to determine direct binding of ERα 
at the SNAI1 promoter. First, we mined the Ross-Inness et al ERα ChIP-Seq data and located a 
conserved estrogen response element (ERE) approximately 1 kb upstream of the SNAI1 promoter 






Figure 11: A Conserved ERE is Upstream of the SNAI1 Promoter 
In silico analyses were performed on the Ross-Inness et al publicly available ERα ChIP database 
to search for conserved EREs upstream of the SNAI1 transcriptional start site (TSS)[187]. Data were 
aligned in Integrative Genomics Viewer (IGV), a program generated by the Broad Institute[188]. 




Next, we performed ERα ChIP in MDA-MB-134-VI after E2 deprivation and treatment 
with 10-fold molar excess 4OHT or E2 to induce maximal binding at 45 minutes, 3 hours, or 8 
hours. Prior to processing samples for ChIP qRT-PCR, we confirmed successful IP of ERα 
(Appendix B Figure 68). Then, we completed the ChIP qRT-PCR with primers designed around 
the SNAI1 promoter region. We observed that 4OHT induced recruitment of ERα to SNAI1 
significantly over IgG and Vehicle controls only at the latest time point tested, 8 hours (Appendix 
B Figure 69). E2 caused significant recruitment of ERα for all gene regions tested. These data were 
confirmed at the 8-hour time point, and were consistent with the preliminary results obtained, with 
successful IP and induction of SNAI1 at the time point with matched concentrations of 4OHT or 
E2 (Figure 12A, B). Additionally, we observed recruitment of ERα at GREB1 with E2, and 
IGFBP4 with E2 or 4OHT treatments, respectively (Figure 12C). Therefore, we concluded that 
both 4OHT and E2 can promote recruitment of ERα directly to the promoter region for SNAI1, and 




Figure 12: ERα is Recruited to the SNAI1 Promoter at 8 Hours 4OHT or E2 Treatment 
MDA-MB-134-VI cells were treated to E2 deprivation followed by treatments with 4OHT or E2 
for 8 hours. Samples were processed for (A) ERα IP confirmation (Negative Control: MDA-MB-
231; Positive Control: MCF-7), (B) qRT-PCR for SNAI1 or GREB1, and (C) ChIP qRT-PCR for 
SNAI1, GREB1, IGFBP4, or negative control NFERE. Data represent one experiment with 
technical triplicates plated during the qRT-PCR ± STDEV. Asterisks depict significance compared 
to (B) Vehicle (0.1% DMSO) or (C) Fold Enrichment (FE) Vehicle after correction to Vehicle IgG 
for all samples. Statistics were performed with One Way ANOVA followed by Tukey’s post-test 
with comparisons to Vehicle displayed (*p < 0.05, **p < 0.005, ***p < 0.0005).   
 
 
2.3.4 SNAI1 and EMT-TF-Regulated Genes are Basally Upregulated in ILC Cell Lines 
Though 4OHT was capable of upregulating SNAIL in ILC cells, we were also curious about basal 
EMT-TF and EMT-TF-regulated gene expressions in ILC as compared to IDC. Thus, we probed 
a panel of EMT-TF targets including SNAI1, TWIST1 (TWIST1), N-cadherin (CDH2), Fibronectin 
(FN1), and Vimentin (VIM) in ILC and IDC cell lines. qRT-PCR analyses revealed a trend in 
upregulation for the entire EMT-TF panel tested in ILC cells (Figure 13). Specifically, SNAI1 was 




Figure 13: EMT-TFs and EMT-TF-Regulated Genes are Upregulated in ILC 
qRT-PCR was performed for SNAI1, TWIST1, and a panel of downstream EMT-TF-regulated 
genes (CDH2, FN1, VIM). Quantifications are three independent experiments ± SEM, with 
technical triplicates in each experiment. One Way ANOVA followed by Tukey’s post-test results 
are displayed with asterisks comparing cells to MCF-7 expression for each gene of interest (*p < 
0.05, **p < 0.005, ***p < 0.0005). 
 
 
Further, TWIST1, a potential upstream regulator of SNAI1, was upregulated in three out of four of 
the ILC cell lines (MDA-MB-134-VI, Sum44PE, MDA-MB-330). CDH2, FN1, and VIM were 
most highly induced in MDA-MB-134-VI relative to IDC cells, but were also induced in 1-2 
additional ILC cell lines, for each gene (CDH2: Sum44PE; FN1: Sum44PE, BCK4; VIM: 
Sum44PE, MDA-MB-330). We next confirmed ERα and E-cadherin protein statuses in the cell 
line panel prior to probing the levels of the major transcription factors SNAIL and TWIST1. All 
cell lines were ERα+, and MCF-7, T47D, and MDA-MB-330 expressed E-cadherin, as expected 
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(Appendix B Figure 70). Then, we assessed levels of SNAIL and TWIST1 in our cell lines. As 
both SNAIL and TWIST1 are incredibly labile proteins with short half-lives circa 15 minutes, we 
chose to include proteasomal degradation inhibitor MG132 in our study[189]. SNAIL and TWIST1 
were both consistently expressed in MDA-MB-134-VI cells, and usually observed in Sum44PE 
cells, with very low levels observed in all other cell lines tested (Figure 14). These data suggested 
that EMT-TFs and downstream gene targets (FN1, VIM, CDH2) were already expressed in our 
ILC cells, most significantly in MDA-MB-134-VI, and could contribute to the EMT-like 




Figure 14: SNAIL and TWIST1 are Relatively Highly Expressed in MDA-MB-134-VI and 
Sum44PE, and Can Be Further Induced by Inhibition of the Proteasome 
IB was performed with 50 µg protein/lane for SNAIL, TWIST1, and Actin (internal control) after 
treatment ± 5 μM MG132 for two hours. Data are representative of a set of three independently 




2.3.5 Transient Knockdown of SNAI1 in ILC Cells Leads to Minimal Impacts on EMT-
TF-Regulated Gene Expressions, Opposing 2D/ULA Proliferation Phenotypes in Full 
Serum 
Due to the relatively higher expression of EMT-TF SNAI1 in MDA-MB-134-VI and Sum44PE 
cells, and the 4OHT agonist phenotype, we decided to first transiently knock down SNAI1 to assess 
changes in the EMT-TF-regulated genes. We attempted to perform a dose response for SNAI1 
transient knockdown in MDA-MB-134-VI and Sum44PE, but only had consistent knockdown in 
MDA-MB-134-VI, the model with the more robust 4OHT-driven phenotype (Appendix B Figure 
71). Thus, we first pursued knockdown of SNAI1 in MDA-MB-134-VI. We noted that of the 
previous genes assessed, only FN1 was significantly and consistently altered in expression in 
conjunction with knockdown of SNAI1 (-45%), suggesting that abrogation of SNAI1 expression 




Figure 15: Knockdown of SNAI1 Significantly Decreases FN1, But Not VIM or CDH2 
Expressions 
Transient knockdown of SNAI1 was performed in MDA-MB-134-VI and qRT-PCR was 
performed for EMT-TF panel genes. Quantification represents technical triplicates ± STDEV. 
Students t-test was performed with asterisks denoting significance (*p < 0.05, **p < 0.005, ***p 




Next, we pursued alteration of the 2D and ULA proliferation phenotypes in full serum for 
the MDA-MB-134-VI cells. We hypothesized that loss of SNAI1 would lead to decreased 
proliferation. Intriguingly, opposite phenotypes were observed in the two settings; knockdown of 
SNAI1 in MDA-MB-134-VI led to increased 2D proliferation and decreased ULA proliferation 
(Figure 16). These results suggest that the context of SNAI1 knockdown can influence phenotypes 




Figure 16: Loss of SNAI1 Causes Opposite 2D, ULA Proliferation Phenotypes in MDA-MB-
134-VI 
MDA-MB-134-VI cells were exposed to transient SNAI1 knockdown for a period of 6-8 days. (A) 
2D proliferation was measured with six technical replicates per treatment group ± STDEV, and 
data were quantified with normalization to D1 values with non-linear regressions applied to test 
differences between slopes (*p < 0.05, **p < 0.005, ***p < 0.0005). qRT-PCR for SNAI1 was 
performed at D2,4,6 with technical triplicates ± STDEV and Students t-test for each siScramble 
versus siSNAI1 comparison shown (*p < 0.05, **p < 0.005, ***p < 0.0005). (B) ULA experiments 
were performed with the same technical replicate numbers and statistical considerations as in 2D 
experiments. However, qRT-PCR was only performed at D2-3 to assess knockdown relative to 
siScramble controls. Data are representative of three independently performed experiments. 
 69 
As we did not anticipate the increased 2D proliferation phenotype that was observed with 
transient SNAI1 knockdown, we decided to perform the transient SNAI1 knockdown assay in 
MDA-MB-134-VI cells out to 8 days to ensure stability of the increased proliferation. We 
confirmed this increased 2D proliferation at later time points, along with knockdown of mRNA 
and protein throughout experiments (Appendix B Figure 72). We then asked if transient SNAI1 
knockdown led to increased 2D proliferation in another ILC cell line, Sum44PE, or in IDC cell 
lines MCF-7 and T47D. The phenotypes observed in the additional ILC and IDC cell lines tested 
were inconsistent or not significant, and SNAI1 expression rebounded in all cell types typically by 
day 4 of the assay (Appendix B Figure 73). Overall, our data suggested a role for increased 2D 
and decreased ULA proliferation in MDA-MB-134-VI when SNAI1 expression was repressed. 
2.3.6 SNAI1 Knockdown is Difficult to Achieve in Deprivation Settings with siRNA 
Though our full serum 2D proliferation data suggested an alternative role for SNAI1 than what we 
had originally hypothesized, we decided to pursue transient knockdown of SNAI1 in the E2 
deprived setting to assess the hypothesis that loss of SNAI1 would inhibit or decrease the 4OHT 
2D partial agonist proliferation previously observed (see Figure 4). We performed this experiment 
in MDA-MB-134-VI cells multiple times, but were unable to alter the 4OHT-driven 2D 
proliferation or SNAI1 gene expression inductions when combining the deprivation and transient 
knockdown experiments (Figure 17). Often, the siScramble cells did not proliferate differently 
than Vehicle control in the CSS control treatment group, suggesting the cells were highly stressed 
after the deprivation, trypsinization, and knockdown process (Appendix B Figure 74). These 
observations did not allow for conclusions to be made regarding proliferation alterations in 
siSNAI1-treated cells. Additionally, SNAI1 expression between siScramble and siSNAI1 Vehicle-
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treated cells was not significant, never exceeding 20-40% knockdown. These observations were 
not surprising, considering the depletion of SNAIL protein levels that was observed during the 
deprivation process (see Figure 10). In addition, 4OHT induction of SNAI1 expression was 
consistently not significantly altered between siScramble and siSNAI1 treated cells (see Figure 
17B). However, transient knockdown of SNAI1 led to decreased E2 agonist induction of SNAI1 
expression in higher concentration 25 nM siSNAI1 experiments (Figure 17B, right panel). This 
outcome suggested that the E2 agonist induction of SNAI1 was more feasibly abrogated than the 
4OHT induction of SNAI1 in this experimental design. A summary of the full serum and 




Figure 17: Knockdown of SNAI is Inconsistent in the E2 Deprivation Setting 
Multiple attempts were performed to combine the transient SNAI1 knockdown/E2 deprivation 
assay with Vehicle (0.1% DMSO), 1 nM E2, or 1 µM 4OHT treatments. One attempt of four is 
shown above. (A) 2D proliferation with (left panel) 10 nM or (right panel) 25 nM siScramble 
versus siSNAI1 treatments are shown with five technical replicates per condition/time point ± 
STDEV, normalized to each respective day 2-time point plate and fitted with non-linear 
exponential regressions with comparisons of rates displayed beneath each graph in a matrix (*p < 
0.05, **p < 0.005, ***p < 0.0005; any significant changes are shown in red font). (B) qRT-PCR 
was performed for SNAI1 in simultaneously treated samples with technical duplicate samples ± 
STDEV, normalized to the siScramble Vehicle control. Statistics are One Way ANOVA followed 
by Tukey’s post-test with assessments between siScramble Vehicle and respective treatments 
shown (*p < 0.05, **p < 0.005, p < 0.0005). Only one other comparison is displayed that was 







Table 3: Summary of SNAI1 Transient Knockdown Phenotypes 
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The following were concluded from the deprivation/siRNA studies performed: (1) the 
process of combined E2 deprivation and transient knockdown with treatments was a stressful 
process for the cells to go through (observed in the decreased 4OHT-driven phenotype in Scramble 
controls relative to CSS (see Appendix B Figure 74)), (2) 4OHT induction of 2D proliferation 
agonist phenotype was modest, showing a ~1.5-FC in 2D proliferation relative to Vehicle control 
over a period of one week (see Figure 4), (3) 4OHT agonist induction of SNAI1 was also not 
consistently observed, (4) the more significant E2 induction of SNAI1 was altered by knockdown 
of SNAI1 (see Figure 17B, right panel), (5) SNAI1 levels were already depleted after deprivation, 
and thus, difficult to knock down further, and (6) changing of CSS lots (Gibco, homemade, 
Gemini) made apparent that residual estrogens and inconsistent removal of other lipophilic factors 
contributed to the 4OHT-driven phenotypic outcomes (Appendix B Figure 75). Though these 
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issues remained, we decided to pursue generation of stable knockdown and overexpressing SNAIL 
cell lines to see if observation (1) could be the rationale for not observing an alteration in 
phenotype.   
2.3.7 Stable SNAIL Knockdown is Difficult to Maintain in MDA-MB-134-VI Cells and 
Transient Virus Knockdown Produces Conflicting Results 
Due to difficulties in decreasing partial agonist 4OHT induction of 2D proliferation with siSNAI1 
experiments, we sought to generate stable constitutive SNAIL knockdown MDA-MB-134-VI 
cells. Lentiviral shRNA constructs obtained from Timothy Burns, MD, PhD were first utilized 
(shSNAI118, 19, 20, 21, 22), and preliminarily provided successful protein knockdown of SNAIL 
in two cell lines generated (shSNAI118 and shSNAI120) (Figure 18A). Interestingly, shSNAI121 
cells never survived selection, and were not able to be tested in this setting. No major 
morphological changes were noted in the knockdown cells as compared to shScramble control 
cells (Figure 18B). We tested 2D proliferation with all these cells in the presence of full serum. 
We found that knockdown of SNAIL led to decreased 2D proliferation in cell line shSNAI118; 
however, this was not significantly decreased relative to shScramble control cells (p = 0.0980) 
(Figure 18C). We attempted to repeat this experiment, but found that SNAI1 expression was similar 
between shScramble and knockdown cells, strongly suggesting rapid outgrowth of cells without 




Figure 18: Lentiviral Stable Knockdown of SNAIL Did Not Reveal Significant Effect on 2D 
Proliferation 
MDA-MB-134-VI cells were stably infected with lentiviral shSNAI1 constructs, or shScramble 
control. (A) Preliminary IB was performed immediately upon sufficient cell density. (B) Phase 
contrast microscopy was performed on cells (10X magnification; scale bars represent 100 µm). 
(C) Simultaneous to (A) and (B), 2D proliferation in full serum was assessed for all 
shScramble/shSNAI1 cells with six technical replicates per cell line ± STDEV, data normalized to 
respective D1 values, and rate comparisons performed with non-linear exponential regression fits 
(*p < 0.05, **p < 0.005, ***p < 0.0005). Uninfected MDA-MB-134-VI cells of similar passage 
were used as an additional control in experiments from (A) and (C).   
 
 
We next attempted to utilize the same constructs that had worked effectively in generating 
stable constitutive knockdown SNAIL cell lines in a transient virus assay. Though we could see a 
decrease in 2D proliferation with application of virus generated from shSNAI118 (*p = 0.0228) 
and shSNAI120 (NS p = 0.2307) relative to shScramble, we were unable to show knockdown by 
qRT-PCR or IB for shSNAI118 virus-treated cells (Figure 19). In fact, shSNAI120 virus-treated 
cells showed no significant phenotype, but showed more robust SNAI1/SNAIL knockdown. A 
further attempt to utilize this system with these two constructs and the original panel of all shSNAI1 
constructs (shSNAI118, 19, 20, 21, 22), was also unsuccessful (Appendix B Figure 77). The 
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Figure 19: Transient Viral Knockdown of SNAIL Yielded Conflicting Results 
Successfully used shSNAI1 constructs for shSNAI118 and shSNAI120 were used (along with 
shScramble control) in a transient virus assay to knock down SNAIL for a short-term assay. (A) 
2D proliferation in full serum (FS) with quantification data as previously, was performed; six 
technical replicates ± STDEV are shown with non-linear regression fits applied and comparison 
of rates to shScramble treated cells (*p < 0.05, **p < 0.005, ***p < 0.0005). (B) qRT-PCR for 
SNAI1 or (C) IB for SNAIL was performed on D2,4,6. qRT-PCR data consisted of technical 
triplicates ± STDEV for each time point and treatment, normalized to shScramble treated cells, 
with One Way ANOVA followed by Tukey’s post-test performed (*p < 0.05, **p < 0.005, ***p 
< 0.0005). Data represent a single experiment, with subsequent attempts producing inconsistent 
results. FS cells were MDA-MB-134-VI cells that were not subjected to virus treatment. 
 
 
Thus, we generated new shRNA sequences to target SNAI1, and cloned these new 
constructs into a retroviral system containing GFP, such that we could track the cells that were or 
were not expressing shRNA. miRE-LEPG shSNAI1 sequences were developed as described in the 
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methods section for regions called shSNAI1150, shSNAI1544, shSNAI1763, shSNAI11019, 
shSNAI11307, and shSNAI11666. The shRenilla713 construct was utilized as a control vector. 
shSNAI11307 was not effectively cloned and was not utilized in these studies. Preliminary GFP 
assessment in the infected MDA-MB-134-VI cells revealed ~80% or greater of the cells were 
expressing GFP, and four out of five of the cell lines generated had decreased protein expression 
of SNAIL (all except shSNAI11666) (Figure 20). However, there was a notable decrease of SNAIL 




Figure 20: Initial Retroviral Stable SNAIL Knockdown Showed Potential for Most 
Constructs 
Immediately after generation of retroviral stable SNAIL knockdown cell lines, lysates were 
measured by SNAIL IB relative to Actin internal control with 50 µg/lane. Data represent a single 




Immediately after this preliminary expression check, we assessed alteration in 2D or ULA 
phenotypes of these MDA-MB-134-VI miRE-LEPG shSNAI1 cells. There were no significant 
effects on 2D (Figure 21A) or ULA growth (Figure 21B). It was additionally concerning that the 
shRenilla713 cells grew significantly worse in 2D than the MDA-MB-134-VI control cells (**p = 
0.0021). An IB revealed by this second passage only shSNAI1544 cells had protein knockdown 
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relative to control cells for this experiment (Figure 21C). This trend in increase of SNAIL 
expression continued by the next passage, with levels of shSNAI1150, 1019, and 1016 infected cell 
lines showing no SNAIL knockdown, and shSNAI1763 superseding shRenilla713. Due to these 
observations, it was concluded that overall, constitutive knockdown of SNAIL was difficult to 
achieve in these cells, as was transient viral knockdown; both stable knockdown attempts resulted 
in SNAIL expression rebound, and phenotypes obtained were inconsistent in both settings. While 
these results suggested that even partial loss of SNAIL resulted in cell death, we concluded that 




Figure 21: Retroviral Stable SNAIL Knockdown Cells Regained SNAIL Expression in All 
But shSNAI1544 After Two Passages 
Stable retroviral SNAIL knockdown cells were processed for (A) 2D and (B) ULA proliferation 
assays in full serum one passage after confirmation of SNAIL knockdown. Data were processed 
as previously with six technical replicates per group ± STDEV, and comparisons performed using 
non-linear regression comparison of rates (*p < 0.05, **p < 0.005, ***p < 0.0005). (C) IB for 
SNAIL was simultaneously performed with this experiment to show loss of SNAIL knockdown in 
most infected cell lines. Data represent a single experiment of the second passage of cells after 
generation. 
 78 
2.3.8 Inducible Knockdown of SNAI1 was Also Unsuccessful 
As SNAIL was clearly very tightly regulated in the MDA-MB-134-VI cells, we next attempted to 
generate an inducible SNAI1 knockdown system, in which knockdown could be controlled by 
treatment with Dox in a transient manner[190]. We subcloned the miRE-LEPG retroviral shSNAI1 
constructs (shSNAI1150, etc.) into an LT3GEPIR shRNA backbone containing GFP. To utilize this 
system, we used previously generated MDA-MB-134-VI reverse tetracycline (rtTA) cells, which 
were infected with a construct to produce rtTA protein required to drive the Dox-inducible 
system[191]. Also, due to the concerning alterations in SNAI1 expression observed in the miRE-
LEPG shRenilla713 MDA-MB-134-VI cells, we included an additional shRenilla826 construct in 
our cloning efforts.  
We tested phenotypes, SNAIL expression, and GFP production with Dox treatment in the 
first cell lines that grew out during selection, shRenilla826 and shSNAI1763. Though GFP was 
observed in Dox-only treated cells, protein knockdown was not apparent in the shSNAI1763 cells 
tested, and altered phenotypes were not observed (Appendix B Figure 78). When sufficient cells 
were available from most of the panel (shRenilla713, shRenilla826, shSNAI1544, shSNAI1763), 
we tested mRNA expressions of SNAI1, and observed that Dox treatment significantly reduced 
expression of SNAI1 in shSNAI1763; however, SNAI1 expression was already decreased without 
Dox treatment in these cells (Figure 22). This unanticipated outcome led us to consider alternative 




Figure 22: Dox Inducible SNAI1 Knockdown is Minimally Effective 
A 24-hour treatment of ± 0.5 µg/mL Dox was given to the inducible retroviral knockdown SNAI1 
cells and associated controls. qRT-PCR was performed with technical triplicate samples, data 
displayed ± STDEV, with comparisons to shRenilla713 -Dox after One Way ANOVA followed 




Tet-contaminants that resemble Tetracycline or Doxycycline are commonly found at low 
levels in FBS. This is largely due to the addition of antibiotics to the feed of cows from which FBS 
is obtained. Low concentrations of these could be sufficient to induce expressions of Tet-driven 
constructs (Timothy Burns, MD, PhD unpublished observations). We therefore hypothesized that 
low level contaminants of Tet could be in our FBS containing media that we used to generate our 
inducible shSNAI1 cell lines; if knockdown of SNAI1 was potentially lethal to cells, these cells 
were dying off during selection and during use in experiments, leaving the most highly expressing 
SNAI1 cells in the population. We confirmed with our serum provider that there were low 19 
ng/mL levels of Tet in our serum. So, we decided to regenerate the LT3GEPIR shSNAI1 cell lines 
in Tet-free competent serum. 
Regeneration of these MDA-MB-134-VI rtTA Tet-free (TF) LT3GEPIR shRNA cells 
produced similar results to what was observed in the previous attempt in non-TF serum 
supplemented media. Once sufficient cells were available, a Dox dose and time course was 
performed. shSNAI1763 cells showed the most trending response to Dox in time and dose 
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dependent manners, but the trends of increased growth were insignificant (Figure 23A). 
Interestingly, 1 µg/mL Dox was very toxic to the shRenilla826 cells, as they did not proliferate 
(*p = 0.0452). It should also be noted that none of the -Dox treatment groups were significantly 
different than the shRenilla826 -Dox control, except for shSNAI11019 -Dox (*p = 0.0279). While 
all cells could induce GFP expression with Dox treatment relative to controls, mRNA knockdown 
was only present in the shSNAI1763 from 0.5-1 µg/mL (~55%) (Figure 23B). Due to the low basal 
expression of SNAIL in MDA-MB-134-VI, even though relatively higher than in other cell lines 
quantified in this chapter, we found great difficulty in manipulating its levels to influence 
phenotypes. Any future experiments attempting to manipulate this protein in these cells should be 
attempted either transiently, as previously described, or with a more stringent method, such as 





Figure 23: Tet-Free Inducible SNAI1 Retroviral System Reveals Similar Phenotype to 
Transient SNAI1 siRNA in shSNAI1763 Cells, Only 
Retroviral Inducible SNAI1 Knockdown cells were generated in TF competent serum/media. (A) 
Dox dose/2D proliferation responses were performed for all cells generated with technical 
triplicates ± STDEV, normalized to day 1 values, and non-linear regressions fitted with 
comparisons of rates (*p < 0.05, **p < 0.005, ***p < 0.0005). (B) qRT-PCR for SNAI1 was 
simultaneously performed on single replicates for each dose at the 24-hour time point. Data are 
shown in comparison to shRenilla826 -Dox for SNAI1 expression. 
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2.3.9 Stable Inducible SNAIL Overexpression Leads to Decreased Proliferation, Invasive, 
and Stem Cell Phenotypes  
As we faced great technical difficulty in knockdown of SNAIL, we decided to attempt the opposite 
approach by overexpressing SNAIL in lower SNAIL expressing ILC cell lines BCK4, MDA-MB-
330, and Sum44PE (refer to Figure 13, 14). We first attempted to generate constitutive stable 
overexpressing SNAIL cells with Empty Vector (EV) or SNAI1 containing lentiviral constructs in 
BCK4 cells. The cloned construct was first tested in HEK293T cells to ensure it worked as a viral 
backbone to produce SNAIL protein and mRNA products (Appendix B Figure 79). Once this was 
confirmed, the same constructs were utilized on the BCK4 and Sum44PE cells. As soon as 
sufficient cells to test protein induction became available from BCK4 cells, an IB was run and 
confirmed protein upregulation of SNAIL in overexpressing cells (Appendix B Figure 79). 
However, in subsequent passages, this protein overexpression was lost, much like what was 
observed in the stable constitutive knockdown studies (Appendix B Figure 79, refer to Figure 21, 
see Appendix B Figure 76). We therefore resolved to attempt to generate a Dox inducible SNAI1 
overexpression system for BCK4, MDA-MB-330 and Sum44PE using inducible construct 
pINDUCER20-SNAI1. 
Lentiviral infection of pINDUCER20-SNAI1 constructs in BCK4, MDA-MB-330, and 
Sum44PE produced successful protein overexpression of SNAIL in all three cell types relative to 
no Dox controls (Figure 24A). This was consistent, and did not change with passage or repetition. 
Dox treatment at 0.5 µg/mL was performed in these cells and we quantified protein expression, 
2D, and ULA proliferation phenotypes in all three cell line derivatives. SNAIL overexpression 
produced an opposite phenotype to transient siSNAI1 knockdown 2D studies; transient 
overexpression of SNAIL in all three cell lines led to a decreased proliferative phenotype in both 
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2D and ULA settings (Figure 24B, C). This phenotype was visible in a dose response in both 2D 
and ULA environments, and simultaneously given doses of Dox did not impact growth of control 




Figure 24: Transient SNAIL Overexpression Leads to Decreased 2D, ULA Proliferation in 
ILC Cells 
Three ILC cell derivatives were generated using pINDUCER20-SNAI1 lentiviral infection. (A) 
After treatment ± 0.5 µg/mL Dox for 24-48 hours, IBs were performed for SNAIL with internal 
control Actin with 25 µg/lane. (B) 2D or (C) ULA proliferation were measured on D2,4,6,8 for all 
three cell line derivatives with six technical replicates per treatment/time point observed, displayed 
as ± STDEV. Data were fitted with non-linear regressions with comparisons of rates (*p < 0.05, 




Increased expression of SNAIL has been previously described to contribute to decreased 
proliferative phenotypes to allow for cell cycle arrest and invasion phenotypes[193]. We first 
measured cell cycle profiles in BCK4 pINDUCER20-SNAI1 ± Dox treated cells at the D4 time 
point, a middle point of our previous assays that had dictated the presence of the decreased 
proliferation phenotypes. We observed cell cycle arrest in G0/G1, with concurrent decreases of 
fraction of cells in G2/M and S phases (Figure 25A). No phenotypic or cell cycle alterations were 




Figure 25: Overexpression of SNAIL Causes Arrest in G0/G1 
BCK4 pINDUCER20-SNAI1 and BCK4 control cells were simultaneously subjected to triplicate 
plating for cell cycle analyses, with treatment of ± 0.5 µg/mL Dox for four days. (A) Phase contrast 
images were taken and cell cycle profile was measured (10X magnification; scale bars represent 
100 µm). (B) Simultaneous experiments were performed in control cells to ensure that Dox was 
not the cause of any alterations observed. Data are representative of two independently performed 
experiments with similar outcomes. Students t-test (*p < 0.05, **p < 0.005, ***p < 0.0005) was 




We next pursued testing of invasive phenotypes in our models by plating cells on top of 
Matrigel, or embedding cells in Matrigel or Collagen I[194]. MCF-7 and MDA-MB-231 cells served 
as controls in these experiments. Robust colony formation and invasion were not seen in the BCK4 
or MDA-MB-330 pINDUCER20-SNAI1 cell lines, but were present in control cell lines and in 
Sum44PE pINDUCER20-SNAI1 –Dox cells (Figure 26). Intriguingly, this invasive/colony 
formation phenotype was decreased with induction of SNAIL, an unanticipated outcome. We 
concluded that overexpression of SNAIL leads to decreased 2D and ULA growth, concurrent with 




Figure 26: Increased Levels of SNAIL in ILC Reduce Colony Formation in Matrigel, 
Collagen Environments 
ILC inducible overexpression cell lines were seeded into (Matrigel, Collagen I), or on top of 
(Matrigel) 3D environments to test colony formation in response to SNAIL overexpression by Dox 
treatment (± 0.5 µg/mL; replenished ~3-4 days) over a period of 24 days. Colonies were imaged 
as under phase contrast microscopy (10X magnification; scale bars represent 100 µm). 
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Induction of SNAIL has also been shown to contribute to stem cell behaviors[195, 196]. These 
phenotypes have been shown to contribute to therapeutic resistance, and might contribute to the 
observed 4OHT induction of 2D proliferation phenotype in MDA-MB-134-VI. To directly test 
this, we determined expression of stem cell markers, and performed functional stem cell assays. 
We first measured ALDH expression in our BCK4 pINDUCER20-SNAI1 ± Dox cells, a commonly 
noted feature of stem cell populations[197]. However, we did not detect an ALDH population of 
stem cells in the inducible overexpressing SNAIL population, unlike our positive control cell line 
SKBR3 (Appendix B Figure 82). Still, ALDH expression is not a definitive indicator of stem 
cells[198]. Current data in our lab also showed that alternative stem cell markers CD24low/CD44high 
are not expressed in our highest SNAIL expressing cell line, MDA-MB-134-VI (Nilgun Tasdemir, 
PhD unpublished data).  
We next conducted a functional mammosphere assay to further test this stem cell 
hypothesis, and used MCF-7 and MCF-10A cell lines as controls in this experiment. BCK4 and 
MDA-MB-330 cells did not form proper architecture expected of mammospheres, instead forming 
lattices of cells that were loosely connected into one mass in each well (Appendix B Figure 83)[199]. 
Sum44PE cells also did not form proper mammospheres, but did form clusters of loosely 
aggregated cells that decreased with induction of SNAIL expression, and were consistently 
downregulated from primary to tertiary sphere formation assays (Figure 27). In conclusion, 
overexpression of SNAIL performed in ILC cell lines BCK4, MDA-MB-330, and Sum44PE led 




Figure 27: SNAIL Overexpression Causes a Loss of Stem-Like Phenotypes in Sum44PE Cells 
Inducible overexpression SNAIL cells or control MCF-7 cells were seeded into a mammosphere 
assay. (A) Quantifications of mammospheres formed were generated for each technical triplicate 
sample ± STDEV for primary, secondary, or tertiary assays. Comparisons were performed by One 
Way ANOVA followed by Tukey’s post-test with comparisons against -Dox displayed (*p < 0.05, 
**p < 0.005, ***p < 0.0005). (B) Representative phase contrast images are shown from D17 of the 
assay (20X magnification; scale bars represent 50 µm). 
 
 
2.3.10 SNAIL Overexpression is Not Sufficient to Induce 4OHT-Driven 2D Proliferation 
Phenotype in ILC Cells 
We finally asked if induction of SNAIL would lead to induction of 4OHT-driven 2D proliferation 
in ILC cells other than MDA-MB-134-VI. We performed E2 deprivation of our inducible SNAIL 
ILC cell lines and downstream 4OHT dose response assays, as previously performed (see Figure 
4), with or without the addition of Dox. We observed no 4OHT-induced phenotype in these 2D 
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proliferation assays relative to -Dox controls, in any of our ILC cell lines (Figure 28). These data 
further supported our findings that SNAIL was not directly contributing to the 4OHT-driven 
phenotype in ILC that was previously observed (see Figure 4), but suggests that it may instead 





Figure 28: 4OHT-Driven 2D Proliferation is Not Caused by Induction of SNAIL in ILC Cells 
BCK4, MDA-MB-330, and Sum44PE pINDUCER20-SNAI1 cells were plated in six technical 
replicates per dose of 4OHT/Dox given and quantified for dose response at D7 post treatment. Dox 
was given at 0.25 µg/mL final concentration. Data were quantified ± STDEV with normalization 
to Vehicle (0.1% DMSO) control, representing one experiment. 
 
 
2.3.11 Minimal Clinical Evidence Currently Supports a Role for SNAIL in ILC 
Current literature supports a role for increased SNAIL expression in malignancies, but these data 
are not clear with respect to ILC[64, 174]. We decided to probe SNAI1 expression in ERα+ n = 184 
ILC versus n = 534 IDC primary tumors from TCGA, but found that there was no significant 
difference in expression of SNAI1 between these two groups (Figure 29A). Additionally, SNAI2 
and SNAI3 were decreased significantly in ILC primary tumors (*p = 0.019, ***p = 2.7e-15) 
(Figure 29B, C). Only SNAIL was available from TCGA RPPA analyses, and was also not 
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significantly differentially expressed between ILC and IDC (Appendix B Figure 84). It should be 
noted that these conclusions were drawn from expressions of SNAI1/SNAI2/SNAI3 in primary 




Figure 29: SNAI2 and SNAI3, But Not SNAI1 Are Significantly Different Between ILC and 
IDC Primary TCGA Lesions 
TCGA ERα+ ILC (red) versus IDC (blue) lesions were probed for mRNA expressions of (A) 
SNAI1, (B) SNAI2, or (C) SNAI3. Mann-Whitney U p-values were applied to each data set. 




We then probed survival data in the METABRIC cohort of ILC tumors and asked if high 
SNAI1 expression delineated patients into a poorer outcome group as opposed to low SNAI1 




Figure 30: Differential SNAI1 Expression is Not Associated with Survival in ILC Patients 
from METABRIC 
Data from the METABRIC consortium were accrued and analyzed through collaboration with 
Kevin Levine, BS. (A) All ILC patients, (B) ERα+, and (C) ERα- ILC patients were separated by 
Kaplan-Meier curves based on high or low SNAI1 expression. Log ranks were utilized to test 
differences in survival. 
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Though we did not see a significant difference in protein expression for SNAIL from the 
TCGA RPPA data, we were interested in answering whether protein was differentially expressed 
in ILC compared to IDC samples in an independent cohort. We first optimized use of the SNAIL 
antibody on our positive (BCK4 pINDUCER20-SNAI1 +Dox, MDA-MB-134-VI) and negative 
(BCK4 pINDUCER20-SNAI1 –Dox) control FFPE sections, and determined that the antibody was 
effective for use at 1:100 dilution. We then stained a TMA containing ILC and IDC cores 
simultaneously with the BCK4 controls. 5/5 ILC ERα+ and 12/12 IDC ERα+ tumors displayed 
SNAIL staining, but most staining appeared present in the stroma (e.g.: ILC1) or cytoplasmic 
(ILC2-5, IDC1-5) (Figure 31A). Cytoplasmic SNAIL is indicative of an inactive form of the protein, 
and is usually not considered positive in IHC practices[200]. The ILC samples that were stained on 
this TMA were also recently assessed in a panel of n = 131 primary ILCs curated, collected, 
isolated, and assessed by NanoString for a panel of genes of interest in our laboratory (Matthew 
Sikora, PhD unpublished results). ILC1-5 were included on this panel, as was a SNAI1 probe for 
gene expression. Interestingly, the NanoString data was consistent with the visual TMA outcomes 
(ILC1 > ILC2 > ILC3 > ILC4 > ILC5 for SNAI1 expression). Further validation of additional samples 
and appropriate histological review will be required of these samples to generate further 
conclusions. Additionally, as samples were treatment naïve at time of excision, it would be difficult 
to interpret the meaning of lack of or presence of SNAIL/SNAI1 expression without additional 
samples from the same patients post treatment regimens. 
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Figure 31: SNAIL is Localized to Cytoplasm in the Majority of TMA IHC Staining 
(A) SNAIL protein was stained by IHC in ILC and IDC primary samples from the described TMA. 
All 5/5 ERα+ ILCs and 5/12 ERα+ IDCs with similar staining patterns are displayed above from 
bright field microscopic imaging (20X magnification). (B) NanoString data from the five ILC 
samples was mined from the larger data set. (C) Dox inducible SNAIL BCK4 cells were utilized 
to generate positive control FFPE pellets for SNAIL antibody optimization and validation. An IB 
confirmed overexpression of SNAIL on samples that were simultaneously treated to those that 




We then hypothesized that SNAI1 expression may be upregulated during progression, and 
more easily observed in metastatic events. To this end, we mined paired primary-metastatic lesion 
data that we have generated in-house from ILC patient samples. These RNA sequencing data 
spanned brain, bone, gastrointestinal (GI) tract, and ovarian metastases, and 3/11 primary-
metastatic pairs showed increased SNAI1 expression from primary to metastatic lesion (Figure 32). 
It should be noted, however, that the expressions observed in most of these samples were very low 
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with reads below “1.”  Interestingly, one of the increased SNAI1 expressions from primary to 




Figure 32: SNAI1 Expression is Increased from Primary to Metastasis in Three ILC Pairs 
Mined data was generated from samples collected by Nolan Priedigkeit (NP), PhD, Ahmed 
Basudan (AB), MS, and Rebecca Watters (RW), PhD for n = 11 matched primary/metastatic ILC 
pairs from brain (NP), ovary (AB), GI tract (AB), and bone (RW) metastases-afflicted patients. 
Samples with increased SNAI1 expression were denoted in red for ease of visualization. Three out 
of eleven of the primary-metastatic pairs had a second metastatic lesion from the same patient, and 
are denoted with green asterisks. Metastatic sites for each respective pair with increased SNAI1 
expression, receptor status, and therapeutics received are detailed to the right of the main figure.  
 
 
To conclude, the clinical data we currently possess do not indicate a role for (1) increased 
expression of SNAI1 in TCGA primary ERα+ ILC versus IDC tumors (see Figure 29), (2) 
preliminarily suggest expression of SNAIL/SNAI1 in some ILCs in an independently tested cohort 
(see Figure 31), (3) no role for increased SNAI1 expression correlating with decreased survival for 
ILC patients regardless of ERα status (see Figure 30), and (4) limited evidence of increased SNAI1 
expression from primary to metastatic ILC lesions in 3/11 total primary-metastatic ILC pairs (see 
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Figure 32). Overall, this clinical data is not robust, and requires further elaboration and testing in 
additional ILC samples to confirm the few observations made. 
2.3.12 A SNAIL/LSD1 Axis May Play a Role in ILC Phenotypes 
While SNAIL was an interesting entity to study in the disease subtype of ILC, we understand that 
it does not function on its own. An interaction between SNAIL and epigenetic modifier lysine 
demethylase 1 (LSD1/KDM1A) has recently been shown to drive EMT phenotypes in cancer[178]. 
SNAIL acts as a molecular hook for LSD1, by interacting via the highly conserved SNAG domain 
of SNAIL. Together, these proteins are capable of being recruited to the promoter region of genes 
such as CDH1 to repress expression and drive EMT phenotypes[201].  
We decided to probe the potential interaction of SNAIL and LSD1 in our ILC cells. First, 
we measured expression of KDM1A by qRT-PCR and found that MDA-MB-134-VI most 
significantly expressed this entity as compared to MCF-7 cells (+2.87 FC relative to MCF-7) 
(Figure 33A). Then, we measured LSD1 protein levels by IB and observed LSD1 expression in all 
samples (Figure 33B). We also noted that KDM1A expression was upregulated significantly in 
ILC primary tumors as compared to IDCs from TCGA data; this was one of the few EMT-TF 
panel genes upregulated significantly in ILCs relative to IDCs (Figure 33C, Appendix B Figure 






Figure 33: ILC and IDC Cells Express LSD1, But LSD1 is More Highly Expressed in TCGA 
Primary ERα+ ILC Tumors 
The panel of ILC and IDC cells were assessed for basal expression of (A) KDM1A mRNA or (B) 
LSD1 protein. MDA-MB-21 served as a positive control for LSD1 expression in (B). 
Quantifications in (A) represent the combination of three independently performed experiments ± 
SEM with One Way ANOVA followed by Tukey’s post-test with comparisons against MCF-7 
displayed (*p < 0.05, **p < 0.005, ***p < 0.0005). IB is representative of three independently 
performed experiments. (C) Primary ERα+ ILC (n = 184) and IDC (n = 534) RNASeq KDM1A 




With the expression of LSD1 confirmed in our cells and observed overexpression in ILC 
primary tumors, we next attempted to detect co-IP of this interaction in our highest expressing 
SNAIL and LSD1 cells, MDA-MB-134-VI. Endogenous co-IP of LSD1 and SNAIL has not 
currently been performed, to our knowledge. We first confirmed SNAIL-LSD1 interaction 
existence in a manipulated system by transfecting HEK293T cells with SNAIL or LSD1, with 
subsequent co-IP performed (Figure 34A). Then, we performed endogenous co-IP in MDA-MB-
134-VI cells to detect the SNAIL-LSD1 interaction; this interaction was most easily detected by 
first performing IP for LSD1, and then detecting SNAIL (Figure 34B). The reverse process to first 
IP SNAIL and then detect LSD1 did not easily yield co-IP, but this was not surprising as the levels 
of LSD1 are in excess compared to the relatively lower expressed SNAIL protein. We therefore 




Figure 34: SNAIL and LSD1 Co-IP in a Transient Overexpression HEK293T System, and 
Endogenously in MDA-MB-134-VI Cells 
(A) HEK293T cells were transiently transfected with SNAIL-HA or LSD1-FLAG overexpression 
plasmids for 48 hours, and lysates were subjected to Co-IP for SNAIL or LSD1. Insufficient input 
was available for the SNAIL IP, so a positive control was included on each IB. Data represent a 
single experimental attempt to confirm literature claims of SNAIL-LSD1 interaction. (B) Co-IP 
was performed in MDA-MB-134-VI cells for IgG controls, SNAIL, or LSD1. IBs were then 
assessed for interaction of proteins. Data represent two independently performed experiments with 




 We next asked if transient knockdown of KDM1A could influence the EMT-TF panel genes 
that are upregulated in ILC cells. We performed transient knockdown of KDM1A in MDA-MB-
134-VI cells and discovered that this loss contributed to decreases in EMT-TF panel gene 
expressions including SNAI1, FN1, and VIM expressions (Figure 35). Though we did not explore 
this interaction further prior to the defense, the current evidence suggests the potential role for 
LSD1 in driving EMT-TF-regulated gene expressions, potentially upstream or in collaboration 




Figure 35: Knockdown of KDM1A Contributes to Downregulation of EMT-TF Panel Gene 
Expressions 
MDA-MB-134-VI cells were transiently transfected with 10 nM siScramble or siKDM1A1,2 (two 
unique siRNAs targeting KDM1A) in technical triplicates, and were subjected to qRT-PCR for 
EMT-TF panel members. Data are displayed relative to siScramble control ± STDEV with One 
Way ANOVA followed by Tukey’s post-test (*p < 0.05, **p < 0.005, ***p < 0.0005) comparing 




 Though we did not pursue the SNAIL/LSD1 axis further, we conclude the following from 
these data: (1) LSD1 is expressed in both ILC and IDC cells, while SNAIL is only most highly 
expressed in the MDA-MB-134-VI ILC cells relative to other ILC/IDC cells tested (see Figure 13, 
14, 33), (2) LSD1 is not altered in expression by E2 or 4OHT treatments (see Appendix B, Figure 
86), (3) LSD1 and SNAIL interact endogenously in MDA-MB-134-VI ILC cells (see Figure 34B), 
and (4) loss of KDM1A contributes to a downregulation in expression of EMT-TF panel members 
(see Figure 35). As stated, the expression of KDM1A is also significantly higher in ILC primary 
TCGA samples as compared to IDCs (see Figure 33C). These data, though preliminary, warrant 
further investigation.  
2.3.13 Faithfully Recapitulating the EMT-like Phenotypes of ILC in In Vitro Studies 
ILCs have a unique growth pattern in breast tissue that is likely governed by the loss of E-cadherin 
(refer to Figure 2)[28, 59-63]. However, many of our tissue culture studies were performed in standard 
2D proliferation environments, which do not faithfully recapitulate the clinical growth 
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environment of these cells. We included use of the ULA environment in some of our studies, as 
members of our lab have observed an increased preference for ILC cells over IDC cells to grow in 
this environment (Nilgun Tasdemir, PhD unpublished results). Further, additional observations 
have revealed that ILC cells overall do not migrate (scratch assay), invade (coated transmembrane 
insert assays), or form proper mammospheres (see Figure 27, Nilgun Tasdemir, PhD unpublished 
results). With few easily observable phenotypes for ILC cells, and the understanding that these 
environments may not recapitulate appropriate growth environments, we decided to observe the 
phenotypes of our ILC cells in two additional environments that more closely resemble the clinical 
setting: soft agar anchorage independent growth environment and linear protein micropatterned 
2D proliferation.  
Soft agar assays involve use of a 3D environment to suspend the cells without any contact 
to an extracellular matrix[202]. Cells that form colonies in soft agar are considered transformed and 
carcinogenic. Suppression of E-cadherin can promote soft agar anchorage independent growth for 
some cell lines, which was an additional rationale for testing this environment[203]. Soft agar assays 
were performed with MDA-MB-134-VI and MCF-7 cells for 14 days to observe the outgrowth of 
anchorage independent colonies (Figure 36A). We observed classic colony formation from MCF-
7 cells; MCF-7 colonies were dense in the center of each respective colony, and distinctive in their 
morphologies. However, MDA-MB-134-VI cells did not form the same kinds of cohesive 
colonies. Instead, colonies were loosely tethered together as clusters of cells. Additionally, 
significantly fewer colonies formed that were of similar size when equal densities of cells were 
plated for both MDA-MB-134-VI and MCF-7 (Figure 36B). An additional experiment was 
performed using the complete ILC (MDA-MB-134-VI, Sum44PE, BCK4, MDA-MB-330) and 
IDC (MCF-7, T47D) cell line panel, but insufficient colonies were present for counting purposes. 
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We have provided images of the morphologies of these colonies in Appendix B Figure 87. Overall, 
ILC cells did not form many colonies, or formed loosely clustered cell aggregates within the agar. 
From these preliminary data, we concluded that ILC cells do not form classic soft agar colonies 





Figure 36: MDA-MB-134-VI Cells Form Fewer, Smaller, and Discohesive Soft Agar Colonies 
Compared to MCF-7 Cells 
MDA-MB-134-VI and MCF-7 cells were plated at the same density (10,000 cells/dish) in triplicate 
dishes for 14 days to monitor soft agar colony formation. (A) Representative images were taken 
of colonies that were counted in each dish (10X magnification; bars represent 100 µm). (B) 
Colonies were defined as clusters of cells with a diameter of 50 µm or greater. Technical triplicate 
dishes were counted for colonies using cellSens Dimension software, and are displayed ± STDEV. 
Students t-test was used to compare the two groups (*p < 0.05, **p < 0.005, ***p < 0.0005). Data 
represent a single experiment. 
 
 
The second environment in which we tested ILC growth was a linear protein 
micropatterned 2D proliferation environment. We hypothesized that ILC cells would more 
preferentially adhere to and proliferate in an environment that would mimic the clinically observed 
linear growth patterns of ILCs[59-61]. We first generated Fibronectin (FN1) 20 µm micropatterned 
coverslips and seeded MDA-MB-134-VI or MCF-7 cells onto these environments. Initial 
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observations at the 24 hour-time point post plating were promising, with both cell types adhering 
to the micropatterns (Appendix B Figure 88). We next expanded the panel of micropatterned 
proteins tested to include FN1, Collagen I (COLI), Collagen IV (COLIV), and Laminin I (LAM). 
The MDA-MB-134-VI cells adhered only somewhat to the FN1 in this attempt, and did not adhere 
well to the COLI, COLIV, or LAM micropatterns (Figure 37A). Instead of adhering, the cells 
would cluster together and float over the surface of the micropattern. In contrast, MCF-7 adhered 
to the FN1, COLI, and COLIV environments, but also did not adhere to the LAM micropattern. 
We decide to then attempt the experiment again, but with solid coatings of the 
FN1/COLI/COLIV/LAM proteins as opposed to micropatterns. We also included treatment with 
4 nM Batimastat in each third replicate well to attempt to inhibit any matrix metalloproteinases 
(MMPs) that could be inhibiting the proper adherence of MDA-MB-134-VI to the protein 
environments. MDA-MB-134-VI cells did not adhere well to the solid protein micropatterns, with 
or without the addition of Batimastat (Figure 37B), and MCF-7 adhered much like in the previously 
performed micropatterning experiment (see Figure 37A). Due to lack of adherence of MDA-MB-
134-VI to proteins in these repeated experimental attempts, additional attempts of these 
experiments were not performed. Further, ongoing analyses in our lab have shown that MDA-MB-
134-VI cells do not adhere well to all proteins tested in the micropatterning experiments 
(FN1/COLI/COLIV/LAM) relative to uncoated protein wells in an ECM adhesion assay (Nilgun 
Tasdemir, PhD unpublished results). 
These preliminary experiments in soft agar and protein micropatterned growth 
environments suggested the following: (1) ILC cells do not form classic soft agar colonies, and 
take longer periods of time to form (see Figure 36, see Appendix B Figure 87), and (2) MDA-MB-
134-VI cells do not preferentially adhere to protein micropatterned environments as compared to 
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MCF-7 cells (see Figure 37, Nilgun Tasdemir, PhD unpublished results). Further phenotypic 




Figure 37: MDA-MB-134-VI Cells Showed Lower Adherence to Protein Micropatterns or 
Protein Coatings Compared to MCF-7 Cells 
(A) MDA-MB-134-VI and MCF-7 cells were plated on 20 µm linear protein micropatterned, 
PDMS spin-coated coverslips at 200,000 cells/well in technical triplicate wells. Images were taken 
2-3 days post plating under phase contrast microscopy (FN1, COLI, COLIV at 10X magnification; 
bars represent 100 µm) (LAM at 4X magnification; bars represent 200 µm). (B) MDA-MB-134-
VI and MCF-7 cells were plated on glass coverslips, or coverslips completely coated with the same 
concentrations of FN1 (50 µg/mL), COLI (200 µg/mL), COLIV (200 µg/mL), or LAM (200 
µg/mL) as utilized in micropattern assays. Each third replicate well received 4 nM Batimastat, a 
broad spectrum MMPi, denoted by red text. Observations are detailed in the above table after 2-3 
days post plating/treatment. 
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2.4 DISCUSSION 
Recent clinical trial data and observations made in our laboratory suggest a role for endocrine 
therapy resistance in ILC, particularly from Tamoxifen treatment[116-120, 132]. Understanding the 
molecular mechanisms for Tamoxifen resistance will be paramount to informing clinical decisions 
for patients afflicted with ILC. Thus, we decided to pursue the upregulation of SNAIL, an EMT-
TF known to contribute to Tamoxifen resistance in alternate major histological subtype IDC, as a 
key candidate from our ILC 4OHT treatment screen. 
We first confirmed upregulation of SNAI1/SNAIL in MDA-MB-134-VI and Sum44PE, 
two commonly utilized ILC cell line models, by qRT-PCR and IB methodologies (see Figure 5, 6, 
10). This was first observed in the context of 4OHT and E2 treatments, and was not apparent in 
IDC cell lines tested. However, we did not observe 4OHT partial agonist activity in BCK4 or 
MDA-MB-330 ILC cells. BCK4 cells were generated from the murine outgrowth of a human 
mucinous breast cancer with growth patterns and mutations that mimicked ILC, but is not 
representative of classical ILC[181, 204]. Additionally, BCK4 cells maintained lower overall ERα 
expression and response to E2 in our experiments (see Figure 4A, Appendix B Figure 70). MDA-
MB-330 cells are often reported as ERα- cells, though they express ERα (see Appendix B Figure 
70). This characterization was likely based upon lack of response to E2 in classic assays, though 
we see a minor E2 dose response for MDA-MB-330 in our hands (Figure 4A). Still, the lack of 
robust response by ERα in MDA-MB-330 may contribute to the lack of 4OHT agonist activity in 
these cells. We will pursue additional time point analyses of these treatments in the complete panel 
of ILC cell lines in the future, as our studies were limited to 24-hour time points. We could also 
employ the use of additional ER ligands (E1, E3) in our assays to assess the importance of generic 
ER activation in ILC cells to promote SNAI1 expression increases as well as phenotypes. We will 
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also look for changes in SNAIL localization in vitro after 4OHT treatment in our cell lines. Overall, 
these data suggest a unique agonist behavior of 4OHT in some but not all ILC cell lines that we 
hypothesized to be mediated, at least in part, by SNAIL. 
We confirmed direct interaction of ERα with the promoter region of SNAI1 by ChIP after 
4OHT and E2 treatments (see Figure 11, 12, Appendix B Figure 68, 69). This direct interaction 
confirms that 4OHT is directing ERα to upregulate alternative targets in ILC that are known to 
contribute to 4OHT resistance. We noted that this was not restricted to SNAI1, but was also 
apparent in other classic ERα target gene regions (IGFBP4, GREB1). These data suggest that 
4OHT can generically direct ERα to promoters of classic gene targets in MDA-MB-134-VI. This 
partial agonist activity of 4OHT should be further explored to include additional data such as 
altered ERα/coactivator/corepressor interactions and binding affinities of 4OHT to ERα in ILC 
versus IDC cells.  
The observed upregulation of SNAI1 by 4OHT cannot be easily explained simply by the 
loss of epithelial marker E-cadherin. We addressed this question in three ways: we transiently 
knocked down CDH1 in IDC cells (see Figure 9A), utilized a stable CDH1 knockdown IDC system 
(Figure 9B), and we used two ILC-like cell lines that harbor mutations in CDH1 (see Figure 9C, 
9D). However, the loss of E-cadherin either by manipulation of transcript levels or by mutation of 
E-cadherin were insufficient to recapitulate the 4OHT/SNAI1 phenotypes observed in ILC cells. 
These data suggest that there is something else other than E-cadherin loss contributing to the 
observed 4OHT induction of SNAI1 in some ILC cell lines. Additionally, we observed no 
alterations to other EMT-TF panel members in our small panel tested (see Figure 7, Appendix B 
Figure 66), leading us to believe that SNAIL is differentially targeted for upregulation after 
treatment with 4OHT. This upregulation was only formally tested in the 2D environment, and not 
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in the ULA environment; as we only observed the induced proliferation phenotype after 4OHT 
treatment in 2D in conjunction with SNAI1 induction, we will pursue expression analyses in the 
ULA environment to assess the hypothesis that SNAI1 is not upregulated by 4OHT in this 
environment, due to lack of observed phenotype in ULA. We will also probe the expression of 
other EMT-TF panel members that we studied in this environment. 
Interestingly, Sum44TAMR cells, a Tamoxifen resistant derivative of ILC cells, do not show 
upregulation of SNAI1, opposite our original hypothesis (see Figure 8). Instead, expression was 
decreased relative to parental cells. These data were obtained from a manipulated cell line model 
system that was outgrown in a tissue culture incubator, as opposed to in a patient, and may not be 
a true representation of the physiological reaction to ongoing Tamoxifen treatment in an ILC 
patient. We also did not test an acute treatment of 4OHT on the Sum44TAMR cells in a 24-hour time 
point as we performed on our other ILC cell lines. It is possible that these cells do not show a 
transient upregulation of SNAI1 as parental Sum44 cells do. SNAI1 may only have implications as 
a transiently upregulated entity in ILC, either to contribute to short-term manipulations of gene 
expression programs that we were not able to manipulate in our cells, or it may just be upregulated 
in response to 4OHT as a marker. Further, we did not test the basal expression of additional EMT-
TF panel members studied in the Sum44TAMR cells due to limited mRNA available. We will pursue 
expression studies of these additional genes in the future. 
Manipulations of SNAIL were difficult to maintain unless performed in transient siRNA 
assays (see Figure 18-21). This tight regulation of SNAIL in ILC, and in transient experiments 
performed in IDC cells (see Appendix B Figure 73), suggest that alternative methods 
(CRISPR/Cas9) will need to be taken to observe complete loss of SNAIL or that inducible or 
transient experiments will have to be performed to manipulate this protein[205]. If viral methods of 
 106 
infection are attempted again using GFP constructs, we will track the quantity of GFP+ cells present 
in our cell lines over time to assess outgrowth of uninfected cells. Complete loss of gene function 
may lead to alternative phenotypic observations, such as lethality, as presence of low levels of 
SNAIL may be sufficient to override the knockdown cells. However, the manipulation of SNAIL 
leading to increased proliferative phenotypes in the ILC knockdown setting complemented the 
decreased proliferative and invasive phenotypes observed in overexpression settings (see Figure 
16, 24-27). The intriguing portion of our data was the undescribed role of SNAIL induction in 
reducing stem-like phenotypes in our ILC cells (see Figure 33). While SNAIL has been well-
published to induce these phenotypes, it is possible that the unique background of ILC, including 
mutation/loss of E-cadherin, may lead to under described roles for the protein. Context is 
imperative to consider, and SNAIL has not been studied thoroughly in the context of ILC until 
now. Additionally, though we do not currently understand the mechanism behind these 
phenotypes, we will pursue this in future studies. We will also pursue additional phenotypic 
assessments including colony formation in low density growth environments. 
The presence of an EMT-TF and EMT-TF target gene upregulation in ILC as compared to 
IDC cells was apparent in our cell line panel, but not as clear in clinical samples obtained from 
primary lesions of patients (Figure 13, 14, 29-31, Appendix B Figure 84, 85). Our cell lines were 
derived from metastatic outgrowths of breast primary lesions, and may recapitulate what is 
observed in the metastatic as opposed to primary settings[200]. Though not robust, we did observe 
an increase of SNAI1 expression from primary to metastatic lesion in 3/11 ILC pairs (see Figure 
32). Alternatively, as described previously, SNAI1 may be upregulated only transiently in ILC to 
contribute to resistance phenotypes, or as a marker. Future studies could pursue regulation of 
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SNAI1 in tumor explants obtained from ILC patient tissue. These data may assist in concluding the 
transient upregulation of SNAI1 between these systems post 4OHT treatment. 
The intriguing interaction between SNAIL and LSD1 was confirmed for the first time, 
endogenously, in our ILC cells MDA-MB-134-VI (see Figure 34)[206]. LSD1 is also upregulated 
in both ILC and IDC cells, and its knockdown in MDA-MB-134-VI led to significant decreases in 
EMT-TF programs (see Figure 33, 35). Additionally, promising increased expression of KDM1A 
in primary ILCs as compared to IDCs was observed (see Figure 33C). Manipulation of this 
SNAIL/LSD1 axis may be achieved by treatment with LSD1-specific inhibitors that are currently 
under clinical development for use in cancer[207]. LSD1 belongs to the overarching protein family 
of Monoamine Oxidases. Interestingly, the class of Monoamine Oxidase inhibitors (MAOis), have 
been in use clinically for decades for the indication of depression[208]. The role of LSD1 in 
controlling EMT programs has now been well-described[178, 209]. Further, the interaction between 
LSD1 and ERα in MDA-MB-134-VI was detailed recently, and may provide an interesting 
strategy for alleviation of 4OHT-driven phenotypes as compared to targeting SNAI1[210]. 
Altogether, these data suggest that repurposing of MAOi therapeutics, or use of these more 
targeted inhibitors should be thoroughly explored in the context of ILC. 
Finally, we observed the general growth phenotypes of ILC cells in two additional 
environments that may more faithfully recapitulate the clinical setting for ILC cells: soft agar and 
protein micropatterned growth environments. The loss of E-cadherin in ILC cells likely contributes 
to their decreased soft agar colony formation and generally discohesive growth pattern (see Figure 
36, Appendix B Figure 87). Our difficulties with adherence of MDA-MB-134-VI cells in the 
micropatterning experiments were an interesting observation (see Figure 37). These data have been 
recapitulated in an ECM adhesion assay with the same proteins and the same cells, performed by 
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a colleague (Nilgun Tasdemir, PhD unpublished results). However, the lower attachment in all 
protein environments was most apparent in MDA-MB-134-VI cells compared to the other ILC cell 
lines. Further exploration regarding growth of ILC cells in multiple environments will be required 
in order to understand their basic phenotypes. 
In summary, our results indicate that 4OHT-driven phenotypes are present in some ERα+ 
ILC cells (MDA-MB-134-VI, Sum44PE), and directly causes ERα to promote expression of EMT-
TF SNAI1. Though manipulation of SNAIL was technically difficult to achieve, its transient 
overexpression revealed a previously undescribed role for decreased tumorigenic phenotypes as 
opposed to enhanced EMT. Overall, the EMT panel tested was upregulated in ILC relative to IDC 
cells, but this does not fully translate to the clinical setting in primary samples studied. Further 
studies in metastatic lesions are necessary, and will assist in elucidation of the EMT-TF program 
as a potential target in ILC. LSD1 is an attractive and interesting novel target in ILC that we have 
identified. Finally, context of ILC proliferation is imperative; cells responded differently to SNAI1 
manipulation in 2D versus ULA, and soft agar growth and protein micropatterning experiments 
showed that ILC cells do not have the same phenotypes as IDC cells. Overall, our studies provide 
the first molecular descriptions of SNAIL in ILC, provide evidence for alternative functions for a 
well-studied protein, suggest a novel therapeutic target for ILC patients that may be confronted 
with currently FDA-approved inhibitors, and encourage further exploration of the environmental 
contexts that affect ILC growth. 
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3.0  ESTABLISHMENT AND CHARACTERIZATION OF NOVEL INVASIVE 
LOBULAR CARCINOMA CELL LINE WCRC0025-76M (WCRC-25) 
3.1 INTRODUCTION 
Immortalized and transformed cell line models serve as important tools to understand the etiology, 
mechanisms, and basic characteristics of diseases[211]. Use of these in vitro systems have various 
benefits including the ability of cells to indefinitely replicate, generally maintain a homogenous 
population to allow assessment of specific scientific questions in a focused manner, and ease or 
accessibility for a variety of researchers to obtain and maintain as compared to in vivo or clinical 
models[212, 213]. While highly beneficial to the field of science, cell line models also have 
limitations. These include the questionable representation of a single cell line for a given subtype 
of disease, lack of appropriate culture methods to effectively and faithfully recapitulate the clinical 
setting, and widespread issues with reproducibility due to the existence of variants or 
unauthenticated cultures[214-216]. To counteract some of these pitfalls, consortiums have been 
developed to provide guidelines for the proper development and characterization of cell lines, a 
process that was followed rigorously in the following study[217]. Despite these drawbacks and 
ongoing rigor and reproducibility concerns, cell line research has successfully contributed to the 
vast majority of scientific studies that have been undertaken in the last half century.  
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3.1.1 Brief History of Cell Line Derivation 
The first immortal cell line was established by Dr. Gorge Otto Gey of Johns Hopkins University 
in 1951 from the biopsied cells of a cervical cancer patient, Henrietta Lacks[211-218]. These cells are 
commonly known by their moniker “HeLa,” a nomenclature derived from the first two letters of 
Lacks’ first and last names, respectively. Dr. Gey was a University of Pittsburgh alumnus, having 
spent his undergraduate years immersed in studying biology, and subsequently moving on to Johns 
Hopkins to complete his medical degree and initiate a nearly four decades’ long tenure as a teacher 
and researcher[219]. Dr. Gey and his wife, Margaret, are credited with establishing the Tissue 
Culture Laboratory at Johns Hopkins and attempting to generate immortal cell lines for decades 
prior to the fortuitous discovery of the special nature of HeLa cells. One of the largest barriers to 
cell line establishment was identifying a cell population that had lost control of the ability to 
senesce, or to stop dividing, as most cells do after a few dozen divisions[220-222]. Beyond the lack 
of these “molecular brakes,” it was also known that cells required a highly specialized growth 
environment with temperature control and complex mixtures of growth factors to support 
continued proliferation[223-225]. Dr. Gey’s highly intuitive roller drum technique allowed him to 
nurture HeLa cells for use in experiments that have spanned decades of research, covering 
multitudes of diseases[226]. His pioneering work has become a foundation for cell line 
establishment, both in the positive aspects described and in the negative, unethical nature by which 
the original HeLa sample was obtained. This example has spurred ethical considerations regarding 
informed consent, a process that is now highly respected and upheld within the field of medicine, 
today[227, 228]. 
  The first breast cancer cell line was established in 1958 in the laboratory of Lasfargues 
and Ozzello, and is called BT-20[229]. BT-20 was isolated from a primary lesion of a ductal 
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carcinoma of no special type, and is classified as triple negative (ER-/PR-/HER2-)[230-233]. Unlike 
HeLa, BT-20 was derived using a methodology known as “spilling,” where epithelial cells were 
collected from sliced donor tissue, soaked in culture media in a gentler format devoid of harsh 
chemical or mechanical dissociation[234]. In a more natural progression, epithelial cells from 
tumors would leach from tumor tissue along with various other cell types (lymphocytes, 
fibroblasts, etc.) to generate semi-turbid, heterogeneous cultures. Differential centrifugation or 
colony picking methodologies such as the “glass ring technique” were utilized to separate precious 
epithelial tumor cells from the fibroblast compartment, which tended to outgrow all other cell types 
in a culture dish. Additionally, collagen-coated plates were often employed to mimic a more 
physiologically relevant growth environment. However, the use of collagen was sometimes 
unsuccessful, with cells mechanically pulling on the collagen fibers to induce tears, exposing the 
glass plate, or collagen peeling off plates after media changes. The complexity of media additives 
also became quickly apparent, as researchers attempted to use umbilical cord sera, add or remove 
hormones, growth factors, and eventually find the importance of use of standard fetal bovine 
sera[235]. Further, scientists understood that metastatic lesions, particularly from ascites or pleural 
effusions, were some of the most successful samples to produce stable cultures[236]. 
3.1.2 ILC Cell Line Models Overview 
Though the isolation and cultivation of BT-20 gave hope to the field of breast cancer research in 
the late 1950s, and a few cell lines followed, there were many difficulties encountered in the 
derivation of additional cell lines[237]. Thus, it was not until the 1970s that a series of breast cancer 
cell lines were established and characterized at MD Anderson in Houston, Texas[236]. This cell line 
series was indicated with “MDA-MB” in the first portion of their collective names, and include 
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the first established lobular carcinoma cell line, MDA-MB-134-VI. Initially described in 1974 by 
Cailleau and colleagues as derived from the pleural effusion of a ductal carcinoma, it was not until 
2006 that Reis-Filho and colleagues reclassified MDA-MB-134-VI as a Luminal A ILC through 
extensive molecular genetics and expression profiling comparisons against classic ILC lesions[238]. 
Current literature is still filled with conflicts about the origin of this cell line, with many 
publications citing the original pathology calls given to the patient samples obtained in the early 
1970s[204]. This example of reexamination of cell lines by focusing on key genetic aberrations, 
such as well-established CDH1 mutations described in ILC clinical samples, may allow for future 
reclassifications of other cell lines that maintain ILC-like phenotypes and have potentially been 
misclassified as ductal or adenocarcinomas of the breast (e.g. CAMA-1, ZR-75-30)[186, 239].  
The general molecular and physiologic characteristics of MDA-MB-134-VI have been 
recently described[132, 240]. MDA-MB-134-VI are ER+/PR-/HER2-, and have LOH of CDH1 due to 
deletion of exon 6, leading to a frameshift mutation and premature stop codon[172]. Additionally, 
MDA-MB-134-VI have overexpression of FGFR1, attributed to a commonly observed lobular 
chromosomal gain at 8p11-p12[238, 240]. MDA-MB-134-VI cells are predominantly a rounded 
morphological cell population, with occasional spindle-shaped cells that seem to become more 
apparent in higher passage cultures. Doubling times for MDA-MB-134-VI cells are also the fastest 
among all established ILC cell lines, estimated around two days. Our group is among the first to 
characterize the limited stable phenotypes of MDA-MB-134-VI. These include generally slower 
2D proliferation and enhanced ULA proliferation in comparison to IDC cultures, limited migratory 
and invasive capacities, and decreased anchorage-independent soft agar growth (see Chapter Two, 
Nilgun Tasdemir, PhD unpublished results). As described in the previous chapter of this 
dissertation, our group has also recently used this model system to uncover a role for de novo 
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Tamoxifen resistance in lobular carcinoma; 4OHT leads to upregulation of EMT-TF SNAI1, and 
4OHT partial agonist 2D proliferation induction is abrogated by inhibition of FGFR1[132]. Beyond 
our group’s descriptions of these cells, few studies have utilized MDA-MB-134-VI to describe 
ILC phenotypes, or ineffectively detailed the capacity of use of the model. For example, only one 
study previously dictated that injection of MDA-MB-134-VI by tail vein into nude mice did not 
lead to generation of xenografts[184]. In direct contradiction to this finding, our laboratory has 
recently discovered the effective use of MDA-MB-134-VI as a xenograft by tail vein injection 
(nude mice), mammary fat pad injection (NSG mice), and in a Mammary Intraductal Injection 
(MIND) model (Nilgun Tasdemir, PhD unpublished results)[241, 242]. Potential rationales for this 
discrepancy include the use of subcutaneously implanted slow-release estradiol pellets in our 
studies to drive the ERα+ tumor growth, and patience in waiting for the cell line xenograft to 
establish. Future studies will focus on the elucidation of molecular mechanisms that drive the 
homing of these cells to niches, and establishment of cultures that can be serially transplanted to 
increase the organ tropism preference of cells. Though these observations will not be detailed in 
this thesis, they will contribute to our basic understanding of ILC and its general phenotypes. These 
data challenge the previously stated lack of utility of these cell line model systems in a translational 
capacity[204]. 
After MDA-MB-134-VI, MDA-MB-330 was the first cell line pathologically defined to be 
derived from an ILC pleural effusion in 1974[184]. Conflicting reports dictate that it was devoid of 
ERα expression, but we have shown that this observation is likely based off its limited response to 
estradiol as opposed to a lack of mRNA and protein expression[243-245]. Thus, we describe MDA-
MB-330 as an ERα+ ILC cell line model. In addition, MDA-MB-330 cells are PR- and HER2+, 
with HER2 expression being rare among ILC cell lines and lesions[67]. This expression likely 
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contributes to its mixed classification as having Luminal-HER2 subtype[233]. E-cadherin is also 
still expressed at both transcript and protein levels in MDA-MB-330[239, 246]. Instead, these cells 
harbor a mutation in CTNNA1, or α-catenin, which leads to dysfunctional E-cadherin that is 
incapable of interacting at the adherens junction[63]. The doubling time of MDA-MB-330 is one 
and a half to two weeks, limiting the use of this culture in many classic phenotypic experiments. 
The morphology of these cells is more cobblestone-like in appearance, differing greatly from the 
observed rounded morphology in ILC patient specimens and commonly used MDA-MB-134-VI 
cell line. Like observations made with cell line xenografts in MDA-MB-134-VI, our group has 
already assessed that there is potential utility of this cell line in various injection models 
(experiments in progress). MDA-MB-330 was a model of utility in the work of this dissertation, 
and will likely grow in popularity as a model of ILC as it becomes more well-known in upcoming 
publications. 
Sum44PE is a member of the “SUM” series of cell lines derived by Ethier and colleagues 
at the University of Michigan in the early 1990s from a malignant pleural effusion[247]. Sum44PE 
is ER+/PR-/HER2-, and classified as Luminal A. A truncation mutant of E-cadherin is produced in 
Sum44PE by the deletion of a thymidine at position 423 of exon 9. The morphological 
characterization of Sum44PE is highly heterogeneous, with the existence of three distinct cell 
populations noted: round, spindle-shaped, and a larger cell type. Careful observation of these 
populations over time has shown the predominance of the spindle-shaped cell in higher passage 
cultures. Doubling time has been noted by some groups to be as short as one day, but our group 
has observed that the doubling time of Sum44PE is closer to five to seven days, with cultures 
taking the longest period to adhere to culture vessels and often becoming detached easily by 
premature agitation of a flask[204]. Like MDA-MB-134-VI, Sum44PE is more highly utilized in 
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ILC research, and maintains amplification of the 8p11-p12 chromosomal locus and FGFR1 
overexpression[247]. However, Sum44PE is also maintained in the most complex tissue culture 
medium, containing many unique growth factors that were deemed necessary during initial 
epithelial cell selection on collagen-coated plates[248]. Much like previous observations made 
regarding MDA-MB-134-VI and MDA-MB-330, we find interesting in vivo applications for 
Sum44PE xenografts, and will elucidate on these outcomes in upcoming publications (Nilgun 
Tasdemir, PhD unpublished results). 
The next ILC cell line model that was utilized in this dissertation is not a classical ILC cell 
line. BCK4 cells were derived from a mucinous breast cancer pleural effusion that had been 
exposed to Tamoxifen, chemotherapy, and radiation treatments, was xenografted into nude mice, 
and grew out in rounded morphological appearance similar to ILC with a slow doubling time of 
approximately five to seven days[181, 249]. This ILC-like lesion was established as a tissue culture 
model by Jacobsen and colleagues, having ER+/PR+/HER2- expressions, and is currently undefined 
by molecular subtyping. BCK4 cells do not express E-cadherin protein, and the mechanism of loss 
is currently under investigation in our laboratory. We are also currently establishing the phenotypic 
and tumorigenic capacity of these cells in in vitro and in vivo studies (experiments in progress). 
Though this model was utilized throughout this dissertation as a representation of ILC, caution 
should be taken in interpreting results obtained from BCK4 cells as directly representing ILC. 
Instead, this model is more “ILC-like,” and was used due to limitations in numbers of currently 
available ILC models. 
The final ILC cell line that was obtained for limited use in this dissertation is called IPH-
926, and was recently derived by Christgen and colleagues in 2009[182]. The cells were established 
from metastatic ascites from an originally ER+ ILC that was refractory to Tamoxifen and 
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chemotherapies. After establishment, IPH-926 displayed ER-/PR-/HER2- expressions. Despite loss 
of ER and PR, IPH-926 is still classified as Luminal by molecular subtyping, suggesting that 
expression of luminal markers is maintained by proteins other than ER[250]. Interestingly, IPH-926 
also has the lobular chromosomal gain of 8p11-p12, but does not have concomitant FGFR1 
overexpression. Cells maintain a rounded morphology and double at a time of two weeks. Due to 
this final description, and the lack of ERα expression, these cells were utilized the least in all 
studies. 
A few other ILC or “ILC-like” cell line models exist, and have been described, but were 
not employed in this dissertation. These include the ILC cell line MA-11 (ER-/PR-/HER2-/E-
cadherin+), established in the 1990s from a bone marrow metastasis, and HCC-2185 (ER-/PR-
/HER2+/E-cadherin?) from a pleural effusion of an ILC[251, 252]. Additional cell lines are currently 
under consideration for being reclassified as ILC and include previously mentioned CAMA-1 and 
ZR-75-30, as well as HCC-1187, MDA-MB-453, MDA-MB-468, EVSA-T, MPE600, OCUB-F, 
OCUB-M, SK-BR-3, and SK-BR-5[186, 239]. However, these cell lines are not currently accepted as 
ILC cell models, and were only recently described as “ILC-like” by Michaut and colleagues in 
2016 in a supplemental figure to an ILC proteomic publication[186]. The rationales for not including 
these additional ILC or “ILC-like” models in the dissertation were inaccessibility (HCC-2185, 
discontinued by ATCC), lack of use as an ERα+ model (all except CAMA-1 and ZR-75-30), or 
lack of current acceptance as cell lines as ILC models (all except MA-11 and HCC-2185). 
Additionally, tissue xenografts have been established and characterized in recent reviews, but were 
of limited utility in the previous chapter (HCI-013, HCI-013 EI, and WHIM-9 models did not 
express SNAIL protein)[204, 253]. All described ILC cell lines are detailed in the table below (Table 
4). 
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Table 4: ILC Cell Line Models and Their Basic Characteristics 
Cell Line Source Doubling 
Time (Days) 
ER PR HER2 E-cad 
MDA-MB-134-VI[184, 204, 238] Pleural Effusion 2 + - - -mut 
MDA-MB-330[204, 243-245] Pleural Effusion 7-10 + - + +wt 
Sum44PE[247] Pleural Effusion 5-7 + - - -mut 
BCK4[181, 249] Mucinous Breast Carcinoma 7 + + - -
? 
IPH-926[182] Ascites 14 - - - -mut 
MA-11[251] Bone Metastasis ? - - - + 
HCC2185[252] Pleural Effusion ? - - + ? 
   Abbreviations: mutant (mut), wildtype (wt), unknown (?); Cell lines in italics were used in  
   this dissertation. Note: BCK4 is “ILC-like” and not derived from classical ILC. 
 
3.1.3 Rationale for Establishment of WCRC0025-76M (WCRC-25) 
A clear rationale for the subsequent work arose during the progress of this dissertation: few 
accepted ILC cell line models exist, and additional models of utility and proper characterization 
are desperately needed to push ILC research in a forward trajectory. Thus, we undertook the task 
to (1) establish a novel ILC cell line, (2) characterize its general phenotypes and behaviors in vitro 
and in vivo, (3) compare and contrast observations with currently available ILC cell lines, (4) 
describe drug response in targets of interest for ILC as well as became apparent by various 
DNA/RNA profiles, (5) provide as comprehensive a clinical and computational analyses possible, 
and (6) set an example for how future cell line models could be established, characterized, utilized, 
and distributed in a short period of time. While we do not claim to have novel approaches for every 
aspect of this described work, we do believe that we have combined observations, successes, 
failures, techniques, and hindsight to tell the story of the generous donation of human tissue 
samples from an ILC-afflicted patient, whose ultimate demise gave way to a model of utility in an 
otherwise understudied field of cancer research. The characterization of Women’s Cancer 
Research Center WCRC0025-76M, or WCRC-25, is a culmination of the efforts of a patient, 
 118 
clinicians, and researchers who all deserve credit for the work described in this chapter. I am 
humbled to compile these data for the first time, and look forward to the utility of WCRC-25 as a 
model of ILC in decades to come.     
3.2 MATERIALS AND METHODS 
3.2.1 Acquisition of Patient Samples 
Informed patient consent was performed by trained University of Pittsburgh Cancer Institute 
(UPCI) staff. The sample utilized to generate the cell line was obtained from the patient 
“WCRC0025” or “WCRC-25” at Magee Women’s Hospital remaining from an aspiration of left 
pleural fluid (code: 76M). The sample was processed for tissue culture four days after removal 
from the patient. Remaining samples were obtained and assessed by appropriate immunostaining 
(see 3.2.5). Staining calls were generated by certified pathologists in respective hospitals from 
which samples were obtained. Commentary to assist with macrodissection was supplied by 
certified pathologist Dr. Peter Lucas. 
3.2.2 Establishment of Cell Line 
Pleural fluid was obtained as previously described. Cells were plated in either standard tissue 
culture conditions (37°C, 5% CO2, 21% O2, 95% Humidity; hereafter referred to as 5% CO2) or in 
low oxygen tissue culture conditions (37°C, 5% CO2, 5% O2, 95% Humidity; hereafter referred to 
as 5% O2) in complete Conditioned Media (hereafter referred to as Conditioned Media, or “CM”) 
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prepared by a modified Schlegel method (Figure 38)[254, 255]. Cells were initially plated in either 
standard 2D plates or ULA plates, with or without supplementation of Rock inhibitor (±Rocki) (Y-
27632, Enzo Life Sciences#ALX-270-33-M005). 
 
 
Figure 38: Modified Schlegel Method for Establishment of WCRC-25 Cell Line 
Media were prepared in collaboration with Ms. Julie (Arlotti) Scott by the method shown 
above[254, 255]. J2 fibroblast media were stored in aliquots at -80°C until needed for culturing. 
Cells were established in both oxygen level environments. 
 
3.2.3 Cell Lines Utilized 
ILC cell lines utilized for comparisons to WCRC-25 were previously described in the prior chapter, 
and include MDA-MB-134-VI, Sum44PE, and IPH-926. IDC cell lines utilized in this chapter 
include previously described MCF-7, T47D, and MDA-MB-231. The non-tumorigenic human 
mammary epithelial cell line, MCF-10A, was used as a control for immunofluorescence studies. 
Also, the triple negative breast cancer cell line, BT-549, was used as a control for 
immunofluorescence studies (ATCC) (RPMI-1640/10% FBS). Finally, murine (BALB/c) stromal 
associated fibroblasts (SAFs) stably infected with shScramble or shPRDX1 were graciously 
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provided by Carola Neumann, MD, and were maintained in DMEM supplemented with 10% FBS, 
5% O2. Both cell types were used, but only shPRDX1 SAFs were shown imaged in the 
immunofluorescence, as the loss of PRDX1 has been published to lead to a cancer associated 
fibroblast (CAF) phenotype, with expression changes in stromal markers such as α-Smooth Muscle 
Actin (αSMA)[256-258]. For in vivo studies, WCRC-25 cells were stably infected with lentivirus 
containing red fluorescent protein (RFP) and luciferase, and sorted for the top 5% of highly 
expressing cells by Flow Cytometry by Nilgun Tasdemir, PhD. As a control for the MIND study, 
DCIS Sum225 cells were graciously provided by Priscilla McAuliffe, MD, PhD. 
3.2.4 Immunofluorescence (IF) 
IDC, SAF, or MCF-10A control cells were plated at 100,000 cells/well on autoclaved glass 
coverslips (Fisher#12-545-84) in 12-welled plates, and ILC cells at 300,000 cells/well. Cells were 
allowed to adhere for 1.5 days in respective media and incubator conditions, then media was 
removed, and cells were fixed in 4% final concentration paraformaldehyde (Electron Microscopy 
Services#15710-S) diluted in 1X DPBS for 30 minutes at room temperature. Coverslips were then 
stored in 1X DPBS at 4°C until use, not to exceed 1.5 weeks of storage. Coverslips were transferred 
to 1X DPBS moistened parafilm in large opaque boxes, and were kept moist and unexposed to 
light throughout the staining process. Samples were blocked in blocking buffer (0.3% Triton X-
100 (Sigma#T8785-50ML), 5% BSA (Sigma-Aldrich#A9647-500G), 1X DPBS) for 30 minutes at 
room temperature. Blocking buffer was removed from all but the “No Primary Control” coverslips, 
and samples were incubated in primary antibodies at ~100-200 µL/slip for one hour at room 
temperature (Appendix A Table 11). Coverslips were then washed in 1X DPBS three times, and 
then were all incubated in respective secondary antibodies at ~100-200 µL/slip for 45 minutes at 
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room temperature (Appendix A Table 11). Samples were again washed in 1X DPBS three times, 
and then remaining liquid were carefully wicked with a KimWipe prior to application to ~15 µL 
DAPI Prolong Diamond (Thermo Fisher#P36962) on glass slides. Slides were stored at room 
temperature in a dark drawer, overnight, and then stored long-term at 4°C in a light-resistant folder. 
Preliminary images were obtained on the Inverted IX83 Olympus Microscope/Nikon Camera and 
final images were taken on a Confocal Microscope at 40X with assessment of No Primary Controls 
and adjustments made to the most/least expressing entities prior to taking images at the same 
exposure settings.    
3.2.5 Clinical Sample IHC 
Hematoxylin and Eosin (H&E), E-cadherin/p120, and ERα staining was performed within the 
University of Pittsburgh Medical Center hospital system. Slides were deparaffinized at 72⁰C and 
conditioned by ULTRA cell conditioner process. Then, slides were incubated with E-cadherin 
antibody, ultra-blocked, and denatured at 80⁰C. Dual staining was performed by incubating slides 
with p120 antibody, then counterstaining with hematoxylin, and completing by addition of a 
coverslip. A similar process was performed for ERα, but without dual staining. Antibodies used 
can be found in Appendix A Table 12. 
3.2.6 IB 
Immunoblotting was performed as previously described in the prior chapter by the RIPA/SDS 
Protocol. Antibodies and concentrations used can be found in Appendix A Table 6.  
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3.2.7 FFPE Generation and E-cadherin/p120 IHC 
WCRC-25 cells were cultured in CM-Rocki or DMEM/10% FBS, 5% O2 until P17. Cells were 
grown to ~90% confluence in 15 cm2 dishes, and samples were processed as previously described 
(see 2.2.15). The Magee-Womens Research Institute Histology and Microimaging Core facility 
embedded, cut, and stained samples for E-cadherin/p120 (see 3.2.5). Images were obtained on a 
bright field microscope at 20X magnification. Unstained sections were used for isolation of 
mRNA/DNA to control for FFPE degradation of nucleic acids. 
3.2.8 E2/SERM/SERD Response Assays 
Estrogen deprivation assays were performed as previously described (see 2.2.2). mRNA studies 
utilized 1 nM E2, 1 µM 4OHT, or 1 µM ICI. Vehicle conditions were matched when required in 
experiments performed. Downstream assessment of mRNA expression was performed after 24 
hours of treatment, as previously described, with 500 ng of converted mRNA per triplicate sample. 
qRT-PCR primers used can be found in Appendix A Table 5. Dose responses were performed with 
5,000, 10,000, or 15,000 cells/well in CM-Rocki, 5% O2 in 2D 96 welled plates containing 6 
technical replicates per dose E2 given. One plate was also assessed with 15,000 cells/well in CM-
Rocki, 5% CO2. Plates were collected at D7 and measured by Hoechst Fluorescence with correction 
and normalization as previously described (see 2.2.3). 
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3.2.9 Sequencing for CDH1/CDH1 Mutation 
mRNA was converted into cDNA using standard protocol previously described, and then CDH1 
primers were supplemented to products and sent to Genewiz for Sanger Sequencing (primers are 
listed in Appendix A). Genomic DNA (gDNA) were isolated from WCRC-25 cells using the 
DNeasy Blood & Tissue Kit manufacturer’s protocol (Qiagen#69506). gDNA were amplified by 
PCR using the primer set surrounding Exon 13, listed in Appendix A Table 13. Amplified products 
were run on a 1% agarose gel by standard gel electrophoresis, and the band of interest was excised 
and purified using the QIAquick Gel Extraction Kit manufacturer’s protocol (Qiagen#28706), 
followed by concentration of product using the DNA Clean & ConcentratorTM-5 Kit 
manufacturer’s protocol (Zymo Research#D4014). Samples were sent to Genewiz for Sanger 
Sequencing (WCRC-25 Mutant Forward Primer: GAAGCCAAAGATGGCCTTAGA; WCRC-25 
Mutant Reverse Primer: GGCATAACTTGGGAGTCTCTTT). 
3.2.10 Circulating Free DNA (cfDNA) Isolation and Droplet Digital Polymerase Chain 
Reaction (ddPCR) 
cfDNA were isolated in collaboration with Ahmed Basudan, BS and Karthik Kota, MD. The 
ddPCR probe was custom-generated through Thermo Fisher Scientific. Blood samples were 
obtained through patient consent at Magee Women’s Hospital. Sterile isolation was performed in 
a circulation-free environment with Qiagen QIAamp Circulating Nucleic Acid Kit (Qiagen#55114) 
using LoBind/PCR clean Eppendorf Tubes and Filter Tips, only (Eppendorf). Plasma samples 
were first centrifuged at 1,500 rpm for 5 minutes to pellet any potential debris, and clear 
supernatant were kept for cfDNA isolation. Supernatant were combined with 10% (of original 
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plasma volume) volume Qiagen Proteinase K (Qiagen#19131), followed by 80% (of original 
plasma volume) volume Buffer ACL. Samples were pulse-vortexed for 30 seconds, or until a 
homogenous solution formed. Samples were then incubated at 60°C in a water bath for 30 minutes. 
After incubation, 180% (of original plasma volume) volume Buffer ACB were combined with the 
samples, followed by pulse-vortexing for 30 seconds, and incubation on ice for 5 minutes. Samples 
were then applied to a QIAamp Mini column vacuum system. Buffer ACW1 (600 µL), Buffer 
ACW2 (750 µL), and 100% Ethanol (750 µL) were then passed through the vacuum in sequential 
order. The columns were then centrifuged at 14,000 rpm at room temperature for 3 minutes in 
collection tubes to remove residual Ethanol. The columns were then transferred to new collection 
tubes with incubation at 56°C for 10 minutes to dry the membrane completely. Columns were 
finally transferred to final collection tubes and cfDNA were eluted in 25 µL volumes of Buffer TE 
after incubation at room temperature for 3 minute and centrifugation at 14,000 rpm for 1 minute. 
Samples were always eluted this way, twice, with the same 25 µL of original flow through to 
maximize yield. cfDNA were quantified by Qubit High Sensitivity dsDNA measurement 
(Qubit#Q32871) with 1 µL sample volume. cfDNA were measured by ddPCR using a probe for the 
CDH1 Q706* mutation, ordered through Life Technologies (see Appendix C) on the BioRaad 
QX100 ddPCR System. 4 to 10 ng of unamplified or target amplified cfDNA, WCRC-25 DNA, or 
non-template control (NTC; quality control) were mixed with 1X final concentration ddPCR 
Supermix (BioRad#1863024) and 1X final concentration probe with remaining volume in Nuclease 
Free Water to 26 µL total volume. Droplets were generated using 20 µL of reaction mixture and 70 
µL droplet generation oil. The cell line served as a positive control for the mutation, and the Buffy 
Coat from the patient samples served as the negative control. Samples were assayed in single 
replicates, with minimum 10,000 genome equivalents measured. 
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3.2.11 Population Doubling Assessment 
Immediately after sufficient WCRC-25 cells were available for use from the established CM-
Rocki, 5% O2 environment, cells were split into four conditions for assessment of population 
doubling (5% O2 or 5% CO2; CM-Rocki or DMEM/10% FBS). After minimum two passages in 
these environments, population doubling was measured by plating cells at three differing densities 
(5,000, 10,000, or 15,000 cells/well) in six replicate wells of 2D 96 welled plates. This was 
performed at passages (P) P3, P5, and P7. For the first doubling assessment at P3, multiple plates 
were collected from D0, D3, D7, D10, and D14 time points, but subsequent data only included D0 
and D7.  
Calculations for population doubling were performed as follows: 
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝑇𝑇𝐷𝐷𝑇𝑇𝑇𝑇 𝐷𝐷𝐷𝐷 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 =  
𝑑𝑑𝐷𝐷𝑑𝑑𝑑𝑑𝑑𝑑𝐷𝐷𝐷𝐷𝐷𝐷 𝐷𝐷𝑜𝑜 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝐷𝐷𝐷𝐷 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 ∗ log (2)
log(𝐹𝐹𝐷𝐷𝐷𝐷𝑑𝑑𝐷𝐷 𝑇𝑇𝐷𝐷𝑇𝑇𝑇𝑇𝑇𝑇𝐷𝐷𝐷𝐷𝐷𝐷𝑑𝑑 𝑉𝑉𝑑𝑑𝐷𝐷𝐷𝐷𝑇𝑇) − log(𝐼𝐼𝐷𝐷𝐷𝐷𝑑𝑑𝐷𝐷𝑑𝑑𝐷𝐷 𝑇𝑇𝐷𝐷𝑇𝑇𝑇𝑇𝑇𝑇𝐷𝐷𝐷𝐷𝐷𝐷𝑑𝑑 𝑉𝑉𝑑𝑑𝐷𝐷𝐷𝐷𝑇𝑇)
 
3.2.12 Proliferation and Soft Agar Anchorage Independent Assays 
2D and Soft Agar Anchorage Independent Assays were performed as described in the prior chapter 
(see 2.2.9 and 2.2.16, respectively). Both incubator settings (5% O2 and 5% CO2) were used as 
described in the appropriate figure legend. 
3.2.13 RNA Sequencing 
Samples were prepared and analyzed in collaboration with Ahmed Basudan, BS. FFPE samples 
with pathologist-directed marodissection notes were isolated for RNA and DNA simultaneously 
using manufacturer’s protocol of the AllPrep DNA/RNA FFPE Kit (Qiagen#80234). RNA 
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concentration was determined with the Qubit. DV200 metrics were performed using the Agilent 
4200 TapeStation. Exome-capture RNA-sequencing was performed at the Health Sciences 
Sequencing Core at Children’s Hospital (Pittsburgh, PA) using 25 ng or more RNA in Illumina’s 
TruSeq RNA Access Library with sequencing 40-50 million reads per sample on the Illumina 
NextSeq 500 platform with High Output flow cell (2 x 75, stranded, paired-end reads). FASTQ 
files were mapped and quantified with k-mer based lightweight-alignment with seqBias and gcBias 
corrections (Salmon v0.8, quasimapping mode, 31-kmer index built from GRCh38 Ensembl v82 
transcriptome annotations). Tximport255 was used to collapse gene-level estimates from 
transcript-level abundance, and log2 transformed TMM-normalized CPM (log2normCPM) values 
were utilized for outputs. 
3.2.14 Dose Responses for Chemotherapeutics of Interest 
Dose responses were performed as previously described (see 2.2.3) in 2D or ULA 96 welled plates 
with a control breast cancer cell line with known response (from nM to mM potency) or WCRC-
25. Cells were plated at 5,000 cells/well if IDC, 15,000 cells/well if ILC other than WCRC-25, 
and 10,000 cells/well if WCRC-25. Doxorubicin Hydrochloride (Fisher#D1515), Cisplatin 
(Selleckchem#S1166), and Paclitaxel (Sigma-Aldrich#T7402-5MG) were dissolved in DMSO. 
NVP-BEZ235 (BEZ235; Selleckchem#S1009) was dissolved in Dimethylformamide (DMF; 
Fisher). Plates were collected at D5 and measured by Hoechst Fluorescence or CellTiter-Glo, as 
previously described, with corrections and normalization as previously performed (see 2.2.9).  
 127 
3.2.15 In Vivo Studies 
All mice used were female. Collaborative efforts were undertaken to perform initial injections of 
cells: WCRC-25 RFP cells were injected by Mr. Weizhou Hou into the tail veins (TVs) of n = 6 
NU/J (nude), 6-week old mice (Jackson Laboratories, Stock#002019), by Ms. Julie (Arlotti) Scott 
into the mammary fat pads (MFPs) of n = 8 NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG), 6-week old 
mice (Jackson Laboratories, Stock#005557), or by Daniel Brown, PhD by MIND injection into the 
fourth and fifth, left and right inguinal nipples of n = 8 NSG, 12-week old mice (Jackson 
Laboratories, Stock#005557). One control NSG mouse was simultaneously injected with DCIS 
control cell line Sum225. Due to lack of ERα expression and response, animals were not initially 
given E2 pellets. TV and MFP mice were housed at the Hillman Cancer Center Animal Facility, 
and MIND mice were housed at the MWRI Animal Facility. TV and MFP animals were imaged 
by luciferin injection (Gold Bio#LUCK-1G) of 100 µL/mouse with imaging performed on an IVIS 
200 (Xenogen) after 5 minutes of anesthetization and circulation of luciferin. Imaging was 
performed immediately after respective injections on auto exposure, the subsequent week at 60 
seconds exposure, and then on a biweekly basis until palpable tumors formed. Imaging was 
quantified by measuring luciferase intensity in regions of interest (ROIs). Animal studies are 
currently ongoing, and will be completed after the publication of this dissertation. Preliminary 
outcomes and experimental descriptions are provided within this chapter for discussion purposes. 
3.2.16 Statistics 
Statistics were performed as described in the previous chapter, and are described beneath 
respective experiments for clarification (see 2.2.18). 
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3.3 RESULTS 
WCRC-25 cells were established from the ERα- pleural effusion of a 76-year old Caucasian 
woman afflicted with ER+ ILC. 
3.3.1 Patient WCRC-25 Had a Complex Clinical History 
Patient WCRC-25 was a postmenopausal, Caucasian woman, admitted to the hospital with 
complaints of gastric discomfort. Initial biopsies were taken from the stomach and duodenum, 
revealing poorly-differentiated adenocarcinoma with signet ring features. Routine mammography 
had been performed merely weeks prior to this visit, with notations of the presence of dense breast 
and some scattered calcifications, assessed to be benign. The patient returned to the hospital for an 
additional biopsy of the gastroesophageal junction, which revealed the same pattern of carcinoma. 
A short period later, the patient was readmitted to have an aspirate of pleural fluid and biopsy of 
falciform ligament obtained. The diagnoses for these lesions were all stated to be gastric 
carcinoma, and the patient was subsequently treated with Folinic Acid, Fluorouracil, and 
Oxaliplatin (FOLFOX), a common chemotherapeutic for gastric cancers[259]. WCRC-25 continued 
FOLFOX for approximately 5 months until the appearance of peritoneal lesions, which were 
diagnosed to be consistent with the gastric carcinoma. The chemotherapy regimen was thus altered 
to a combination of Carboplatin and Paclitaxel, additional accepted therapies for advanced, pre-
treated gastric carcinoma[260]. 
Approximately two weeks into the combined treatment regimen, the patient noted concern 
over changes in her right breast. A routine breast exam performed revealed central retraction, 
nipple and areola distortion with crusting, and a large palpable mass. No obvious abnormalities or 
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palpable masses were noted in the left breast, and no palpable lymph nodes were felt on either 
side. A bilateral mammogram and ultrasound were performed shortly thereafter.  
Upon examination, the bilateral mammogram revealed a large mass in the central portion 
of the right breast and associated calcifications. In addition, the left breast had a heterogeneous 
breast tissue appearance with scattered calcifications, again assessed to be benign. The ultrasound 
that was performed next confirmed the presence of the large right mass, and did not reveal any 
additional lesions on this side or in the axilla. However, the left breast had hyperechoic regions in 
two portions, and no associated adenopathy. A final bilateral tomosynthesis was utilized to confirm 
the findings of the initial mammogram and ultrasound. Thus, WCRC-25 was subjected to core 
needle biopsies; one in the right breast, and one of the two regions in the left breast. Staining of 
these core biopsies confirmed ER+/PR-/HER2-/Ki67moderate/E-cadherin- status. It was at this point 
that the patient was diagnosed with ILC in both breasts. Retrospective immunohistochemistry was 
performed on the available original lesions, and these were diagnosed as metastatic ILC lesions 
showing ER expression. 
As WCRC-25 had ER+ ILC, and was postmenopausal, the treatment course was altered to 
Anastrazole in combination with Fulvestrant. An addition of Denosumab was given shortly into 
this endocrine regimen, to offset the negative impacts of bone loss and osteoporosis that afflict 
patients undergoing AI therapy, and to prevent or control potential bone metastases[261, 262]. Amidst 
this treatment course, the region that had not been biopsied originally in the left breast was then 
checked by core biopsy for presence of carcinoma. Staining of this potential unique primary or 
local recurrence revealed the presence of ER-/PR-/HER2- ILC cells. This observation prompted the 
examination of left sentinel nodes, which were positive for metastatic carcinoma. This informed 
the decision to perform bilateral mastectomies. The right breast lesion and both left breast lesions 
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were confirmed to be of the same receptor status and diagnoses given to prior core biopsies. 
WCRC-25 remained on endocrine treatments, and stopped Fulvestrant treatment abruptly (16.3 
months total treatment time) prior to the removal of left pleural fluid aspirate. This sample was 
confirmed to be metastatic ILC, ER-/PR-/HER2-/Ki67high, and remaining sample was given to our 
laboratory for generation of the subsequently described cell line. 
Treatment was again altered for the patient to include Pegylated Liposomal Doxorubicin 
in combination with Anastrazole and Denosumab. Two additional pleural fluid aspirates were 
taken, one of which was confirmed by pathology records to be ER-/PR-/E-cadherin-. Doxorubicin 
was stopped, and small biopsies from the stomach and gastroesophageal junction revealed the 
presence of minimal carcinoma with ER expression. The patient then stopped Anastrazole 
treatment and was immediately put on Exemestane. Shortly after, more pleural fluid (ER-/PR-
/HER2-) was aspirated, prompting the addition of Gemcitabine to the treatment. Skin biopsies, 
further pleural fluid aspirates, and pericardial fluid aspirates taken during this time period were 
also determined to be ER- breast cancer metastases. Gemcitabine was then switched to Eribulin, 
still in conjunction with the Exemestane and Denosumab. During the Gemcitabine and Eribulin 
treatments, four blood draws were taken over a 4-month period; three were from the Gemcitabine 
treatment and one during the Eribulin. These were promptly processed for isolation of cfDNA in 
our laboratory, and will be described in a later section of this chapter. Pleural fluid aspirates and 
peritoneal fluid aspirates continued to persist until the patient’s death. This complex clinical course 
and clinical sample collection is detailed in Figure 39 (sample numbers included in similar version 
in Appendix C Figure 89), with sample images and associated IHC in Figure 40-44, and an 




Figure 39: WCRC-25 Patient Clinical and Sample Acquisition Timeline 
A compressed timeline (not to scale) of the WCRC-25 patient’s clinical course is detailed above. 
De-identified clinical information was provided by Karthik Kota, MD. Samples pertinent to this 
project were listed. Asterisks (*) denote samples taken during biopsy. Dashed boxes around the 




Figure 40: IHC from Therapy Naïve Samples from WCRC-25 Patient 
IHC including H & E, E-cadherin/p120, and ERα staining was performed on WCRC-25 patient 
samples. Above are 20X magnification, bright field images from the therapy naïve samples taken 




Figure 41: IHC from Breast Biopsy Samples from WCRC-25 Patient 
IHC including H & E, E-cadherin/p120, and ERα staining was performed on WCRC-25 patient 
samples. Above are 20X magnification, bright field images from the chemotherapy treated (Left 
Biopsy1, Right) and endocrine therapy treated (Left Biopsy2) samples. It should be noted the E-




Figure 42: Double Breast Mastectomy IHC for WCRC-25 Patient 
IHC including H & E, E-cadherin/p120, and ERα staining was performed on WCRC-25 patient 
samples. Above are 20X magnification, bright field images from the chemotherapy and 
endocrine therapy treated left and right double mastectomy samples. The Left Mastectomy1 and 
Left Mastectomy2 coordinate with the positions of appropriately numbered biopsies. Left 






Figure 43: IHC from WCRC-25 Cell Line Sample of Origin 
IHC including H & E and ERα staining was performed on WCRC-25 patient samples. E-cad/p120 
was not performed for this sample. Above are 20X magnification, bright field images from the 
chemotherapy and endocrine therapy treated Pleural Fluid Left Side1 sample, the same sample that 
was used to establish the WCRC-25 cell line. 
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Figure 44: IHC from All Chemotherapy or Endocrine Therapy Treated Metastatic Lesions, 
Except WCRC-25 Cell Line Origin Sample 
IHC including H & E, E-cadherin/p120, and ERα staining was performed on WCRC-25 patient 
samples. Above are 20X magnification, bright field images from the chemotherapy (Peritoneum) 
and endocrine therapy treated (all other) samples. Samples are in chronological order of resection 
from the patient. The Pleural Fluid Left Side2 was the last sample acquired from the patient prior 
to death that is in our possession. 
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3.3.2 Establishment of WCRC-25 Cell Line from Patient Sample 
As described in the methods section, a left pleural effusion sample aspirate was obtained in our 
laboratory and processed for tissue culture establishment. Evaluation of FFPE sample was 
immediately performed, and revealed ERα- status, as previously described (see Figure 43). Cells 
plated in the ULA plates in CM±Rocki at 5% CO2 had zero viability, but those in the 5% O2 
incubator had some viability. A later attempt to resuscitate the ULA CM-Rocki 5% O2 cells was 
performed, and though cells were kept in culture for a few months, viability was determined to be 
very low by Trypan Blue exclusion, and cells were frozen down for liquid nitrogen storage. 
Unfortunately, due to a malfunction in the liquid nitrogen tank where these ULA CM-Rocki 5% 
O2 cells were being stored, the cells were lost, and cannot be replaced. However, the vial of ULA 
CM+Rocki 5% O2 remains in an alternative storage location, and may be used in the future should 
an attempt to expand these cells be deemed necessary. 
 Attempts to establish the WCRC-25 cell line in the 2D plates was successful. Cells adhered 
to plates in all conditions, and showed the most viability in the 5% O2 CM-Rocki condition. Cells 
were partitioned from the 5% O2 CM-Rocki condition into an additional media condition of 
DMEM supplemented with 10% FBS, in either incubator setting, and were cultured for all 
downstream studies from P3. Phase contrast images revealed a similar morphology for these cells 
in all conditions, with less viability noted in the CM-Rocki 5% CO2 environment (Figure 45). In 
addition, these cells appear larger than other ILC cells, such as MDA-MB-134-VI, BCK4, or IPH-
926, and have a less rounded morphology with faster adherence to 2D plates compared to MDA-
MB-134-VI or Sum44PE.  
 138 
 
Figure 45: Established WCRC-25 Cell Line in Differing Culture Conditions 
WCRC-25 cells were established in the Conditioned Media (CM)-Rocki media, 5% O2 incubator 
(top left). Cells were then distributed four ways: CM-Rocki versus DMEM/10% FBS, and 5% O2 
versus 5% CO2. Cells were imaged under phase contrast at P11 (10X magnification; bars represent 
100 µm). 
3.3.3 Expression of Epithelial/Stromal Markers in WCRC-25 
WCRC-25 cells cultured in CM-Rocki 5% O2 were assessed for expression of a panel of epithelial 
and stromal markers to characterize basic luminal/basal marker expression and to exclude these 
cells from the stromal compartment. WCRC-25 cells expressed high levels of epithelial luminal 
markers CK8/18 and epithelial marker EpCAM, as did IDC cell line MCF-7 and ILC cell line 
MDA-MB-134-VI (Figure 46). EpCAM was noted to be “patchy positive” upon examination of 
the original pleural effusion sample tested in clinic, per retrospective pathology report analyses. 
The cell line staining suggests a potential enhancement for this expression through the short-term 
culturing that had occurred, perhaps by outgrowth of the epithelial cells as opposed to any 
contaminating stromal or immune cells[263]. Further, lack of expression of the most commonly 
cited fibroblast marker αSMA in WCRC-25 confirmed the presence of epithelial as opposed to 
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stromal cells in the continued cultures. Lack of αSMA expression in WCRC-25 was also confirmed 




Figure 46: WCRC-25 Cells Express Epithelial, Not Stromal Markers 
WCRC-25 cells and appropriate negative (CK8/18, EpCAM, and αSMA: MDA-MB-231) and 
positive (CK8/18 and EpCAM: MCF-7; αSMA: shPRDX1) controls were stained for epithelial 
markers CK8/18, EpCAM, and stromal marker αSMA. Images were taken on a confocal 
microscope at 40X (CK8/18, EpCAM) or an inverted fluorescent microscope (αSMA) at 40X 




 IF was then performed for E-cadherin and ERα in WCRC-25. Punctate, cytoplasmic E-
cadherin staining was observed in WCRC-25, much like MDA-MB-134-VI, and unlike the cell 
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membrane localized E-cadherin visualized in MCF-7 cells (Figure 47). Though highly vibrant 
puncta were observed in the ILC cells, little concern was felt. This is because punctate E-cadherin 
staining has previously been visualized in ILCs, sometimes called a “beaded” staining pattern by 
pathologists[75, 173, 264, 265]. ERα expression appeared only as a haze across the entire cell for WCRC-
25, as observed in negative control cell line MDA-MB-231. Positive nuclear ERα staining was 




Figure 47: E-cadherin and ERα Are Not Expressed in WCRC-25 Cells 
WCRC-25 cells and appropriate negative (E-cadherin and ERα: MDA-MB-231) and positive (E-
cadherin and ERα: MCF-7) controls were stained for E-cadherin and ERα. Images were taken on 




E-cadherin was confirmed to not be expressed at the protein level in both WCRC-25 and 
MDA-MB-134-VI by IB and in WCRC-25 by IHC, with characteristic cytoplasmic p120 staining 
observed in IHC (Figure 48A, B). ERα was also confirmed to not be expressed at the protein level 
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in WCRC-25 by IB (Figure 48A). Together, these data confirmed the lack of E-cadherin and ERα 




Figure 48: E-cadherin and ERα Are Not Expressed at the Protein Level in WCRC-25 
(A) E-cadherin, ERα, and internal control Actin were probed by IB in WCRC-25 cells beside 
control cell lines MCF-7 (E-cadherin+, ERα+) and MDA-MB-134-VI (E-cadherin-). IB is 
representative of three independently performed experiments. (B) IHC was performed on FFPE 




As WCRC-25 appeared to have more basal expression characteristics, two basal markers 
that have been classically associated with poor prognosis were also assessed by IF: CK5 and 
CK14[266]. WCRC-25 did not express CK5, but did express CK14 (Figure 49). Interestingly, a 
recent study has indicated the existence of a basal subtype of ILC tumors that express CK5/6; this 
study did not measure CK14 in this basal subtype of ILC tumors, so it is possible that CK14 could 
also be a marker for this subset of ILCs[267, 268]. MDA-MB-134-VI, a noted luminal cell line, 
expressed CK14. This observation may be explained by identification of a basal marker-expressing 
(CK5, CK14, EGFR) subset of luminal tumors with ER+/HER2- status[269]. This unique subtype 
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has been preliminarily described to have better prognosis than other subtypes, such as TNBC, that 




Figure 49: CK14, But Not CK5, Is Expressed in WCRC-25 
WCRC-25 cells and appropriate negative (CK5: MDA-MB-231; CK14: MCF-7) and positive 
(CK5 and CK14: MCF-10A) controls were stained for basal markers CK5 and CK14. Images 




Overall, we identified the expression of epithelial markers (CK8/18, EpCAM), a basal 
marker (CK14), and the lack of ERα, E-cadherin, CK5, or stromal marker αSMA in WCRC-25. 
We thus concluded from these data that WCRC-25 is an epithelial ILC cell line with loss of 
expression of characteristically expressed ERα and potential basal characteristics.  
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3.3.4 A Continued Elaboration on ERα Function in WCRC-25 
Though ERα did not appear to be expressed at the protein level by IF or IB, the original pleural 
effusion FFPE IHC we had in our possession had suggested potential low levels of ERα expression 
(see Figure 43). To assess if there was still some small residual amount of ERα left in WCRC-25 
that was difficult to visualize by IF or IB, we first performed qRT-PCR for ESR1 with WCRC-25, 
MDA-MB-231 (negative control), and MCF-7 (positive control) cells. We observed significantly 
higher ESR1 expression in MCF-7 as compared to WCRC-25 and MDA-MB-231 cells (***p < 
0.0005) (Figure 50A). Though not significant, we did observe an increase in ESR1 expression in 
WCRC-25 cells relative to MDA-MB-231 cells (WCRC-25: Ct = 35-36; MDA-MB-231: Ct = 38 
or N.D.). This observation of ESR1 mRNA expression in WCRC-25 led us to next test if this low 
level ESR1 was producing low level functional protein product. We treated WCRC-25 CM-Rocki 
5% O2 cells with 1 µM ICI for 24 hours to see if any endogenous ERα activity could be decreased 
through classic target gene GREB1 expression or ESR1 expression itself; however, this was not 
observed (Figure 50B). We also performed E2 deprivation of our CM-Rocki 5% O2 cells followed 
by treatment with Vehicle control, 1 nM E2, or 1 µM 4OHT for 24 hours to assess ERα-regulated 
gene expression, and found only mild and non-significant inductions of GREB1 and ESR1 (Figure 
50B). A similar mild induction of SNAI1 was observed in WCRC-25 cells when E2 or 4OHT were 






Figure 50: ESR1 is Expressed at Low Levels in WCRC-25 and ERα-Targets Are Not 
Regulated by Endocrine Treatments 
(A) WCRC-25, positive control (MCF-7) and negative control (MDA-MB-231) cells were first 
assessed by qRT-PCR for ESR1 expression. (B) Then, WCRC-25 cells were treated to 1 µM ICI 
or E2 deprivation followed by 1 nM E2 or 1 µM 4OHT with assessment of GREB1 or ESR1 
expression alterations by qRT-PCR. Quantifications are a representative single experiment of three 
independent attempts (A) or of a single experiment with technical triplicates ± STDEV, normalized 
to WCRC-25 without treatment (B). Statistics were performed with One Way ANOVA followed 





Additionally, endogenous GREB1 expression patterns matched with each cell line based 
on measured ESR1 expression (highest to lowest: MCF-7 > WCRC-25 > MDA-MB-231), even 
though we were unable to decrease GREB1 expression by inhibiting ERα activity with ICI 
treatment (Appendix C Figure 91, see Figure 50B). Interestingly, treatment with E2 and 4OHT did 
lead to slight inductions of GREB1, but these levels were variable and not significant relative to 
Vehicle control. PGR was only expressed in MCF-7 cells with no Cts or occasional Cts around 38 
observed in WCRC-25 cells. SNAI1 expression was higher in WCRC-25 than in both MCF-7 and 
MDA-MB-231, an endogenous expression pattern observed in other ILC cell lines. However, 
induction of SNAI1 by E2 or 4OHT treatment, like GREB1, revealed highly variable expression 
changes that were not significant relative to Vehicle control (Appendix C Figure 91). 
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We next performed dose response with E2 in the WCRC-25 cells to assess any effect on 
proliferation for these cells. E2 treatment did not influence the 2D proliferation of WCRC-25 over 
6-7 days in the 5% O2 incubator (Figure 51). Intriguingly, low doses of E2 caused inductions in 
2D proliferation for WCRC-25 cells cultured in the 5% CO2 incubator at high density (5K O2 v 
15K CO2 **p = 0.0088; 10K O2 v 15K CO2 ***p = 0.0005). Overall, we concluded that there was 
no phenotypic response to E2 for WCRC-25 in these environments tested with a minimal induction 
in the CO2 environment that will be further explored in future studies. Altogether, our data indicate 
that these cells are functionally ERα-. We are currently pursuing obtaining the original stain 
performed within the hospital that was used to make the pathology call for the patient sample and 




Figure 51: WCRC-25 Cells Do Not Respond to E2 with Increased Proliferation by Dose 
Response 
WCRC-25 cells were E2 deprived and plated at three densities (5-15,000 cells/well) or one density 
(15,000 cells/well) in the 5% O2 or 5% CO2 incubators, respectively. Plates were collected at D6-
7. Samples were plated in six technical replicates per dose and data were displayed ± SEM with 
three parameter non-linear curves fit, as previously. Data represent one experiment. Non-linear 
comparisons of Top dose responses were performed and comparisons are displayed by asterisks 
(*p < 0.05, **p < 0.005, ***p < 0.0005). 
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3.3.5 Discovery of a Novel E-cadherin Mutation in WCRC-25 and LOH 
Loss of E-cadherin is the most common molecular feature that differentiates ILC from IDC, and 
WCRC-25 did not express E-cadherin protein by IF or IB. We next sought to understand the 
mechanism for this loss of E-cadherin protein expression by sequencing mRNA and DNA products 
from the cell line. A primer scheme was first developed to cover the entire CDH1 coding region, 
as the location of a potential mutation was unknown (Figure 52A). In cDNA samples (converted 
from mRNA), we observed a nonsense mutation at Q706 of a C>T conversion, leading to the 
formation of a premature termination codon (PTC) (NM_004360.4:c.2240C>T, p.Q706*) (Figure 
52B). This mutation was confirmed with genomic DNA isolated from WCRC-25 






Figure 52: A Novel CDH1 Mutation is Present in WCRC-25 at Q706* 
 (A)  Primer scheme for complete coverage of the coding regions of CDH1. (B) Sanger sequencing 
results from cDNA amplifications after alignment to a wildtype (WT) CDH1 sequence. (C) 
Confirmation of cDNA results were performed for gDNA with Sanger sequencing. Mutations are 
denoted in chromatograms with red boxes. 
  
 
This mutation was discovered in exon 13 of CDH1, which would potentially generate a protein 
product that would be truncated in the transmembrane domain. However, nonsense mutations 
should be recognized by the nonsense-mediated RNA decay (NMD) machinery, leading to 
identification of the PTC, and targeting for degradation[270]. We will discuss the implications of 
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these statements further in section 3.3.8 and in the overall discussion for this chapter. The mutation 
of a single nucleotide causing PTC, and the lack of E-cadherin protein expression (see Figure 47, 
48) made us ask if the other allele was lost by a common mechanism observed in ILC: LOH. 
Therefore, in addition to probing the mechanism of CDH1 mutation in WCRC-25, we 
asked if LOH was responsible for the complete loss of E-cadherin protein by assessing copy 
number status of CDH1. We mined Copy Number Alteration (CNA) NanoString data previously 
performed by our group and revealed that WCRC-25 had only one copy of a CDH1 allele, much 
like ILC cell lines MDA-MB-134-VI and Sum44PE, and unlike MCF-7, which had two copies of 
the allele (Figure 53). We then concluded that one copy of CDH1 is lost in WCRC-25, and one 
copy is mutated at Q706*, leading to LOH of CDH1 in this cell line; these observations are 




Figure 53: LOH of CDH1 is the Mechanism of E-cadherin Loss in WCRC-25 
IDC and ILC copy number quantifications were mined from NanoString data available in the 
Oesterreich Lab. MCF-7 cells were used as a control for presence of both alleles, while MDA-
MB-134-VI and Sum44PE were used as controls for presence of only one allele, each, due to LOH.  
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3.3.6 Measurement of Q706* in cfDNA Samples from WCRC-25 Patient 
Since we had established the position of the CDH1 mutation in WCRC-25 cells, we next asked if 
we could detect this mutation in cfDNA samples obtained from blood obtained from the patient. 
These samples were taken when the patient had high metastatic burden, so the likelihood of the 
blood samples containing cfDNA shed from the tumors was increased[271]. We isolated cfDNA 
from these samples and from our WCRC-25 cells, and used a custom ddPCR probe for our CDH1 
Q706* mutation or a control wildtype CDH1 probe to assess presence of this mutation in the 
longitudinal samples. 
 Buffy coat contained nearly 100% allele frequency (AF) of the wildtype CDH1 allele, and 
a 0.6% AF of the CDH1 Q706* (Figure 54). The low expression of the mutant in the buffy coat 
confirmed that the mutation was somatic as opposed to germline, which we would hypothesize to 
be enriched. As expected, the cell line WCRC-25 contained 97.9% AF of CDH1 Q706*, and 0% 
AF of the wildtype CDH1. In the first and final draws taken from the patient, an increase of CDH1 
Q706* was observed from 0.27% (draw 1, data not shown) to 8.3% (draw 4). The higher level of 
detectable mutant in the buffy coat from draw 4 compared to the cfDNA fraction in draw 1 (Buffy 
= 0.6% versus Draw 1 cfDNA = 0.27%) was not concerning, as the same buffy coat was utilized 
in other experiments and showed 0.19% AF of the CDH1 Q706* (data from Ahmed Basudan, BS, 
not shown). This suggests the potential of minor contamination of the buffy coat during the PCR 
procedure. The enrichment for the CDH1 Q706* mutation over time and increased disease burden 
for the patient confirms that this technique is feasible for clinically tracking disease progression 





Figure 54: ddPCR Shows Q706* is Detected in cfDNA from WCRC-25 Patient 
ddPCR was performed in the WCRC-25 cell line, Buffy Coat, or cfDNA (draw 4 shown) from the 
WCRC-25 patient. Probes were utilized against either wildtype (wt) CDH1 or the Q706* mutant 
CDH1 (mut). Blue or green dots represent droplets that contained DNA with each respective 
genotype (mutant or wt). Black dots indicate droplets that did not contain DNA. Mutant allele 
frequencies (MAF) are displayed beneath each respective plot. 
 
 
3.3.7 Phenotypic Characteristics of WCRC-25 
We next assessed three basic phenotypes or characteristics of WCRC-25: (1) population doubling, 
(2) 2D proliferation, and (3) soft agar anchorage independent growth. Population doubling assays 
were performed in P3, P5, and P7 of the WCRC-25 cells after two, four, or six passages in 
respective incubator/culture environments, as described. We assessed the average doubling time 
of WCRC-25 to be approximately 5 days, a comparable time to other ILC cell lines (MDA-MB-
134-VI: 2 days, Sum44PE: 5-7 days; Figure 55). Population doubling remained most stable in all 
conditions, across passages for the middle density of cells tested (10,000 cells/well). It was 
therefore determined that WCRC-25 cells had a stable population doubling in DMEM/10% FBS 
5% O2 conditions, and cells were continually maintained in this condition for future experiments. 
To ensure that this alteration in media type did not greatly influence major changes in population 
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doubling later, a side-by-side comparison of all media growth conditions will be performed once 
cells reach ~P50, or the Hayflick limit[220]. Additionally, to confirm that this media choice did not 
overtly influence major changes in gene expression programs, cell pellets were generated in FFPE 
blocks from P17 CM-Rocki 5% O2 and P17 DMEM/10% FBS 5% O2 WCRC-25 cells for use in 




Figure 55: Population Doubling Time for WCRC-25 is Circa 5 Days 
Population doubling was assessed in WCRC-25 cells in the four conditions previously mentioned, 
at three densities (5-15,000 cells/well), and over three different passages (P7, P9, P11). Data were 




 Our 2D proliferation assays confirmed our population doubling observations. Cells 
proliferated efficiently in DMEM/10% FBS, 10,000 cells/well, 5% O2, expanding to 
approximately 2-3 fold the original cell population over 6 days of growth (Figure 56A). Though 
increased growth of DMEM/10% FBS, 10,000 cells/well was noted in 5% CO2, these assays were 
performed with later passage (~P30) cells than performed with our population doubling assays. 
Additionally, these cells were in stated media/incubator environments for only two passages prior 
to using in experiments, and our population doubling assays tested whether cells established long-
term in these environments would have set doubling times.  
 For our final preliminary phenotype assessment, we chose to pursue anchorage 
independent growth, or soft agar growth, as an environment of interest for WCRC-25. Our 
preliminary studies have shown that ILC cells do not form cohesive soft agar colonies like control 
IDC cell line MCF-7, and instead form small, discohesive clusters of cells. This is likely due to 
their loss of E-cadherin. In addition, these loose colonies take an extended period of time to form 
that are not conducive to ease in experimental use (MCF-7 ~2 weeks; MDA-MB-134-VI ~4 weeks; 
IPH-926 ~18 weeks). We tested our WCRC-25 cells in the soft agar assay at either a low density 
(10,000 cells/well) or high density (50,000 cells/well) for a period of 2 weeks against MCF-7 
control cells. As expected, MCF-7 cells formed countable, cohesive colonies in this timeframe, 
but WCRC-25 formed few colonies at either density, in either incubator setting, with much smaller, 
discohesive structures (Figure 56B, C). Ongoing assays are probing the length of time to form 
significant numbers of soft agar colonies. 
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Figure 56: 2D Proliferation and Soft Agar Growth Phenotypes for WCRC-25 
WCRC-25 cells were plated for (A) 2D Proliferation assay or (B) Soft Agar Anchorage 
Independent Growth assay. Both assays were performed in either the 5% O2 or 5% CO2 incubators. 
2D proliferation was performed in both media conditions with six replicates per condition and data 
quantified as previously ± STDEV, non-linear exponential regressions fitted to data. Soft agar was 
performed with either 10,000 cells/dish (low density) or 50,000 cells/dish (high density) in 
triplicate dishes for each condition, for 2 weeks MCF-7 served as a control. Both assays are single 
experiments with two similar experimental outcomes observed for (A), only. (C) Representative 
images of the soft agar colonies formed for WCRC-25 by 2 weeks were taken (10X magnification; 
bar represents 100 µm). 
 
 
3.3.8 RNA Sequencing Analyses of Patient Samples and Cell Line 
We then asked about the transcriptional programs in WCRC-25 and in all of the patient samples 
we obtained. We isolated RNA from FFPE cell blocks (WCRC-25) or patient samples and 
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measured for FFPE RNA quality using Illumina DV200 (in collaboration with Ahmed Basudan, 
BS). DV200 is a measurement of the percentage of RNA fragments obtained that have more than 
200 nucleotides present. This metric is more sensitive than previously used RNA Integrity Number 
(RIN) assessment, due to its heightened sensitivity for FFPE fragments. A DV200 value of 30 or 
less is highly degraded and of too poor quality for use in RNA Sequencing. For all samples 
prepared except for the peritoneum sample, DV200 values of greater than 30 were achieved. 
Although the value from the peritoneum sample was quite low (13.45), we proceeded to use this 
sample in the subsequent RNA Sequencing run. Samples were sequenced (see 3.2.13 for methods) 
and data were first quality checked for interpretability (Appendix C Figure 92). 
  We next performed principle component analysis (PCA) for the top 5,000 most variable 
genes. This measurement transformed the original data to enable better resolution of the variation 
between samples. PCA showed that most of the ER+ samples clustered together, except for the 
peritoneal fluid sample, which clustered closer to the ER- samples from the left breast (Figure 57). 
Additionally, the two skin samples clustered together, as anticipated. The cell line samples from 
either CM-Rocki or DMEM/10% FBS clustered together and also with other pleural fluid samples 
taken. Finally, and not completely unexpected, the stomach sample did not cluster with any of the 
samples, further suggesting that this sample was an outlier (see Appendix C Figure 92). 
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Figure 57: PCA from WCRC-25 RNASeq 
PCA was performed for WCRC-25 RNASeq analyses to show clustering of data using the top 
5000 most variable genes interquartile range (IQR) log2CPM. Samples are labeled with their 
location of collection, ER status, and numerical description. 
 
 
PAM50 calls were then made with the sequencing data for all samples using the genefu R 
package. We noticed that different samples had different calls, comprising all call types (Luminal 
A, Luminal B, HER2, Basal) (Figure 58). All the ER+ samples were called as Luminal A, with the 
exceptions of the peritoneal fluid sample (Luminal B) and the stomach sample (HER2). The 
stomach sample call may be explained by the aforementioned potentially poor quality of the data 
from this sample. Interestingly, the left breast ER- samples and right pleural fluid ER- samples 
were also called as Luminal B. All remaining samples, including the cell line samples, were called 
as HER2, except for the left superior skin ER- sample, which was called as Basal. Upon close 
examination of the numerical calls, it appeared that many the samples were a nearly 50:50 ratio 
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for the Luminal B or HER2 call. Though no bi-call is currently in existence for PAM50 subtypes, 
it is possible that either by tumor heterogeneity or expression of certain entities (e.g. Ki67) drove 





Figure 58: PAM50 Subtypes for WCRC-25 Patient Samples Suggest Heterogeneity in the 
Disease 
PAM50 subtypes were called using genefu package and probabilities of calls were displayed for 
each sample with a definitive PAM50 call listed in the far-right column. Samples are listed from 




Assessment of expression of genes of interest was performed to confirm pathology 
interpretations of original samples and to probe expression of genes of interest. ESR1, PGR, HER2, 
and Ki67 expressions were as anticipated based off pathological interpretations (Figure 59A, B). 
ESR1 expression was also low in the stomach sample, which agreed with our observations of the 
ER IHC (see Figure 40, Appendix C Table 16) even though pathological calls had stated the sample 
was ER+. PGR was not expressed in the cell line samples, as we observed in our qRT-PCR studies 
(see 3.3.4). ERBB2 expression was relatively high, which contradicted clinical observations that 
samples were HER2- (data not listed in pathology calls as was not available for every sample). 
As anticipated from observations of other ILC cell lines, CDH1 was still expressed at the RNA 
level in all samples (Figure 59B, Left Panel). The overall levels of RNA were high (compare to 
ESR1) and suggest that though the ILC maintained mutated CDH1 at Q706*, the cells still 
attempted to generate RNA. These observations are being probed in ILC cell lines in our lab, as 
we have made similar observations of high detection of CDH1 mRNA by qRT-PCR (data not 
shown). MKI67 levels were similar in all samples except the Left Breast Mastectomy1 sample 
(ER+; Figure 59B, Middle Panel). TP53 levels were also similar across all samples (Figure 59B, 
Right Panel). Finally, a brief assessment of PI3K pathway members was performed. We included 
PIK3CA, the gene that encodes for PI3K, and two downstream gene targets related to survival, 
CCND1 and BIRC5.  While PIK3CA and CCND1 levels were similar across all samples, BIRC5 
was slightly more highly expressed in the samples taken toward the end of the patient’s life (Figure 
59C). These preliminary observations confirm the original pathology calls made for each sample, 
and give further confidence to the quality of RNA Sequencing data. Additionally, we probed the 
expression of multiple genes in the PI3K pathway (PIK3CA, CCND1, BIRC5) and cautiously 




Figure 59: RNASeq Data Confirms Clinical Observations and Allows for Probing of PI3K 
Signaling 
Gene expression for (A) ESR1, PGR, and ERBB2, (B) CDH1, MKI67, and TP53, and PI3K 
pathway members (C) PIK3CA, CCND1, and BIRC5 were called from RNASeq data. ER- patient 
samples are highlighted in green, metastases are orange, primary breast samples are in red, and 





As RNA Sequencing data was obtained and processed shortly before the compilation of 
this dissertation, only the described data were available. A forthcoming publication will detail 
further analyses including pathway analyses, probing expression of genes of interest related to 
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ILC, and alterations in genes of interest by targeting aforementioned gene products with siRNA or 
drugs to alter phenotypes in WCRC-25. 
3.3.9 Drug Responses in WCRC-25 
Two approaches were taken to assess therapeutic responses in WCRC-25. First, the patient clinical 
history was examined and therapeutics were selected from the treatment regimen with hypotheses 
of dose response outcomes designated based upon the original pleural effusion sample of origin in 
relation to treatments given. For example, we hypothesized that since WCRC-25 cells were already 
exposed to Carboplatin and Paclitaxel (a platinum-based DNA interfering and taxane-based 
tubulin inhibitor, respectively), they would thus be more resistant to these therapies. To test this 
hypothesis, we chose to use Cisplatin, another platinum-based DNA interfering chemotherapeutic 
with similar mechanism and outcome to Carboplatin, and Paclitaxel to perform 2D proliferation-
inhibitory dose responses. Paclitaxel was highly potent compared to Cisplatin; an IC50 value of 0.4 
nM was obtained for WCRC-25 cells for Paclitaxel compared to 2 mM for Cisplatin (Figure 60A, 
B). The lack of observed resistance to Paclitaxel was intriguing, as WCRC-25 responded with a 
similar IC50 as compared to cell line MCF-7 (IC50 = 0.2 nM). Additionally, it should be noted that 
the potency of Paclitaxel was higher in WCRC-25 at higher doses, as compared to MCF-7 (WCRC-
25 IC75 = 1.1 nM; MCF-7 IC75 = 6.2 nM). Cisplatin IC50 values were quite high for both cell lines 
tested (WCRC-25 IC50 = 2 mM; T47D IC50 = 1.5 mM). This is perhaps not surprising, as Cisplatin 
is often utilized in combination therapies in the clinic to increase its effectiveness as a 
therapeutic[273]. Thus, future studies will probe the combination of these therapeutics in order to 
ascertain if the combination of Paclitaxel and Cisplatin are more resistant in WCRC-25 compared 
to a positive control cell line. It is also important to remember that patient WCRC-25 received 
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endocrine therapies after the course of Paclitaxel/Carboplatin, which may have led to further 




Figure 60: Dose Responses of Paclitaxel and Cisplatin in WCRC-25 Cells 
WCRC-25 cells or cells known to produce some kind of dose response to each drug ((A) MCF-7, 
(B) T47D) were treated to dose responses for (A) Paclitaxel or (B) Cisplatin in 2D proliferation 
environments for 5 days. Data were fit with three parameter agonist non-linear regression curves 
after normalization to each respective Vehicle, with six replicate data points per point shown ± 
STDEV. Data represent a single experiment performed. 
 
 
We next asked if a therapeutic that the cells had not yet been exposed to prior to the 
acquisition of the sample would be highly potent in inhibiting 2D proliferation of WCRC-25. We 
chose to test Doxorubicin dose response in WCRC-25 against positive control cell line MCF-7. 
The IC50 of Doxorubicin in WCRC-25 was 7.3 nM compared to 11.3 nM in MCF-7 (Figure 61). 
As only a subtle increased sensitivity was noted in WCRC-25 cells, these data suggest that 




Figure 61: Doxorubicin Dose Response in WCRC-25 Cells 
WCRC-25 or MCF-7 cells were treated to dose responses for Doxorubicin in 2D proliferation 
environments for 5 days. Data were fit with three parameter agonist non-linear regression curves 
after normalization to each respective Vehicle, with six replicate data points per point shown ± 




 For our second approach, we chose to test response of WCRC-25 to a drug that the patient 
was not exposed to during treatment. The choice of this drug was based off of prior indication for 
rationale of use in the literature. First, we tested 2D dose response of the dual PI3K/mTOR 
inhibitor, Dactolisib (BEZ235). Though BEZ235 is not currently FDA-approved for use in the 
clinic, mounting scientific evidence for targeting of the PI3K/mTOR axis has led to its use in 
clinical trials since 2006[274, 275]. As described in the introduction, targeting of the PI3K/mTOR 
pathway may provide clinical benefit for ILC patients, whose tumors often carry elevated 
PI3K/AKT signatures or PI3K mutations[67, 94]. 2D proliferation-inhibition dose response revealed 
that WCRC-25 had a BEZ235 IC50 of 1 nM, while positive control cell line MDA-MB-134-VI had 
an IC50 of 3.7 nM (Figure 62A). These inhibitions were very promising, especially when observed 
at nM potency, and we thus decided to ask if this inhibition was present in other growth 
environments, such as ULA. BEZ235 ULA IC50 for WCRC-25 was right-shifted slightly to 1.7 
nM, while MDA-MB-134-VI positive control cell line had an IC50 of 3.1 nM (Figure 62B). We 
then decided to observe the signaling effects of BEZ235 in 2D and ULA.  
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Using 1 nM BEZ235 treatment for 24 hours in both 2D and ULA environments, we 
measured alterations in levels of total AKT, pAKTS473, pAKTT308, total S6, and pS6S235/236, all major 
components of the PI3K/AKT/mTOR pathway. pAKTS473 levels were low in both cell lines, and 
only interpretable in WCRC-25 cell lysates (Figure 62C). Interestingly, WCRC-25 had higher 
pAKTS473 levels in ULA than in 2D, while total AKT levels appeared relatively similar between 
both settings. This increase in pAKTS473 in ULA may be explained by the anoikis resistance 
phenotype exhibited by successful ULA proliferation; it has been shown that upregulation of the 
PI3K pathway is one of the most common mechanisms for anoikis resistance in breast cancer[276]. 
In both 2D and ULA settings, BEZ235 showed a minor reduction in pAKTS473 levels. A slight 
decrease in total AKT levels was also detected in the 2D setting for WCRC-25 when BEZ235 
treatment was given. pAKT308 was difficult to visualize in all samples tested. As a side note, total 
levels of total AKT were decreased in MDA-MB-134-VI after BEZ235 treatment in 2D, an 
unexpected outcome. No current explanation is available for this observation, but it is possible that 
a previously undescribed role for BEZ235 promoting protein degradation mechanisms may be at 
play[277]. For mTOR pathway, we observed a different pattern of total S6 and pS6S235/236 protein 
expressions and alterations in WCRC-25. Both total and phosphorylation levels of S6 were 
elevated in WCRC-25 2D compared to ULA environments, and slight decrease in pS6S235/236 was 
evident after BEZ235 treatment in the ULA environment, only. MDA-MB-134-VI were impacted 
differently, with higher total S6 levels in the 2D environment, decreased total S6 levels observed 
in 2D with BEZ235 treatment, and pS6S236/237 observed in both environments. These data led us to 
conclude the following: (1) WCRC-25 have higher overall PI3K/AKT/mTOR signaling than 
MDA-MB-134-VI, (2) WCRC-25 have higher basal PI3K/AKT signaling in ULA than in 2D, and 
the decrease in pAKTS473 was seen more effectively in the 2D setting, and (3) the mTOR pathway 
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observed was relatively unaffected by treatment with BEZ235, unlike what was observed in the 
MDA-MB-134-VI cells. The lack of mTOR pathway response observed is interesting, but we only 
tested one marker of mTOR activity (pS6235/236). The PI3K/AKT/mTOR pathway is very complex, 
and we are pursuing experiments that will assess the impacts of BEZ235 on other parts of mTOR 
signaling. Overall, these interesting outcomes suggest that environmental context can influence 
major oncogenic pathway signaling and response to therapeutics, suggesting the rationale to screen 






Figure 62: BEZ235 is a Potent Inhibitor of WCRC-25 2D and ULA Proliferation with 
Impacts on P13K Signaling 
WCRC-25 cells were treated to dose responses along with positive control cell line (MDA-MB-
134-VI) in (A) 2D or (B) ULA proliferation environments. Data were analyzed as in Figure 61. 
(C) IC50 concentrations of therapeutics were utilized to treat WCRC-25 or MDA-MB-134-VI for 
24 hours prior to protein acquisition and IB for markers of the PI3K/AKT/mTOR pathways relative 
to Actin internal control.  
 
 
 In summary, we designed a series of dose response assays to test various therapeutic 
responses of WCRC-25. In our clinical treatment approach, we observed little resistance of 
WCRC-25 to Paclitaxel or Cisplatin treatments relative to positive control cell lines, and indicate 
that resistance may only be observed when both therapeutics are used in combination. 
Alternatively, the cells may no longer be resistant to aforementioned therapies, as they were also 
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exposed to endocrine therapies prior to being established. Also, environmental context is 
important, as shown in our 2D v ULA BEZ235 assays (see Figure 62); our cells may not respond 
to therapeutics the same in all environments tested. We observed a potent response of WCRC-25 
to Doxorubicin relative to the positive control cell line tested. Then we tested efficacy of a 
clinically relevant, targeted therapeutic against PI3K/mTOR (BEZ235). BEZ235 showed promise 
as a slightly more potent therapeutic in WCRC-25 than in positive control ILC cell line MDA-
MB-134-VI (2D WCRC-25 IC50 = 1 nM v 2D MDA-MB-134-VI IC50 = 3.7 nM), with 
downregulation of pAKTS473 noted in WCRC-25. The lack of inhibition of the mTOR pathway in 
WCRC-25 was interesting, but may suggest that another portion of the PI3K/AKT pathway is 
being inhibited, or an mTOR specific targeted agent such as Rapamycin may be needed to decrease 
the S6/pS6S236/237 signaling observed[278]. Also, we noted that BEZ235 showed potent inhibition of 
WCRC-25 cells in ULA, an important note for an ILC cell type that has shown preferential anoikis 
resistance phenotypes[276].  
3.3.10 Ongoing In Vivo Studies 
A final important question in assessing the utility of WCRC-25 as a model of ILC is to understand 
if WCRC-25 has tumorigenic properties in an in vivo setting. As previously described in the 
introduction to this chapter, ILC cell line xenograft models appear to be of limited utility due to 
the length of time required to form palpable tumors[204]. WCRC-25 cells were determined to be 
ERα-, and thus the animals were not supplemented with E2 pellets at the time this dissertation was 
completed. Injections performed in the Tail Vein (TV), Mammary Intraductal (MIND), and 
Mammary Fat Pad (MFP) models have already begun to yield potential development of metastatic 
lesions in athymic nude (TV) or NSG (MIND, MFP) mice. The TV and MFP mice are currently 
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bi-weekly analyzed by IVIS imaging, and will continue to be monitored for development of 
outgrowths. An example of the beginning of potential abdominal or ascites outgrowths can be seen 
in some of our TV mice that were injected approximately two months prior to the images shown 
in Figure 63A. In addition, our MFP tumors are growing and will be palpable for measurement at 
the time of publication of this dissertation (Figure 63B). We look forward to the utility of these 




Figure 63: IVIS Imaging Examples from TV or MFP Mice Injected with WCRC-25 
Mice were injected by (A) TV or (B) directly into MFPs with WCRC-25 cells labeled with RFP 
for visualization on the IVIS system. Representative images of mice at 2 months or 3 weeks, 
respectively, post injections are displayed. 
3.4 DISCUSSION 
Cell line models are important tools for uncovering the molecular, phenotypic, and basic 
characteristics of diseases. For ILC, few cell line models exist, and have been minimally explored 
as appropriate model systems to represent the disease[204, 249-251]. We have therefore provided a 
detailed account of the establishment and characterization of a novel ILC cell line, WCRC-25, 
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which we believe represents some of the many characteristics observed in other ILC cell lines and 
in the clinical setting. Further, we present the WCRC-25 cell line as a potential model of endocrine 
therapy resistance, a common issue in breast cancer and within ILC[8, 165].   
Patient WCRC-25 had a complicated clinical course that initiated with a misdiagnosis of 
gastric carcinoma (see Figure 39). Gastric carcinoma does maintain some signet ring cell features 
that mimic the morphology of cells in ILC, and case studies have attempted to inform clinicians 
of the initial presentation of ILC as gastric metastasis[279, 280]. Further, CDH1 mutations and loss 
of expression are also a key feature of Hereditary Diffuse Gastric Carcinoma (HDGC). The 
similarities between features of the diseases and the indolent nature of ILCs, particularly in 
reference to their visibility in mammograms, may continue to cause difficulties in diagnosing the 
disease. Further research is currently required to understand the relationship between the two 
diseases and to prevent misdiagnoses. Beyond this point, endocrine therapy resistance played a 
role in the progression of lesions in WCRC-25, as most outgrowths toward the end of the timeline 
were from the ER- potential local recurrence in the left breast that had seeded from the ER+ original 
left breast primary. The contralateral tumor in the right breast also followed with the known 
predominance of this to occur in patients afflicted with ILC[60]. 
 We successfully established WCRC-25 using a newer method of cell reprogramming, and 
then characterized its marker expression, growth characteristics, and mutational profile against 
original clinical samples from the patient[254]. We determined that WCRC-25 is an epithelial, ERα- 
cell line harboring basal characteristics of CK14 expression. While at first this was concerning to 
us, the literature provided clues that basal marker expression was perhaps not an anomaly for ILCs. 
In a recent study, Fadare and colleagues measured the expression of another basal marker, CK5/6, 
in n = 82 ILCs, and noted that 17% of these lesions maintained positive expression[267]. They 
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concluded from these data that there exists a basal-population of ILC cells. In contrast, Khilko and 
colleagues published IHC of CK5/6, CK14, and CK17 in a smaller cohort of n = 53 ILC patients, 
whose tumors were all negative for these markers[268]. Engstrom and colleagues further 
complicated the data observed in their recent study of a larger Norwegian cohort of n = 1423 ER+ 
breast cancers; they revealed that luminal tumors that express basal markers have better survival 
outcomes compared to those that do not, challenging prior accepted clinical observations[269]. The 
ILC cohort listed in this study was larger than in the previously described studies, including n = 
176 patient samples. Interestingly, 22 of these ILC patient samples did express basal markers, 
though which markers and relationship to survival were not specified. Finally, we note that the 
previously described studies were performed in primary ILC, whereas our samples were generated 
from metastatic ILC samples. These points suggest that our data for prevalent CK14 expression in 
ILC cells is feasible, and that expression of basal markers may influence survival outcomes for 
ILC patients. 
Importantly, our IB and IHC data indicated that E-cadherin was not expressed in WCRC-
25, but more highly sensitive IF did reveal the presence of diffuse, punctate E-cadherin staining. 
Due to the peptide recognition of our antibody for E-cadherin (C-terminus; aa735-883), it does not 
seem likely that this staining is E-cadherin as this region is not present in WCRC-25 or MDA-MB-
134-VI due to PTC locations being upstream of this region and LOH of the alternate allele. As 
previously stated, this punctate E-cadherin has been seen in other ILC cell lines (MDA-MB-134-
VI), which also harbor PTCs upstream of this peptide detection region. Thus, there are two 
possibilities: (1) there exists cross-reactivity of our antibody with another protein that is detected 
more easily by IF (possibly another cadherin, such as P-cadherin, that is suggested by the 
manufacturing company BD Biosciences), or (2) there is a small population of CDH1 wildtype 
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allele cells within the overall cell population, insufficient to be detected by IB or IHC, but sufficient 
to be detected by sensitive IF. Future analyses will be performed by our group to discern the 
rationale for observation of punctate E-cadherin staining in ILC cells. We will also continue to 
probe the role of mRNA expression of CDH1 that is observed in ILC cells, and in the WCRC-25 
clinical samples (see Figure 59B, Left Panel). 
Using our cells, we established the presence of a novel CDH1 mutation in Q706*, 
generated a ddPCR probe for this mutation, and used this tool to detect the mutation in cfDNA 
obtained from patient sample blood draws. While this practice is not currently utilized in the clinic 
on a regular basis, our data suggest that sequencing a patient’s tumor for genetic aberrations (e.g. 
CDH1 mutations in ILC patients) can allow for the development of a feasible, non-invasive test 
for tracking of disease progression. The increase in WCRC-25 blood draws of the CDH1 Q706* 
mutation was striking, and tracked with metastatic burden.  
Though the loss of ERα was unfortunate due to the necessity for additional ERα+ ILC cell 
line models, we could focus on other mechanisms of therapy resistance/response in WCRC-25 
without restriction. The therapeutic responses to drugs given to the patient during the treatment 
course (Doxorubicin, Cisplatin, Paclitaxel), as well as rationally chosen experimental drug 
BEZ235, were particularly informative considering recent knowledge regarding novel pathways 
of interest in ILC. PIK3CA mutations have been well-described in cancer, and are becoming very 
intriguing in ILC research[67, 275, 276]. The potency of BEZ235 in WCRC-25 will make it a useful 
model for the growing field of PI3K/AKT inhibitor work in ILC and in cancer. Also, our unclear 
observations of the role of BEZ235 in inhibition of PI3K/AKT/mTOR signaling will be further 
probed considering the increased expression of downstream pathway member BIRC5, or Survivin 
(See Figure 59C, Right Panel). This protein has been shown to inhibit apoptosis, is a newer 
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therapeutic target in cancer research, and will be among many other interesting targets that we will 
further explore in this system[281]. These observations were preliminary, and much remains to be 
discovered in relation to WCRC-25’s response to other therapeutics.  
For example, an additional therapeutic we will test in WCRC-25 is Palbociclib, a recent 
FDA-approved inhibitor of CDK4/6[150]. The use of Palbociclib combination therapy has been 
approved for use in advanced metastatic hormone receptor positive, HER2- breast cancer, a group 
of tumors that have essentially become endocrine therapy resistance. If we hypothesize that the 
loss of ERα expression in our WCRC-25 cells is the result of pressures induced by endocrine 
therapy resistance, it would be rational to further hypothesize that Palbociclib may show efficacy 
in this setting. In addition, and as described in the introduction to the dissertation, the ongoing 
PELOPS trial will evaluate the outcome of combination endocrine therapy and Palbociclib or 
endocrine therapy alone in ILC and IDC patients. The outcomes of studies like these will be 
detailed in our upcoming manuscript. 
Phenotypically, we observed WCRC-25 behaved similar to other ILC cells. WCRC-25 
doubles similarly to MDA-MB-134-VI (~2-3 days) and Sum44PE (5-7 days) ILC cell lines, and 
faster than comparably sized ILC cell line, MDA-MB-330 (~1.5-2 weeks). The combination of 
larger size and relatively faster doubling time contribute to faster use of media contents, and 
enhanced rate of filling the space of a given well. WCRC-25 cells were also able to adapt to their 
new environments over passage, suggesting that the importance of continuing these cells in their 
CM-Rocki culture setting was likely unnecessary. CM-Rocki may therefore be important for 
establishment of a given culture, but once established, other media types may be evaluated for ease 
of use in future experiments. 
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 Our current phenotypic analyses in ILC have provided little evidence for robust growth 
behaviors in different environments (2D, soft agar). ILC cells proliferate so slowly compared to 
other breast cancer cell lines that either insufficient material is available to pursue many assays or 
to see phenotypes in standard timeframes applied to classic phenotypic assays. For example, we 
know that our ILC cells do not tend to migrate or invade in classic scratch or Boyden Chamber 
assays (Nilgun Tasdemir, PhD unpublished results). The lack of these phenotypes is likely due to 
the loss of polarity in these cells induced by loss of E-cadherin; without polarity, the cells are 
unable to easily follow chemoattractant signals or to collectively invade as IDC cells do[28, 30, 62]. 
Further, most ILC cells are unable to survive in the highly confluent conditions required of certain 
experiments (e.g. Scratch assay), and will instead lift off their growth surface to die. This 
complicates the use of conventional assays and emphasizes the importance of careful tissue culture 
maintenance and establishment of appropriate plating densities for all experiments. In the future, 
we will probe the true behaviors of these indolent cell types further, particularly in novel 
environments of interest for ILC (e.g. ULA). However, the phenotypic assays that will assist in 
defining the characteristics of these cells will likely need to be modified versions of classically 
available assays, or novel approaches that test cells that have slower proliferation and loss of 
polarity.      
In conclusion, our novel established ILC cell line, WCRC-25, is a useful tool for ILC 
research. The comprehensive analyses that we have performed to understand the origin of disease, 
progression, molecular, phenotypic, and in vivo characteristics (ongoing) of this new model would 
not have been possible without collaborative and trans-disciplinary efforts by a team of 
investigators. We highly support the use of this novel model as a tool in ILC and cancer research, 
and look forward to seeing the utility of this system explored further. 
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4.0  DISCUSSION 
Breast cancer is a complex disease comprised of two major histologic subtypes, ILC and IDC. 
Though nearly 40,000 women are diagnosed annually in the U.S. with ILC, it remains a highly 
understudied disease[1]. Few studies to date have provided comprehensive analyses of ILC, and of 
these, we have gained some clinical insight to the progression of disease[67, 115-120]. ILCs are slow 
growing, difficult to detect, and often recur nearly a decade after the primary diagnosis. These 
factors all contribute to a unique disease phenotype that necessitates further study in light of the 
therapeutic interventions that can be provided to patients. 
Endocrine therapy resistance is a clinical problem for patients with ILC, and we have 
observed this phenomenon at a cellular level[132]. Our investigation into the role of 4OHT as an 
agonist in ILC (Chapter Two) provided evidence that ERα is directed to induce proteins, such as 
SNAIL, that could potentially contribute to EMT-like phenotypes that are observed in ILC[64]. 
These data were accompanied by observations of the upregulation of other ERα-regulated targets 
(GREB1, IGFBP4) that are known to be E2-induced in IDC cells[132]. However, our observations 
have suggested that 4OHT can direct the expression of many other proteins (yet to be described) 
in ILC that are normally repressed or unaffected. Though our manipulation of SNAIL was not 
successful in suppressing 4OHT partial agonist activity in MDA-MB-134-VI cells, we did uncover 
a unique limited EMT-TF panel that is upregulated in cell line models (SNAI1, TWIST1, FN1, 
VIM, CDH2) and somewhat in ILC clinical samples (FN1, KDM1A). These data contribute to the 
ILC research field’s understanding of the importance of these EMT profiles in the clinical setting, 
a debated topic[64, 174]. Additionally, we uncovered an understudied role for SNAIL that was 
unanticipated based upon prior literature. Induction of SNAIL led to decreased tumorigenic 
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phenotypes, and suggested that context, both environmentally and of disease subtype, can greatly 
influence the behaviors of commonly known oncogenes. However, we also noted that 
manipulation of SNAIL was not well tolerated by ILC cells (MDA-MB-134-VI and Sum44PE 
knockdown attempts; BCK4 stable inducible overexpression attempt). 
Our brief findings regarding the endogenous interaction of SNAIL and LSD1 in ILC, as 
well as its potential as a therapeutic axis in the disease subtype, should be further explored. The 
clinical repurposing of FDA-approved agents, when successful, can save decades of development 
and research, along with billions of dollars. Most importantly, it is a way to fast-track a drug of 
utility to patients in need. LSD1 inhibitors have been clinically used to treat depression for decades, 
and are being studied for repurposing as targeted agents in various types of cancer[207, 208]. If this 
SNAIL/LSD1 axis that we have discovered in ILC is imperative to the phenotypes observed 
clinically, then LSD1 inhibitors may also have utility in ILC. 
Observations such as those made regarding the SNAIL/LSD1 axis in ILC may or may not 
have direct implications in endocrine therapy resistance. The ongoing window trial by Jankowitz 
and colleagues will provide the first analyses of ER-regulated gene targets in ILC patients treated 
with either Tamoxifen, Anastrazole, or Fulvestrant[121]. It would be beneficial to assess SNAI1 and 
other EMT-TF related target gene expressions in the Tamoxifen treated group, in particular. For 
example, TWIST1 was not modified by 4OHT treatment in our studies, but has been observed to 
be upregulated in LCIS and ILC clinical samples[64, 180]. Further studies related to the implications 
of TWIST1 in ILC would be beneficial, within the scope of endocrine therapy resistance or disease 
development and progression. Overall, these data will provide additional gene targets in the 
clinical setting that are altered in relation to endocrine therapy treatments. 
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The second portion of our work was devoted to the establishment and characterization of 
a novel ILC cell line. There are 7 (now 8 with the characterization of WCRC-25) ILC cell lines in 
existence today, and the classification of many of these cell lines as ILC is still debated in the field. 
We supplied a complete and comprehensive story about WCRC-25, an epithelial, ERα- cell line 
derived from the pleural effusion of an ILC patient (Chapter Three). Our clinical observations of 
the patient were supplemented with genetic and expression analyses that allowed us to reveal a 
novel CDH1 mutation in ILC (CDH1 Q706*).  
We continue to probe additional mutations in MammaSeq analyses. MammaSeq is an Ion 
Torrent sequencing panel comprised of 78 genes, with 688 amplicons targeting 1398 mutations 
(Smith et al in preparation; trademark of UPMC). Preliminary analyses are currently ongoing, but 
we have already observed an additional unique CDH1 mutation at Q23* in some of our patient 
samples, along with mutations in PIK3CA and TP53. These data will assist in our understanding 
of the timeline of the patient’s disease from the primary lesions to the metastatic lesions.  
Importantly, we have contributed a novel model to the field of ILC research, as well as the 
larger cancer research community. WCRC-25 responds to PI3K/AKT/mTOR inhibitor BEZ235 in 
two unique phenotypic environments (2D, ULA). This observation makes sense considering the 
recently defined, common occurrence of PI3K/AKT activation in ILC patients[67]. Interestingly, 
the signaling alterations observed were restricted to a mild decrease of pAKTS473, and less clear 
with regard to mTOR signaling (S6235/236). Our future analyses will probe other parts of the 
PI3K/AKT/mTOR pathway to understand the mechanism behind the 2D/ULA proliferation 
inhibition by BEZ235. Additionally, considering our observations in the WCRC-25 clinical 
samples from the end of the patient’s life, BIRC5 may be another interesting target to pursue in 
relation to PI3K/AKT/mTOR downstream signaling[281]. Finally, the low levels of ESR1 
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expression in WCRC-25 relative to negative control MDA-MB-231 suggest a very low level of 
endogenous expression. This observation will be pursued in future studies by attempting to re-
express ERα in WCRC-25 cells to test response to E2 and other endocrine modalities. WCRC-25 
will therefore be a key model in future analyses related to understanding PI3K/AKT pathway 
regulation in ILC, and endocrine therapy resistance. Our ongoing studies with therapeutics, 
phenotypes, and in vivo modeling will culminate in a publication after the completion of this 
dissertation. 
In summary, ILC is a unique disease within breast cancer, and is characterized by late 
endocrine therapy resistance. Our studies have established the upregulation of an EMT-like 
program in ILC, as well as have contributed a novel model system to the field of research. These 
combined data lay a foundation for future work in understanding the clinical impacts of current 
therapeutic regimens for ILC patients, and offer insight into understanding the complex process of 
disease progression that has been relatively undefined for this patient subset. This basic knowledge 












qRT-PCR primers utilized in Chapters Two and Three are provided below. 
Table 5: qRT-PCR Primers 
Gene Forward Sequence (5’  3’) Reverse Sequence (5’  3’) 
CDH1 GAACAGCACGTACACAGCCCT GCAGAAGTGTCCCTGTTCCAG 
CDH2 GACGGTTCGCCATCCAGAC TCGATTGGTTTGACCACGG 
ESR1 GAGTATGATCCTACCAGACCCTTC CCTGATCATGGAGGGTCAAATC 
FN1 CCGCCGAATGTAGGACAAGA TGCCAACAGGATGACATGAAA 
GREB1 GGTTCTTGCCAGATGACAATGG CTTGGGTTGAGTGGTCAGTTTC 
KDM1A CTAATGCCACACCTCTCTCAA ACACGAGTAGCCATTCCTTAC 
PGR TCGCCTTAGAAAGTGCTGTC GCTTGGCTTTCATTTGGAACG 
RPLP0 TAAACCCTGCGTGGCAATC TTGTCTGCTCCCACAATGAAA 
SNAI1 GGAAGCCTAACTACAGCGAG CAGAGTCCCAGATGAGCATTG 
SNAI2 AGCATTTCAACGCCTCCA GGATCTCTGGTTGTGGTATGAC 
SNAI3 GTGAAAACGCACTCCAGC AGAGCAGGCACCATTGATT 
TWIST1 TGTCCGCGTCCCACTAGC TGTCCATTTTCTCCTTCTCTGGA 
VIM CAACCTGGCCGAGGACAT ACGCATTGTCAACATCCTGTCT 
 
 
Antibodies used in IB experiments from both chapters are listed below. 
Table 6: Antibodies Used in IB Experiments 
Protein Company Catalog Number Host Species Dilution 
αSMA Abcam ab5694 Rabbit 1:1000 
Actin Sigma A5441 Mouse 1:5000 
AKT Cell Signaling 2920 Mouse 1:1000 
pAKTT308 Cell Signaling 13038 Rabbit 1:1000 
pAKTS473 Cell Signaling 4060 Rabbit 1:1000 
E-cadherin BD Biosciences 610182 Mouse 1:1000 
ERα Leica Biosystems 6F11 Mouse 1:200 
LSD1 Cell Signaling 2184S Rabbit 1:1000 
S6 Cell Signaling 2217S Rabbit 1:1000 
pS6S235/236 Cell Signaling 4858S Rabbit 1:1000 
SNAIL Cell Signaling 3895S Mouse 1:500 






Antibodies used in ChIP or IP experiments are provided here. 
 
Table 7: Antibodies Used in ChIP or IP Experiments 
Protein Company Catalog Number Host Species Concentration 
ERα Santa Cruz sc-543 Rabbit 2-4 µg 
LSD1 Abcam ab17721 Rabbit 2-5 µg 
SNAIL Cell Signaling 3895S Mouse 2 µg 
SNAIL R & D Systems AF3639 Goat 10 µg 
IgG Santa Cruz sc-2027 Rabbit 2-4 µg 
ChIP Grade IgG Abcam ab46540 Rabbit 2-5 µg 
IgG Santa Cruz sc-2025 Mouse 2 µg 
IgG Santa Cruz sc-2028 Goat 10 µg 
 
 
ChIP qRT-PCR primers utilized in Chapter Two are listed below. 
Table 8: ChIP qRT-PCR Primers 
Gene Forward Sequence (5’  3’) Reverse Sequence (5’  3’) 
GREB1 GTGGCAACTGGGTCATTCTGA CGACCCACAGAAATGAAAAGG 
IGFBP4 GGGTTGGGCAAGGAAAAGTT GGGTTGGGCAAGGAAAAGTT 
NFERE CTGCCTAGGCTGGGATAACA ATCAGGCATCTGTGCTTCCT 














Plasmids utilized in viral studies in Chapter Two are listed below. 
 
Table 9: Plasmids Used in Viral Knockdown Studies 
Plasmid Backbone Sel GFP Virus Use Sequence 
shPASHA N/A N/A N Lenti RNAi N/A 
pLp1 3rd Gen N/A N Lenti Pack N/A 
pLp2 3rd Gen N/A N Lenti Pack N/A 
pLp3 VSVG 3rd Gen N/A N Lenti Pack N/A 
shScramble pLKO.1 Puro N Lenti Const N/A 
shSNAI118 pLKO.1 Puro N Lenti Const CCAATCGGAAGCCTAACTACA 
shSNAI119 pLKO.1 Puro N Lenti Const CCAAGGATCTCCAGGCTCGAA 
shSNAI120 pLKO.1 Puro N Lenti Const GCAGGACTCTAATCCAGAGTT 
shSNAI121 pLKO.1 Puro N Lenti Const CCACTCAGATGTCAAGAAGTA 
shSNAI122 pLKO.1 Puro N Lenti Const CCAGGCTCGAAAGGCCTTCAA 
VSVG 2nd Gen N/A N Retro Pack N/A 

































pMDL 3rd Gen N/A Y Lenti Pack N/A 
pREV 3rd Gen N/A Y Lenti Pack N/A 
pVSVG 3rd Gen N/A Y Lenti Pack N/A 
shRenilla713 miR-E LT3GEPIR (pRRL) Puro Y Lenti Ind See Above 
shRenilla826 miR-E LT3GEPIR (pRRL) Puro Y Lenti Ind N/A 
shSNAI1150 miR-E LT3GEPIR (pRRL) Puro Y Lenti Ind Subcloned from above 
shSNAI1544 miR-E LT3GEPIR (pRRL) Puro Y Lenti Ind Subcloned from above 
shSNAI1763 miR-E LT3GEPIR (pRRL) Puro Y Lenti Ind Subcloned from above 
shSNAI11019 miR-E LT3GEPIR (pRRL) Puro Y Lenti Ind Subcloned from above 
shSNAI11666 miR-E LT3GEPIR (pRRL) Puro Y Lenti Ind Subcloned from above 
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Table 10: Plasmids Used in Viral Overexpression SNAIL Studies 
Plasmid Backbone Sel GFP Virus Use Sequence 
pLp1 3rd Gen N/A N Lenti Pack N/A 
pLp2 3rd Gen N/A N Lenti Pack N/A 
pLp3 VSVG 3rd Gen N/A N Lenti Pack N/A 
SNAI1 ORF124 pENTR-221 N/A N Lenti Gateway Targets NM_005985.2 
W118 pLENTI-CMV G418 N Lenti Const N/A 
W118-SNAI1 pLENTI-CMV G418 N Lenti Const Targets NM_005985.2 
pMDL 3rd Gen N/A N Lenti Pack N/A 
pREV 3rd Gen N/A N Lenti Pack N/A 
pVSVG 3rd Gen N/A N Lenti Pack N/A 
pINDUCER20 pINDUCER20 G418 N Lenti Ind N/A 
pINDUCER20-SNAI1 pINDUCER20 G418 N Lenti Ind Targets NM_005985.2 
 
 
Below is a table of antibodies utilized for all IF studies in Chapter Three. 
Table 11: IF Antibodies for WCRC-25 Characterization Studies 
IF Marker Company Catalog Number Lot Number Host Species Dilution 
DAPI Thermo Fisher P36962 1850967 N/A ~15 µL 
Anti-Mouse 
AlexaFluor488 
Invitrogen A11017 1694699 Mouse 1:200 
Anti-Rabbit 
AlexaFluor488 
Invitrogen A21206 57542A Rabbit 1:200 
Anti-Rat AlexaFluor488 Invitrogen A11006 1728142 Rat 1:200 
CK5 Leica CK5-L-CE Unknown Mouse 1:200 
CK8/18 DSHB Troma Troma-1-c Unknown Rat 1:200 
CK14 Covance PRB-155P-100 D14IF01918 Rabbit 1:200 
EpCAM Cell Signaling 2929S 5 Mouse 1:200 
α-SMA Abcam ab5694 GR87726-1 Rabbit 1:400 
FAP Abcam ab28244 GR132121-8 Rabbit 1:200 
ERα Leica NCL-L-ER-6F11 6039612 Mouse 1:50 

















Table 12: IHC Markers for Clinical Sample Staining 
IHC Marker Company Catalog Number Host Species Dilution 
ERα Leica NCL-L-ER-6F11 Mouse 1:50 
ERα (SP1) Ventana 790-4324 Rabbit Unknown 
E-cadherin (Clone 36) Ventana/Roche 790-4497 Mouse Unknown 
p120 BD Biosciences 610134 Mouse 1:200 
 
 
Primers used to cover the entire exon regions of CDH1 are listed below. 
 
Table 13: Primers for Complete CDH1 cDNA Sanger Sequencing 
Exon Region Forward Sequence (5’  3’) Reverse Sequence (5’  3’) 
1-5 TGAGCTTGCGGAAGTCAGTT GCGTGAGAGAAGAGAGTGTATG 
5-9 GACAGAAGAGAGACTGGGTTATTC CCATCGTTGTTCACTGGATTTG 
9-11 CAGTCACTGACACCAACGATAA CATCAGACAGGATCAGCAGAAG 
11-14 TGGGCCAGGAAATCACATCC TGCAACGTCGTTACGAGTCA 
13-16 CGACCCAACCCAAGAATCTATC TGGACATCACCACCATGTAAAG 














The following section is comprised of all supplemental data for Chapter 2. 
 
 
Figure 64: CTNNB1 is Not Significantly Different Between ILC and IDC Primary Lesions, 
But Protein is Significantly Reduced in ILC Compared to IDC 
(A) RNA Sequencing data from TCGA primary ILC (n = 184, red) and IDC (n = 584, blue) ERα+ 
samples was analyzed for expression of CTNNB1. (B) RPPA from TCGA primary ILC (n = 137, 
red) and IDC (n = 417, blue) samples was analyzed for expression of β-catenin. Mann-Whitney U 





Figure 65: Complete ILC E2 RPPA 
Complete RPPA data was obtained from the previously described experiment (see 2.3.2) 
performed in MDA-MB-134-VI and Sum44PE for (A) E2-upregulated or (B) E2-downregulated 
proteins in MDA-MB-134-VI (see Figure 5). Data were sorted by log2 normalized median 
centered induction relative to deprived controls. EMT proteins are highlighted with red asterisks. 
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Figure 66: TWIST1 is Not Regulated by 4OHT or E2 in MDA-MB-134-VI 
TWIST1 or SNAI1 qRT-PCR were performed in MDA-MB-134-VI at the 8-hour treatment time 
point after E2 deprivation and treatment with Vehicle (0.1% DMSO), 1 nM E2, or 1 µM 4OHT. 
Quantifications are a representative single experiment ± STDEV of technical triplicates. Asterisks 
depict significance compared to Vehicle from One Way ANOVA followed by Tukey’s post-test 






Figure 67: Dose Responses of 4OHT, E2 Show SNAIL Protein Induction in MDA-MB-134-
VI and Sum44PE ILC Cells 
MDA-MB-134-VI and Sum44PE cells were treated to E2 deprivation assay with increasing doses 
of E2 (0.01, 0.1, 1, 10 nM) or 4OHT (0.01, 0.1, 1, 10 μM) administered for 24 hours. IB is 





Figure 68: ERα ChIP Time Course IP Confirmation 
MDA-MB-134-VI cells were treated to E2 deprivation followed by Vehicle (0.1% DMSO), 10 nM 
E2, 10 µM 4OHT, or combination treatments for 45 minutes, 3 hours, or 8 hours. After initial ChIP 
processing, ERα IP was performed to validate use of samples in ChIP qRT-PCR. Negative control 




Figure 69: ERα ChIP qRT-PCR Time Course 
MDA-MB-134-VI cells were treated to E2 deprivation followed by Vehicle (0.1% DMSO), 10 nM 
E2, 10 µM 4OHT, or combination treatments for 45 minutes, 3 hours, or 8 hours. ChIP qRT-PCR 
was performed for SNAI1, GREB1, and IGFBP4 ERE conserved binding regions. NFERE was 
used as a negative control. Data represent one experiment with technical triplicates plated during 
the qRT-PCR ± STDEV. Asterisks depict significance compared to Fold Enrichment (FE) Vehicle 
after correction to Vehicle IgG for all samples with One Way ANOVA followed by Tukey’s post-




Figure 70: E-cadherin and ERα Protein Statuses of ILC and IDC Cell Lines Utilized in 
Experiments 
Prior to probing for SNAIL and TWIST1 protein expressions, confirmation of E-cadherin and ERα 
statuses was performed in our panel of ILC and IDC cell lines by IB. A representative experiment 
is shown from three independently performed experiments treated ± 5 µM MG132 for 2 hours with 






Figure 71: Transient SNAI1 Knockdown Dose Response in ILC Cells 
MDA-MB-134-VI and Sum44PE were subjected to reverse transfection of escalating doses of 
siScramble or siSNAI1. Full Serum (FS) and Nontransfected cells served as additional controls. 
qRT-PCR for SNAI1 was performed with technical triplicate samples ± STDEV, for a single 
experiment shown. Asterisks depict significance as determined by One Way ANOVA followed by 
Tukey’s post-test with comparisons to each respective concentration-matched siScramble (*p < 








Figure 72: Transient SNAI1 Knockdown 2D Proliferation Phenotype Is Present at Later 
Time Points, as Are mRNA and Protein Knockdown 
MDA-MB-134-VI cells were transiently reverse transfected with 10 nM Scramble or SNAI1 
siRNA. (A) 2D proliferation was measured from D1-8 with six technical replicates per time 
point/condition ± STDEV, normalized to D1 values, and fitted with non-linear regression with 
comparison of rates performed (*p < 0.05, **p < 0.005, ***p < 0.0005). (B) qRT-PCR for SNAI1 
at D2,4,6 was performed with technical triplicate samples ± STDEV. Students t-test was performed 
at each time point, with asterisks denoting significance (*p < 0.05, **p < 0.005, ***p < 0.0005). 
Data are representative of three independent experiments. Protein were isolated at the same time 
points to show levels of SNAIL in full serum (FS), Scramble siRNA (Scr), or SNAI1 siRNA (Sn) 






Figure 73: Transient SNAI1 Knockdown Phenotypes are Not Stable or Repeatable in 
Sum44PE, MCF-7, or T47D, and Knockdown Rebounds 
Sum44PE, MCF-7, and T47D were treated to the same experimental conditions for (A) 2D 
proliferation and (B) qRT-PCR as performed for MDA-MB-134-VI (see Figure 16). 
Representative data from single experiments of two attempts (Sum44PE, T47D) or of three 
attempts (MCF-7) are displayed with (A) six or (B) three replicate samples ± STDEV. Statistics 




Figure 74: E2 Deprivation/siRNA Studies Caused Decreased Proliferation for siScramble 
Cells 
MDA-MB-134-VI cells were subjected to E2 deprivation, followed by reverse transfection with 
nothing (CSS) or siScramble control siRNA. Cells were then treated to Vehicle (0.1% DMSO) or 
1 nM E2 for 8 days. Data were analyzed as in Figure 17 with the same numbers of technical 




Figure 75: Different CSS Lots Were an Additional Source of Experimental Variation 
Changes in CSS lot usage and results obtained were noted throughout this dissertation. Initial 
experiments utilized Gibco CSS, and use transitioned to in-house generated lots that varied with 
each batch, or Gemini. IBs (50 µg protein/lane) from representative comparison E2 deprivation 
experiments in MDA-MB-134-VI are shown above to highlight differences in responses obtained 






Figure 76: Lentiviral Stable Knockdown of SNAIL was Difficult to Maintain 
qRT-PCR was performed on lentiviral stable SNAIL knockdown MDA-MB-134-VI cell lines for 
SNAI1, one passage out from the preliminary experiment (see Figure 18). Data are representative 
of a single experiment with technical duplicates ± STDEV normalized to shScramble control with 











Figure 77: Transient Virus SNAIL Knockdown Panel Often Produced Phenotype and 
Expression Alterations That Did Not Match 
The complete original lentiviral panel against SNAI1 was utilized in the transient virus assay 
format to test effects on (A) 2D proliferation, (B) qRT-PCR of SNAI1 at D2,4,6, and (C) D6 IB. Data 
were analyzed as previously and represent a single experiment containing (A) six technical 
replicates ± STDEV with non-linear regression and comparison of rates (*p < 0.05, **p < 0.005, 
***p < 0.0005), or (B) triplicate samples normalized to shScramble SNAI1 expression on each day 






Figure 78: Inducible SNAI1 Retroviral Knockdown System Generation Was Initially 
Unsuccessful 
Upon acquisition of MDA-MB-134-VI inducible retroviral SNAI1 knockdown cells, (A) 2D 
proliferation, (B) ULA proliferation, and (C) 48 Hour or (D) 96 Hour time point assays were 
plated. Cells were treated to ± 0.5 µg/mL Dox the morning after plating cells. Six technical 
replicates for each treatment/time point were utilized ± STDEV with normalization to D2 and 







Figure 79: Lentiviral Stable SNAI1 Overexpression Also Was Not Effectively Maintained 
Prior to using the lentiviral plasmid for SNAI1 overexpression in ILC cells, (A) Empty Vector (EV) 
W118 or W118-SNAI1 were transfected into HEK293T cells and assessed by technical triplicates 
for both IB and qRT-PCR to assess SNAIL upregulation. qRT-PCR is displayed ± STDEV, 
normalized to EV control, and data compared with One Way ANOVA followed by Tukey’s post-
test (*p < 0.05, **p < 0.005, ***p < 0.0005). (B) BCK4 cells were stably infected with W118 or 
W118-SNAI1 and measured for SNAIL overexpression by IB (50 µg/lane). (C) Lysates were 











Figure 80: Dox Dose Responses in Inducible SNAIL Overexpression Coincide with 
Increased Proliferation in 2D, ULA 
BCK4, MDA-MB-330, and Sum44PE pINDUCER20-SNAI1 cells were plated for a Dox dose 
response. (A) IB for SNAIL was performed at the 48-hour time point with increasing doses of Dox 
loaded from left to right on each respective blot (25 µg/lane). (B) 2D and (C) ULA proliferation 
were assessed with increasing doses of Dox in technical triplicates ± STDEV for each respective 
treatment/time point with normalization to D1 values and comparison of rates after non-linear 




Table 14: Dox Inducible SNAI1 Dose Response p-Values from 2D, ULA Proliferation Assays 
*All comparisons are relative to -Dox 2D ULA 
BCK4 pINDUCER20-SNAI1 
0.125 µg/mL:  




***p < 0.0001 
***p < 0.0001 
***p < 0.0001 
 ***p < 0.0001 
***p < 0.0001 
 
0.125 µg/mL:  




NS p = 0.6336 
  NS p = 0.1270 
  NS p = 0.0587 
  NS p = 0.0551 
    **p = 0.0009 
MDA-MB-330 pINDUCER20-SNAI1 Incomplete 
0.125 µg/mL:  




***p = 0.0003 
    ***p = 0.0003 
   ***p < 0.0001 
   ***p < 0.0001 
   ***p < 0.0001 
Sum44PE pINDUCER20-SNAI1 
0.125 µg/mL:  




NS p = 0.0559 
  *p = 0.0092 
  **p = 0.0015 
  **p = 0.0042 
  *p = 0.0066 
 
0.125 µg/mL:  




NS p = 0.2286 
    *p = 0.0086 
 *** p = 0.0003 
 *** p = 0.0002 
 *** p = 0.0002 
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Figure 81: Dox Dose Responses in ILC Control Cells Show No Impact on Protein, Minimal 
Impacts on 2D, ULA Proliferation 
BCK4, MDA-MB-330, and Sum44PE control cells were plated for a Dox dose response. (A) IB 
for SNAIL was performed at the 48-hour time point with increasing doses of Dox loaded from left 
to right on each respective blot (25 µg/lane). (B) 2D and (C) ULA proliferation were assessed with 
increasing doses of Dox in technical triplicates ± STDEV for each respective treatment/time point 
with normalization to D1 values and comparison of rates after non-linear regression fits (*p < 0.05, 




Table 15: ILC Control Dox Dose Response p-Values from 2D, ULA Proliferation Assays 
*All comparisons are relative to -Dox 2D ULA 
BCK4 (Control) 
0.125 µg/mL:  




*p = 0.0078 
NS p = 0.0763 
*p = 0.0248 
 NS p = 0.1507 
NS p = 0.1108 
 
0.125 µg/mL:  




NS p = 0.3001 
  NS p = 0.8810 
  NS p = 0.4060 
  NS p = 0.5723 
    NS p = 0.9442 
MDA-MB-330 (Control) Incomplete 
0.125 µg/mL:  




NS p = 0.4361 
    NS p = 0.5282 
   NS p = 0.5356 
   NS p = 0.3868 
   NS p = 0.5733 
Sum44PE (Control) 
0.125 µg/mL:  




NS p = 0.8386 
  NS p = 0.3626 
  NS p = 0.9719 
  NS p = 0.8240 
  NS p = 0.9427 
 
0.125 µg/mL:  




NS p = 0.6714 
    NS p = 0.7198 
 NS p = 0.3725 
 NS p = 0.6936 




Figure 82: Inducible SNAIL ILC Cells Do Not Acquire ALDH+ Phenotype with SNAIL 
Overexpression 
ALDH Flow Cytometry assay was performed by Jian Chen, MS. (A) Negative (MDA-MB-231) 
and positive (SKBR3) control cell line ALDH profiles were collected. (B) Inducible SNAIL 
overexpression cells ± 0.5 µg/mL Dox were also assessed for ALDH profiles after 24 hours 
induction of SNAIL. (C) SNAIL protein was confirmed to be upregulated by IB (25 µg/lane). Data 





Figure 83: BCK4 and MDA-MB-330 Cells Do Not Form Proper Mammospheres 
Inducible SNAIL overexpression ILC BCK4 and MDA-MB-330 cells were treated to Dox in a 
mammosphere assay. Phase contrast images are from D17 (20X magnification; scale bars 





Figure 84: SNAIL Protein is Also Not Significantly Different Between ILC and IDC, But E-
cadherin Is 
RPPA from TCGA primary ILC (n = 137, red) and IDC (n = 417, blue) samples was analyzed for 
expression of (A) SNAIL and (B) E-cadherin. Mann-Whitney U p-values were applied to each 
data set. Data were analyzed in collaboration with Kevin Levine, BS. 
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Figure 85: Overall EMT-TF Program is Downregulated in ILC as Compared to IDC 
Primary ERα Positive Lesions 
TCGA ERα+ ILC (n= 184, red) versus IDC (n= 534, blue) lesions were probed for mRNA 
expressions of members of the EMT-TF panel. Mann-Whitney U p-values were applied to each 
data set. Analyses were performed in collaboration with Kevin Levine, BS. 
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Figure 86: KDM1A is Not Regulated by ERα in MDA-MB-134-VI Cells 
MDA-MB-134-VI cells were treated to E2 deprivation followed by Vehicle (0.1% DMSO), 1 nM 
E2, or 1 µM 4OHT for 8 hours. Data represent a single experiment with technical triplicates ± 
STDEV, normalized to the Vehicle with One Way ANOVA followed by Tukey’s post-test (*p < 





Figure 87: ILC Cells Form Discohesive Soft Agar Colonies as Compared to IDC Cells 
ILC (red) and IDC (blue) cells were plated at the same density (10,000 cells/dish; marked as “low 
density for ILCs) or a higher density (100,000 cells/dish; marked as “high density for ILCs) in 
triplicate dishes for 28 days to monitor soft agar colony formation. Representative images were 
taken of colonies that were counted in each dish (10X magnification; bars represent 100 µm). Data 




Figure 88: Preliminary Protein Micropatterning Experiment Was Successful for MDA-MB-
134-VI and MCF-7 Cell Adhesion 
MDA-MB-134-VI and MCF-7 cells were plated on 20 µm linear FN1-micropatterned (50 µg/mL), 
PDMS spin-coated coverslips at 200,000 cells/well in technical triplicate wells. Images were taken 
24 hours post plating under phase contrast microscopy (10X magnification; bars represent 100 
µm). Data represent the pilot study. 
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APPENDIX C 






Figure 89: WCRC-25 Patient Clinical and Sample Acquisition Timeline with Numerical 
Descriptions of Samples 
A compressed timeline (not to scale) of the WCRC-25 patient’s clinical course is detailed above. 
De-identified clinical information was provided by Karthik Kota, MD. Samples pertinent to this 
project were listed. Asterisks (*) denote samples taken during biopsy. Dashed boxes around the 
breast samples indicate the time of double mastectomy. The figure was rotated for ease of 
visualization. 
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Table 16: Clinical Sample Overview for WCRC-25 Patient 





Stomach/Fundus 6 -9.1 
(-2.3) 
+ 
(note: our section 
had no staining) 
-/cyto 








Peritoneum 10 -2.3 
(4.5) 
+ -/cyto 
Right Breast Biopsy 25 1A -1.3 
(5.6) 
+ Uninterpretable 
Left Breast Biopsy1 25 2A -1.3 
(5.6) 
+ -/cyto 
Left Breast Biopsy2 26 8.2 
(15) 
- -/cyto 
Left Lymph Node 27 9.5 
(16.4) 
+ -/cyto 
Right Breast Mastectomy 28 5E 9.8 
(16.6) 
+ -/cyto 
Left Breast Mastectomy1 28 1P 9.8 
(16.6) 
+ -/cyto 
Left Breast Mastectomy2 28 1E 9.8 
(16.6) 
- -/cyto 







(note: indicated from 
pathology report) 
Unknown Side Pleural Fluid 30 17.4 
(24.3) 
- -/cyto 
Left Superior Chest Skin 34 1A 24.1 
(31) 
- -/cyto 
Left Inferior Chest Skin 34 2A 24.1 
(31) 
- -/cyto 
Left Pleural Fluid2 36 30.2 
(37) 
- -/cyto 
Blood1 Draw 1 25.8 
(32.7) 
? 0.27% CDH1 Q706* 
Blood2 Draw 2 27.2 
(34.1) 
? ? 
Blood3 Draw 3 27.7 
(34.6) 
? ? 
Blood4 Draw 4 29.8 
(36.7) 
? 8.28% CDH1 Q706* 
Sample names and numbers coordinate with Figure 39 and Appendix C Figure 89. Red font 
indicates months from initial ILC diagnosis. Black font in parentheses indicates months from 
initial gastric carcinoma diagnosis. Negative values mean prior to the first treatment regimen given 
for particular carcinoma (Anastrazole/Fulvestrant for ILC diagnosis; FOLFOX for gastric 
carcinoma diagnosis). Pathology calls are listed in the table as + for positive, - for negative, and 
cyto for cytoplasmic. A question mark means that the status was not tested. Mutational CDH1 
Q706* frequencies from ddPCR are listed for blood samples that have been tested. 
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Figure 90: Stromal Marker αSMA is Not Expressed by WCRC-25 
IB was performed with positive controls shScramble and shPRDX1 obtained from mouse stromal 
associated fibroblasts for αSMA and Actin internal control in a panel of IDC (MCF-7) and ILC 







Figure 91: GREB1 and SNAI1 Are More Highly Expressed in WCRC-25 Than in MDA-
MB-231; SNAI1 is Mildly Induced by E2/4OHT in WCRC-25  
(A) WCRC-25 cells were assessed by qRT-PCR for expression of ERα target genes GREB1 and 
SNAI1 against MCF-7 and MDA-MB-231 cells. (B) WCRC-25 cells were treated to 1 µM ICI or 
E2 deprivation followed by 1 nM E2 or 1 µM 4OHT with assessment of SNAI1 expression 
alterations by qRT-PCR. Quantifications are representative of a single experiment with technical 
triplicates ± STDEV, normalized to WCRC-25 without treatment. Statistics were performed with 
One Way ANOVA followed by Tukey’s post-test (*p < 0.05, **p < 0.005, ***p < 0.0005) with 





The following is a description of quality checks that were performed on WCRC-25 RNA 
Sequencing data: 
After sequencing data were obtained, quality checks were performed to ensure 
interpretability of data. First, Phred scores were called to measure the base calling accuracy. A 
score of 30 defines 99.9% accuracy in base calling (errors only occur in 1 out of 1,000 bases 
called), a score of 40 defines 99.99% accuracy in base calling (errors only occur in 1 out of 10,000 
bases called), and so on. Phred scores for this sequencing run were called at 37, giving great 
confidence to the accuracy of the sequencing calls made. Next, soft alignment clipping rates were 
measured. Soft alignment took into consideration that all reads did not necessarily align perfectly 
from 5’  3’ with the reference sequence. The rate at which the soft-clipped alignments occurred 
followed a distribution expected with increased reads. Measurement of insert sizes revealed that 
most inserts were between 100-200 base pairs, as expected from degraded FFPE RNA[282]. Next, 
GC content was assessed to determine if there was bias for low or high GC content reads, which 
could have influenced Illumina sequencing reads[283]. GC content was consistent for all samples 
circa 40%. The cumulative gene assignment diversity was next assessed, and hypothesized to be 
similar across all samples. However, the stomach sample taken early in the treatment course 
appeared to have a different trace than all other samples, and was thus considered to be a potential 
outlier in the study. Gene-body coverage was measured to determine that there was no bias in the 
preparation of samples, and subsequent reads, toward the 5’ or 3’ end[284]. Coverage was estimated 
near 50% for all samples, indicating no bias of reads toward either 5’ or 3’ end. Read mapping 
location rates were measured near 80% for unique genes, suggesting that the unique reads were 
mapped to unique regions of the reference or different gene regions. Strandedness was tested to 
assure that a bias did not exist for reads in either sense or antisense strand; no bias existed for either 
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strand in our data ser. Finally, the raw nucleotide rate comparison between cycles indicated read 
concordance between cycles (e.g. C with G in cycle 1 and G with C in cycle 2). The culmination 
of this quality control data gave confidence that the preparation of the library, quality of reads, and 
mapping of data were of high confidence for all samples run, with some concern noted about the 




Figure 92: QoRTs Quality Control Plots from R Analyses for RNASeq 
QoRTs plots were generated based on data and descriptions provided in main text to validate use 
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